Page last updated: 2024-08-18

pyrroles and Neoplasms

pyrroles has been researched along with Neoplasms in 595 studies

Research

Studies (595)

TimeframeStudies, this research(%)All Research%
pre-199019 (3.19)18.7374
1990's3 (0.50)18.2507
2000's144 (24.20)29.6817
2010's343 (57.65)24.3611
2020's86 (14.45)2.80

Authors

AuthorsStudies
Fan, X; Qin, S; Yang, M; Yin, Y; Yu, F; Zhang, H; Zhang, J; Zhang, Y; Zhu, M1
Bora, V; Goyal, RK; Johar, K; Patel, BM; Patel, D1
Cao, Y; Feng, Q; Geng, S; Liu, C; Pan, X; Shou, P; Tian, J; Wang, K; Wu, A; Wu, Y; Xing, J; Yin, C; Yu, Z; Zhou, B1
Langova, V; Nguyen, SM; Thomas, PM; Todd, JE; Tzannes, S; White, J1
Bauer, S; Carpio, C; Cassier, PA; Chatterjee, M; Chromik, J; de Vos, F; DeAngelo, DJ; Esteve, J; Fabre, C; Ferretti, S; Guerreiro, N; Halilovic, E; Kiladjian, JJ; Lin, CC; Mariconti, L; Meille, C; Minami, H; Mous, R; Pereira, B; Radhakrishnan, R; Steeghs, N; Stein, EM; Suarez, C; Tai, D; Yamamoto, N1
Fan, L; Guo, R; Han, J; Sun, X; Wang, J; Wang, Z; Xi, J; Zhu, C1
Bagheri, H; Ghanei, M; Ghazvini, A; Khoshsafar, H; Taheri, N1
Jung, BH; Kong, M; Lee, H; Park, J; Yang, JS; Yoon, N1
Chen, X; Gong, X; Ji, T; Liu, X; Yeleswaram, S1
Hu, H; Li, R; Ren, J; Wei, J; Wong, CY; Xu, Q; Xu, Z; Yang, Z; Zhang, L1
Bertelli, F; Chivers, S; Hartley, JA; Havenith, KE; Hogg, P; Janghra, N; Reinert, HW; Tyrer, P; van Berkel, PH; Zammarchi, F1
Féliz, L; Gutierrez, M; Iannotti, NO; Ji, T; Lihou, CF; Saleh, M; Silverman, IM; Smith, DC; Subbiah, V; Tian, C1
Amin, M; Bagegni, NA; Baggstrom, MQ; Devarakonda, S; Gao, F; Kraft, K; Liang, C; Morgensztern, D; O-Toole, M; Park, H; Ratner, L; Selvaggi, G; Wang-Gillam, A; Waqar, SN1
Greenberg, J; Healey, JH; Hsu, C; LaCreta, F; Lasseter, KC; Marbury, TC; Stacchiotti, S; Tap, WD; Xu, LA; Zahir, H1
Berlin, JD; Ding, K; Garrido-Laguna, I; Geschwindt, R; Leopold, L; LoRusso, PM; Luke, JJ; Mansfield, AS; Messersmith, WA; Naing, A; Nemunaitis, JJ; Powderly, JD; Sahebjam, S; Smith, M1
Fatahala, SS; Mansour, YEE; Mohamed, MS; Sabry, JY1
Bilgin, E; Duran, E; Ertenli, İ; Kalyoncu, U; Kiraz, S; Ünaldı, E1
Chen, T; Hou, L; Huang, Y; Jiang, T; Ma, Z; Shi, Z; Wang, S; Yang, F1
Cui, X; Jia, F; Li, Y; Pan, Z; Wang, X; Wu, Y1
Cheng, Y; Gui, Y; Wu, K; Zhang, Y; Zou, T1
Chen, T; Huang, C; Li, H; Liu, Y; Mei, L; Ou, M; Tang, J; Wang, T; Wu, M; Yi, Y; Yu, M; Zeng, W1
Aubé, J; Baljinnyam, B; Bryant-Connah, M; Davis, D; De, S; Dextras, C; Dutta, D; Ferrer, M; Frankowski, KJ; Henderson, MJ; Huang, S; Jadhav, A; Kabir, M; Li, D; Lin, YH; Marugan, JJ; Mathews Griner, LA; Norton, J; Patnaik, S; Rudloff, U; Schoenen, FJ; Shah, P; Simeonov, A; Southall, N; Titus, S; Wachsmuth, LM; Wang, A; Wang, C; Wang, F; Williams, J; Xu, X; Zheng, W; Zhu, E1
Du, F; Li, Q; Liu, J; Liu, S; Mao, H; Wu, Y; Xu, X; Yang, M; Zhu, J; Zou, S1
Bikinieva, F; Boichuk, S; Galembikova, A; Mustafin, I; Ryzkin, S; Zykova, S1
Dai, H; Hu, L; Li, M; Tian, S; Xie, J; Yan, L; Zhang, H1
Cao, Y; Chen, Z; Ran, H1
Cai, Z; Cui, S; Dai, S; Dong, Y; Lin, N; Liu, P; Shi, J; Tong, B; Wu, X1
Gao, M; Liu, K; Qian, J; Tang, BZ; Zhang, Y; Zhou, Z1
Hathout, RM1
Chen, T; Guan, J; Li, H; Li, Q; Li, W; Liang, H; Mei, L; Wang, X; Wang, Y; Wu, X; Yang, M; Ye, F; Zeng, W; Zhang, F1
Du, YW; Liu, FR; Liu, JH; Qiu, MZ; Shi, YX; Wang, DS; Wang, FH; Wang, ZQ; Wei, XL; Xu, F; Xu, RH; Yu, QQ; Zhang, Y; Zhao, HY1
Aizawa, F; Ando-Matsuoka, R; Goda, M; Hamano, H; Ishizawa, K; Izawa-Ishizawa, Y; Maruo, A; Miyata, K; Niimura, T; Sakaguchi, S; Sakajiri, Y; Sawada, R; Shibata, T; Takaoka, M; Yagi, K; Yamanishi, Y; Zamami, Y1
Li, X; Liu, Z; Sui, C; Tan, R; Xu, W1
Fujiwara, Y; Furukawa, M; Hara, H; Ioka, T; Ji, T; Kuboki, Y; Lihou, C; Mizuno, N; Shimizu, T; Takahashi, S; Takahashi, Y; Takeuchi, S; Tian, C; Ueno, M1
Chen, Y; Feng, W; Guo, J; Hu, Z; Li, T; Miao, Q; Song, F; Wang, Z; Wu, C1
Brachi, G; Geng, H; Grigsby, CL; Li, X; Lupton, EJ; Ma, Y; Stevens, MM; Stuckey, DJ; Sun, R; Zhou, K1
Cao, D; Lai, B; Ran, X; Tang, H; Wang, L1
An, B; Ding, H; Gai, S; Gao, Y; He, F; Song, S; Yang, M; Yang, P; Zhang, X1
Brana, I; Brown, RJ; Doger, B; Galvao, V; Genta, S; Gu, J; Hansen, AR; Hernández, T; Kalota, A; Lauring, J; Lenox, L; Mehta, J; Mistry, P; Moreno, V; Pastore, F; Patel, B; Patel, MR; Preis, M; Spreafico, A; Vieito, M; Wang, JS1
Dong, YB; Feng, J; He, ZL; Shao, YQ; Sun, YY; Wang, Y; Yang, SP; Zhai, YN1
Naing, A1
Hu, X; Li, C; Lin, W; Liu, S; Xie, Z; Zhang, W1
Beaufils, F; Bohnacker, T; Borsari, C; Dall'Asen, A; Fabbro, D; Hebeisen, P; Hillmann, P; Jackson, E; Langlois, JB; Melone, A; Rageot, D; Sele, AM; Wymann, MP1
Buchmann, J; Calderón, M; Laufer, J; Molina, M; Theune, LE; Wedepohl, S1
Blacque, O; Chao, H; Gasser, G; Karges, J1
Blackwood, L; Harper, A; Mason, S1
Burvenich, IJG; Harris, MA; Hawkins, CJ; Parker, BS; Rigopoulos, A; Scott, AM; Shekhar, TM; Spurling, A; Walkley, CR; Zanker, D1
Goh, CC; Liu, B; Liu, J; Ng, LG; Wang, S1
Dekhne, A; Doshi, A; Gangjee, A; Hou, Z; Matherly, LH; O'Connor, C; Xiang, W1
Barry, C; Betancourt, O; Blot, V; Coronella, J; D'Hooge, F; Fujita, R; Galvan, D; Gymnopoulos, M; Hartley, JA; Howard, PW; Lieuw, V; Newman, R; Nguyen, S; Pardo, R; Patel, N; Snedden, J; Stewart, C; Vijayakrishnan, B; Villicana, J; Wojciak, J; Wong, E1
Bychko, A; Byelinska, I; Dziubenko, N; Hurmach, V; Khilya, O; Kuznietsova, H; Lynchak, O; Milokhov, D; Rybalchenko, V1
Ferraldeschi, R; Gordon, MS; Jueliger, S; Keer, H; LoRusso, PM; Mita, AC; Mita, MM; Oganesian, A; Papadopoulos, KP; Su, XY; Tolcher, AW1
Bjelic, S; Friedman, R; Georgoulia, PS1
Felten, A; Hahn, SJ; Klein, HF; Kleindl, PJ; Leamon, CP; Nicoson, J; Parham, GL; Qi, L; Reddy, J; Reno, D; Santhapuram, HKR; Vaughn, JF; Vlahov, IR; Wang, K; You, F; Zou, N1
Jagtap, SV; Rasal, NK; Sonawane, RB1
Hanazono, K; Hoshino, Y; Hosoya, K; Izumi, Y; Takagi, S; Yamazaki, H1
Akiyoshi, H; Mie, K; Miura, N; Nishida, H; Tanaka, T; Yamazaki, H1
Bowman, K; Burke, KA; Burn, TC; Collier, P; Covington, M; Diamond, S; DiMatteo, D; Feldman, P; Gardiner, C; Hansbury, M; He, X; Hollis, G; Huber, R; Klabe, R; Koblish, H; Liu, PCC; Ruggeri, B; Rupar, M; Scherle, P; Soloviev, M; Volgina, A; Wen, X; Wu, L; Wynn, R; Yao, W; Yeleswaram, S; Zhang, Y1
Duan, T; Huang, H; Lu, Y; Ma, H; Peng, A; Shi, Q; Wen, K; Wu, L; Wu, X1
Dou, H; Gao, M; Hu, Q; Huang, W; Leng, T; Liu, L1
Hartley, JA2
Knudsen, ES; Kumarasamy, V; Roberts, PJ; Witkiewicz, AK1
Chan, G; Ciorba, MA; Lawendy, N; Lichtenstein, GR; Nduaka, CI; Panés, J; Pedersen, RD; Quirk, D; Rogler, G; Su, C; Thorpe, AJ1
Dong, S; Fan, H; Hu, W; Ji, J; Reddy, AGK; Sajjad, F; Xing, D; You, Q1
Babar, DA; Chopra, S; Kalari, S; Karale, UB; Kaul, G; Makane, VB; Misra, S; Rekha, EM; Rode, HB; Shukla, M; Sriram, D; Vamshi Krishna, E1
Awadasseid, A; Jiang, SK; Liang, J; Sugiyama, H; Wu, YL; Xiong, XQ; Xu, L; Zhang, M; Zhang, W; Zhao, XY1
Akakuru, OU; Dar, GI; Iqbal, MZ; Li, J; Li, Y; Liu, C; Nosike, EI; Qian, K; Wu, A; Xing, J; Yang, G; Zhang, Z1
Babiker, HM; Chandana, SR; Mahadevan, D1
Chen, J; Duan, W; Hu, Y; Li, Y; Liu, H; Ren, W; Shen, A; Wei, A; Xie, Z; Zhang, J; Zhang, M; Zhang, Z1
Aydın, EB; Aydın, M; Sezgintürk, MK1
De, A; Gopal, MB; Laxman, K; Mishra, SK; Ravikanth, M; Reddy, BPK; Robinson, A; Srivastava, R1
Kasper, B1
Nguyen, VN; Yan, Y; Yoon, J; Zhao, J1
Abida, W; Brownstein, S; Drilon, A; Gounder, MM; Groover, A; Harding, JJ; Hyman, DM; Janku, F; Lacouture, ME; Lezcano, C; Li, BT; Liu, D; Offin, M; Sullivan, RJ; Torrisi, JM; Varterasian, M; Welsch, D; Wu, J1
George, SM; Kandasubramanian, B; McIntyre, R; Tandon, S1
Bando, T; Maeda, R; Sugiyama, H1
Akakuru, OU; Iqbal, ZM; Li, Y; Li, Z; Liu, C; Nosike, EI; Pan, C; Wu, A; Xing, J; Xu, C; Zhang, Z; Zheng, J1
Chan, E; Grierson, PM; Huffman, J; Liang, C; Liu, J; Lockhart, AC; Morton, A; Pedersen, KS; Picus, J; Roth, BJ; Tan, B; Wang-Gillam, A1
Kida, Y; Koshikawa, N; Nagase, H; Shinozaki, Y; Takenaga, K; Tsuji, K; Watanabe, T; Yasui, N1
DuBois, SG; Khosravan, R; Verschuur, AC; Wang, E; Wetmore, C1
Bouakaz, A; Chen, J; Feng, Y; Qin, D; Wan, M; Wu, D; Zhang, L; Zhu, H1
Abebe, M; Abozen, T; Alabanza, PL; Ameni, G; Aseffa, A; Balcha, TT; Baric, RS; Belay, M; Berg, S; Brown, AJ; Chandran, A; Cohen, MS; Coombs, RW; Degli-Angeli, EJ; Demaret, J; Dong, C; Dragavon, JA; Duke, ER; Eltayeb, O; Eron, JJ; Fang, L; Fischer, WA; Forrest, S; Goecker, EA; Harris, KA; Hong, S; Hudgens, MG; Huggett, JF; Jolliffe, DA; Jones, GM; Keys, J; Krajewski, TJ; Li, B; Li, L; Loftis, AJ; Manwandu, H; Martineau, AR; Martineau, HM; Mayito, J; Mollan, KR; Morse, CG; Nikolayevskyy, V; Noursadeghi, M; O'Sullivan, DM; Painter, W; Premkumar, L; Reece, ST; Sheahan, TP; Shuang, S; Szewczyk, LJ; Tayachew, D; Tegegn, M; Tirfie, EA; Tulu, B; Vordermeier, M; Wang, Q; Wang, X; Wohl, DA; Wolfe, CR; Won, JJ; Younis, S; Zewude, A1
Cui, X; Fang, F; Lee, CS; Lu, G; Shen, D; Tian, S; Wan, Y; Wang, H; Xiao, Y; Xiong, Y; Zhang, J1
Abdel-Wahab, O; Bradley, RK; Cho, H; Chow, A; Chowell, D; Cui, D; De Neef, E; Diaz, LA; Durham, BH; Elhanati, Y; Erickson, C; Gabel, AM; Ghosh, A; Gigoux, M; Greenbaum, B; Hogg, SJ; Jin, J; Knorr, DA; Liu, J; Lu, B; Lu, SX; Merghoub, T; Molina, H; Rhodes, MC; Rousseau, B; Sabio, E; Shah, H; Shen, Y; Singer, M; Taylor, RE; Thomas, JD; Wang, E; Wolchok, JD; Xie, A; Zamarin, D1
Apostolidi, M; Gassaway, BM; Gaule, P; Muthusamy, V; Rimm, DL; Rinehart, J; Vathiotis, IA1
Lee, BH; Lee, SB; Moon, S; Muniyappan, S1
Annweiler, C; Cao, Z; Kwok, HF; Li, X; Liu, W; Mu, C; Sabatier, JM; Sun, F; Wu, Y; Xie, Y; Xu, J1
Lin, Z; Liu, JY; Wang, S; Weng, XL; Yang, DC; Zhang, HX1
Cheung, SYA; Cullberg, M; Delff, P; Dota, C; Maroj, B; Parkinson, J; Rekić, D; Schiavon, G; Voronova, V1
Boss, MK; LaRue, SM; Leary, D; Martin, T; Prebble, AR; Thamm, DH; Weishaar, KM1
Ataklti, GY; Choi, J; Doan, VHM; Ly, CD; Mondal, S; Nguyen, VT; Oh, J; Park, S; Vo, TMT; Vu, DD1
Sebastian, J1
Abernethy, DR; Barnett-Griness, O; Gronich, N; Lavi, I; Rennert, G; Saliba, W1
Borkin, D; Chaudhary, A; DeCrescenzo, G; Degrado, S; Dimitrov, DS; Feng, Y; Hilton, MB; Jain, N; Keller, JR; Klarmann, KD; Li, J; Morris, H; Morris, K; Saha, S; Scheiermann, J; Seaman, S; Smith, SW; St Croix, B; Swing, DA; Szot, C; Tessarollo, L; Wang, Y; Welsch, D; Yang, MY; Zhang, XM; Zhu, Z; Zudaire, E1
Crawford, E; Curry, W; Gupton, JT; Harrison, A; Hoerrner, M; Huff, E; Juekun, W; Kellogg, GE; Kimmel, M; Lescalleet, K; Lounsbury, K; Mooberry, SL; Moore-Stoll, V; Obaidullah, AJ; Ortolani, J; Patteson, J; Rohena, CC; Shimozono, A; Sikorski, JA; Telang, N; Yeudall, S1
Goel, Y; Kumar, A; Pandey, SK; Singh, SM; Singh, VK; Yadav, S1
Ambrose, H; Bando, H; Banerji, U; Barrett, JC; Baselga, J; Bedard, PL; Berger, MF; Bouvier, N; Chandarlapaty, S; Chang, MT; Dean, EJ; Donoghue, MTA; Dougherty, B; El-Khoueiry, AB; Erinjeri, JP; Foxley, A; Hyman, DM; Lindemann, JPO; McEwen, R; Mita, A; Pass, M; Pérez-Fidalgo, JA; Reichel, JB; Schellens, JHM; Schiavon, G; Selcuklu, SD; Smyth, LM; Solit, DB; Soumerai, TE; Taylor, BS; Torrisi, J; Westin, SN1
Burger, DM; Desar, IME; Kweekel, DM; Lankheet, NAG; Mulder, SF; van der Graaf, WTA; van Erp, NP; van Herpen, CML1
Ai, X; Fu, L; Hao, P; Li, L; Wei, P; Zhang, J; Zhou, J1
Cook, SJ; Gilley, R; Sale, MJ; Stuart, K1
Aparna, HS; Atreya, HS; Harsha Raj, M; Rashmi, KC; Salimath, BP1
Higginbotham, ML; Hocker, SE; Wouda, RM1
Chang, K; Chen, H; Fang, X; Gao, D; Li, D; Men, X; Wu, C; Yin, S; Yuan, Z; Zhang, J; Zhang, X; Zhou, L1
Cai, Y; Chen, P; Dong, X; Liang, P; Si, W; Tang, Q; Zhang, Q1
Byun, S; Lee, E; Lee, KW1
Chen, J; Hu, Y; Li, X; Li, Y; Liu, H; Peng, Y; Sun, Y; Xu, J; Yin, G; Zhong, S1
Meng, L; Ren, Y; Shao, Y; Wang, D; Yu, D1
Darwish, M; Dela Cruz-Chuh, J; Flygare, JA; Gregson, SJ; Gunzner-Toste, J; Howard, PW; Kang, GD; Kozak, KR; Lau, J; Lewis Phillips, GD; Li, G; Masterson, LA; Ohri, R; Pillow, TH; Polson, A; Raab, H; Safina, BS; Spencer, SD; Wei, B; Yu, SF1
Kanatharana, P; Kangkamano, T; Limbut, W; Numnuam, A; Thavarungkul, P; Vilaivan, T1
Bharathiraja, S; Bui, NQ; Jang, B; Jung, WK; Kim, YM; Lee, KD; Manivasagan, P; Oh, J; Phan, TTV; Santha Moorthy, M1
Berger, EP; Fox, LE; Johannes, CM; Post, GS; Rothchild, G; Shiu, KB; Wetzel, S1
Cuccarese, MF; Kim, E; Kohler, RH; Miller, MA; Pittet, MJ; Plotkin, AL; Prytyskach, M; Weissleder, R1
Balkman, CE; Cawley, JR; Hume, KR; Rizzo, VL1
Cao, H; Gao, Y; Jiang, X; Liu, Y; Qu, Z; Sun, H1
Felten, A; Hahn, SJ; Klein, HF; Kleindl, PJ; Leamon, CP; Nelson, M; Nicoson, J; Parham, GL; Qi, L; Reddy, JA; Santhapuram, HK; Vaughn, JF; Vetzel, M; Vlahov, IR; Wang, K; You, F1
Abel Mahedi Mohamed, H; Nielsen, CEN; Schiodt, M1
Abdel-Mogib, M; Al-Mourabit, A; Atanasov, AG; Bishayee, A; El-Demerdash, A; Hooper, JNA1
Dragovich, PS; Hop, CECA; Khojasteh, SC; Kozak, KR; Ma, Y; Pillow, TH; Polson, AG; Sadowsky, JD; Su, D; Xu, K; Yu, SF; Zhang, D1
Abouzid, KAM; Adel, M; Lasheen, DS; Serya, RAT2
Cai, Y; Dong, X; Fan, L; Tang, Q; Wang, C; Wu, X; Zhang, Q1
Abrahmsen, LB; Green, JA; Von Euler, M1
Ao, L; Chen, J; Ding, Z; Fang, L; Li, H; Liu, K; Liu, X; Pan, Z; Shao, X; Su, W; Sun, H; Tan, Y; Wang, R; Wang, W; Wu, C; Zhang, J1
Bailey, C; Banerji, U; Casson, E; Cripps, D; Cullberg, M; Dean, E; Evans, S; Foxley, A; Jimenez, B; Krebs, MG; Lawrence, P; Lindemann, J; Rugman, P; Schellens, JHM; Taylor, N; Turner, G; van Brummelen, E; Yates, J1
Ge, D; Liu, X; Liu, Y; Shi, W; Su, H; Sun, Y1
Estilo, CL; Huryn, JM; Liang, STY; Owosho, AA; Sax, AZ; Wu, K; Yom, SK1
Chi, W; Ferber, G; Jackson, J; Janku, F; Li, BT; Mendzelevski, B; Sager, PT; Sullivan, RJ; Welsch, D; Weng, O1
Garofalo, A; Grande, F; Ioele, G; Occhiuzzi, MA; Ragno, G1
Inoue, T; Koshikawa, N; Lin, J; Matsuo, N; Mori, Y; Nagase, H; Ozaki, T; Shimozato, O; Shinozaki, Y; Takatori, A; Watanabe, T1
Almeida, RG; Baiju, TV; Brito, LM; Cavalcanti, BC; da Silva Júnior, EN; de Simone, CA; Namboothiri, INN; Pessoa, C; Sivanandan, ST1
Ayyanaar, S; Kesavan, MP; Kotla, NG; Kumar, GGV; Rajagopal, G; Rajesh, J; Sivaraman, G; Webster, TJ1
Blackwood, EM; Cousin, S; DuPree, K; Epler, J; Hamilton, E; Hollebecque, A; Infante, JR; Italiano, A; Lauchle, JO; LoRusso, PM; Lu, X; Mahrus, S; Moein, A; Moore, KN; Murray, ER; Peale, FV; Postel-Vinay, S; Schutzman, JL; Shapiro, GI; Soria, JC; Tagen, M; Tolaney, S; Toulmonde, M1
Chun, S; Hwang, TI; Joshi, MK; Kim, BS; Kim, CS; Maharjan, B; Oh, JM; Park, CH; Tiwari, AP1
Hu, X; Qin, H; Xing, D; Yan, H; Yang, J; Zhai, S1
Bakar-Ates, F; Karakas, B; Kilic-Kurt, Z; Kütük, Ö1
Grant, FM; Gyori, D; Hawkins, PT; Lim, EL; Okkenhaug, K; Roychoudhuri, R; Shuttleworth, SJ; Spensberger, D; Stephens, LR1
Balkman, CE; Hume, KR; Piscoya, SL1
Andrs, M; Gorecki, L; Havelek, R; Jun, D; Korabecny, J; Polednikova, M; Pospisilova, M; Rezacova, M; Seifrtova, M; Tichy, A; Vejrychova, K1
Chapeau, EA; Cortes-Cros, M; Durand, EY; Ferretti, S; Fuchs, J; Furet, P; Gaulis, S; Guerreiro, N; Halilovic, E; Hofmann, F; Holzer, P; Jeay, S; Jensen, MR; Jullion, A; Kallen, J; Kauffmann, A; Kerr, G; Kuriakose, E; Murakami, M; Romanet, V; Ruetz, S; Sellers, WR; Stachyra, TM; Sterker, D; Wartmann, M; Wiesmann, M; Würthner, J1
Berndt, S; Cancho-Grande, Y; Greven, S; Griebenow, N; Johannes, S; Lerchen, HG; Mahlert, C; Rebstock, AS; Sommer, A; Stelte-Ludwig, B; Terjung, C; Wittrock, S1
Pan, H; Sun, SK; Wang, X; Zhang, C1
Azad, N; Iyer, AKV; Kaushik, V; Way, LF; Yakisich, JS1
Fuss, H; Jung, S; Lademann, J1
Attanzio, A; Barraja, P; Carbone, A; Cascioferro, S; Cirrincione, G; Diana, P; Montalbano, A; Parrino, B; Spanò, V; Tesoriere, L; Ullo, S1
Bi, X; Huang, D; Huang, W; Qian, H; Qiang, H; Shi, W1
Biroccio, A; Ciriolo, MR; Del Bufalo, D; Di Leo, L; Iachettini, S; Leonetti, C; Lucidi, A; Mai, A; Rizzo, A; Rotili, D; Salvati, E; Steegborn, C; Trisciuoglio, D; Zizza, P1
Hawkins, CJ; Miles, MA1
Dybdal-Hargreaves, NF; Gangjee, A; Gentile, T; Hamel, E; Mooberry, SL; Pavana, RK; Risinger, AL; Shah, K1
Wang, S; Wu, C; Wu, H; Ye, C; Zhao, J; Zhou, C; Zhu, C; Zou, D1
Choi, YH; Jeon, MY; Kim, DE; Kim, S; Kim, SH; Kwon, TK; Lee, TJ; Min, KJ; Park, JW; Seo, SU; Woo, SM1
Dickinson, NJ; Harper, J; Howard, P; Mao, S; Masterson, L; Pechenov, S; RiosDoria, J; Subramony, JA; Tyagi, P; Wetzel, L; Yo, K1
Arkenau, HT; Bendell, JC; Chua, CC; Dukart, G; Harrow, K; Liang, C; Moore, KN; Patel, MR1
Dong, X; Huang, X; Shao, J; Sun, L; Tang, Y; Wu, C; Xiao, W1
Click, B; Regueiro, M1
Cil, O; Duan, T; Thiagarajah, JR; Verkman, AS1
Alewine, C; Antignani, A; FitzGerald, D; Gadina, M; Hewitt, SM; Simon, N1
Chen, CH; Liou, JP; Liu, YM; Yeh, TK1
Bender, S; Boemer, U; Collin, MP; Ellinghaus, P; Grünewald, S; Héroult, M; Hess-Stumpp, H; Ince, S; Kneip, C; Kopitz, C; Lustig, K; Mumberg, D; Politz, O; Thuss, U; Ziegelbauer, K; Zopf, D1
Chen, TW; Cheng, AL; Chiu, LL; Hsu, CH; Ishizuka, T; Lee, JH; Lin, CC; Oguma, T; Sasaki, SI; Sugihara, M; Tajima, N; Yang, JC; Yen, YH1
Chen, C; Kwok, K; Lee, EB; Liu, Y; Llamado, LJ; Luo, Y; Sugiyama, N; Tanaka, Y; Tsai, WC; Wang, L; Yamanaka, H; Yoo, HJ1
Cao, S; Du, R; Gao, R; Li, X; Wang, J; Wang, P; Wu, W; Xiang, R; Zhang, C; Zhu, H1
Bedford, E; Bedford, MT; Gao, G; He, W; Moh, P; Shen, J; Shi, X; Su, D; Villarreal, OD; Xu, H; Zhang, L1
Fujimura, S; Hirata, M; Kanai, Y; Ohmomo, Y; Sato, T; Temma, T; Yao, T; Yoshimoto, M1
Cohen, S; Curtis, JR; DeMasi, R; Kwok, K; Lazariciu, I; Lee, EB; Mojcik, C; Silverfield, J; Soma, K; Strengholt, S; Terry, K; Wang, L; Wollenhaupt, J1
Fujita, N; Hashimoto, A; Kazuno, H; Komiya, Y; Kumazaki, M; Mizutani, T; Muraoka, H; Nakagawa, F; Ochiiwa, H; Ohkubo, S; Suzuki, S; Takenaka, T; Tsuji, S; Yoshimura, C1
Adewole, KE; Ishola, AA1
Duan, W; Luo, C; Shao, J; Tao, H; Yan, X; Zhang, H; Zhu, K1
Funakoshi, T; Galsky, MD; Latif, A1
Barraja, P; Carbone, A; Cirrincione, G; Diana, P; Fiebig, HH; Kelter, G; Maier, A; Parrino, B; Spanò, V1
Adjei, AA; Belani, CP; Chow, LQ; Dy, GK; Fortin, C; Gupta, A; Jonker, DI; Laurie, SA; Nicholas, G; Park, JS; Patricia, D; Sbar, EI; Zhang, S1
Armand, JP; Bahleda, R; Baselga, J; Berman, D; Calvo, E; Felip, E; Hanna, N; Harbison, CT; Herbst, RS; Kurland, JF; Laurie, SA; Park, JS; Pathak, AK; Shepherd, FA; Soria, JC; Vakkalagadda, B; Zhang, S1
Chen, I; McDermott, DF; Michaelson, MD; Patyna, S; Ruiz-Garcia, A; Ryan, DP; Schwarzberg, AB; Shapiro, GI; Stephenson, P; Tye, L; Zhu, AX1
Hu, Y; Wu, P; Zhang, J1
Chen, H; Guo, Q; Guo, Z; Shen, Z; Yang, Y; Zhou, Z1
Arcari, JT; Beebe, JS; Berliner, MA; Bernardo, V; Boehm, M; Borzillo, GV; Chen, JM; Clark, T; Cohen, BD; Connell, RD; Frost, HN; Gordon, DA; Hungerford, WM; Kakar, SM; Kanter, A; Keene, NF; Knauth, EA; Lagreca, SD; Lu, Y; Martinez-Alsina, L; Marx, MA; Morris, J; Patel, NC; Savage, D; Soderstrom, CI; Thompson, C; Tkalcevic, G; Tom, NJ; Vajdos, FF; Valentine, JJ; Vincent, PW; Wessel, MD1
Deodhar, A1
Chen, D; Murugesan, S; Nadkarni, DH; Qin, JJ; Velu, SE; Wang, H; Wang, MH; Wang, W; Zhang, R1
Prado, CM1
Bitzer, M; Horger, M; Ioanoviciu, SD; Kopp, HG; Schulze, M; Spira, D; Wiesinger, B1
Cheng, L; Li, Y; Li, Z; Liang, C; Liu, Y; Liu, Z; Wang, C; Xu, H; Yang, G1
Blackwood, E; Cain, G; Choi, J; Epler, J; Evangelista, M; Flagella, M; Gazzard, L; Halladay, J; Jackson, PK; Jakubiak, D; Kowanetz, K; Malek, S; O'Brien, T; Ramiscal, J; Schmidt, S; Williams, K; Wong, K; Xiao, Y; Yee, S; Yen, I1
Chen, K; Li, JR; Li, X; Zhu, HL1
Ellegaard, AM; Groth-Pedersen, L; Jäättelä, M; Kirkegaard, T; Klumperman, J; Nylandsted, J; Oorschot, V1
Billard, C1
Kamaike, K; Kashiwagi, K; Kawashima, E; Nakanishi, Y; Ohba, Y; Terui, Y; Tomitori, H1
Blackwood, E; Del Nagro, C; Evangelista, M; Jackson, PK; Kowanetz, K; Malek, S; O'Brien, T; Ramiscal, J; Xiao, Y1
Chang, C; Chen, X; Jiang, H; Lou, D; Qin, Q; Wang, J; Zhang, W; Zhong, D; Zhou, A1
Bernabe, LF; Kisseberth, WC; London, CA; Nguyen, S; Pennell, M; Portela, R; Yancey, MF1
Berardi, R; Burattini, L; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Muzzonigro, G; Pantano, F; Santini, D; Santoni, M1
Bartholomew, P; Elwell, M; Radi, Z; Vogel, WM1
de Wit, D; den Hartigh, J; den Hollander, M; Gelderblom, H; Guchelaar, HJ; Hessing, T; König-Quartel, JM; Sparreboom, A; van Erp, NP1
Bekaii-Saab, T; Clinton, SK; Grever, MR; Kraut, EH; Martin, LK; Monk, P; Serna, D1
Aghebati-Maleki, L; Baradaran, B; Shahneh, FZ; Zamani, F1
Han, Y; Teng, B; Tian, Q; Wang, Q; Yang, S; Yao, KX; Zhang, J1
Beijnen, JH; Huitema, AD; Knapen, LM; Lankheet, NA; Schellens, JH; Steeghs, N1
Waldmann, TA1
Kasak, L; Kauts, ML; Loog, M; Neuman, T; Piirsoo, A; Piirsoo, M; Tints, K; Uusen, P1
Aboulafia, D; Cianfrocca, ME; Deeken, JF; Dezube, BJ; Dowlati, A; Gerecitano, J; Haigentz, M; Henry, DH; Ivy, SP; Little, RF; Mitsuyasu, RT; Moore, PC; Ratner, L; Rudek, MA; Sullivan, R1
Chen, H; Hou, W; Rojas, J; Sampath, P; Thorne, SH1
Cunnane, G; Durcan, L; Gleeson, N; McKiernan, S1
Faivre, S; Ishak, KJ; Korytowsky, B; Proskorovsky, I; Sandin, R; Valle, J1
Devasahayam, N; Krishna, MC; Lizak, MJ; Matsumoto, S; Matsuo, M; Merkle, H; Mitchell, JB; Morris, HD; Munasinghe, JP; Saito, K; Suburamanian, S; Takakusagi, Y; Yasukawa, K1
Cho, Y; Jeon, S; Kim, YH; Lee, ES; Moon, JM1
Guo, C; Li, J; Lin, M; Liu, K; Wang, L; Xu, T; Yang, B; Zhang, H; Zhang, X; Zhou, D1
de Vos, R; Koldenhof, JJ; Teunissen, SC; Tillier, CN; Verheul, HM; Walraven, M; Witteveen, PO1
Kurzman, ID; Pan, X; Tsimbas, K; Vail, DM1
Beijnen, JH; Cirkel, GA; de Jonge, MJ; Gadellaa-van Hooijdonk, CG; Haanen, JB; Huitema, AD; Kloth, JS; Lankheet, NA; Lolkema, MP; Mathijssen, RH; Schellens, JH; Sleijfer, S; Steeghs, N; Voest, EE1
Dai, Z; Jin, Y; Li, Y; Ma, X; Shi, L; Tian, J; Zha, Z1
Heng, DY; Imbulgoda, A; Kollmannsberger, C1
Chai, H; Deng, Y; Keller, WJ; Kinghorn, AD; Li, J; Naman, CB; Pan, L1
Borden, EC; Chen, H; Dowlati, A; Elson, P; Koon, H; Mittal, K; Rini, BI; Triozzi, P1
Breazna, A; Demetri, GD; Ewer, MS; Lenihan, DJ; Motzer, RJ; Niculescu, L; Suter, TM1
Abe, S; Higaki, K; Kimura, T; Ogawara, K; Un, K; Yoshizawa, Y1
Blacher, S; Calligaris, D; Cimino, J; De Pauw, E; De Tullio, P; Debois, D; Mari, B; Mazzucchelli, G; Noel, A; Paye, A; Primac, I; Sounni, NE; Truong, A1
Alfonsi, R; Bai, R; Bolognesi, A; Brancale, A; Coluccia, A; Di Marcotullio, L; Dondio, G; Famiglini, V; Gulino, A; Hamel, E; La Regina, G; Lavia, P; Mazzoccoli, C; Mercurio, C; Miele, A; Nalli, M; Novellino, E; Passacantilli, S; Pelliccia, S; Rensen, WM; Ruggieri, V; Silvestri, R; Sisinni, L; Varasi, M; Vultaggio, S1
Abdel-Rahman, O; Fouad, M1
Rameshthangam, P; Srinivasan, P; Sudha, A1
London, CA1
Cho, Y; Hong, WY; Jeon, SH; Lee, ES1
Chen, JX; Chen, WH; Dong, C; Lin, YL; Sun, B; Wang, B; Yang, JW; Zhou, CQ; Zhou, ZZ1
Arrowood, CA; Honeycutt, W; Howard, L; Hurwitz, HI; Latta, K; Meadows, KL; Niedzwiecki, D; Rushing, C1
Alexandre, J; Behouche, A; Blanchet, B; Boudou-Rouquette, P; Cessot, A; Coriat, R; Dauphin, A; Durand, JP; Goldwasser, F; Golmard, JL; Huillard, O; Loriot, MA; Narjoz, C; Taieb, F; Thomas-Schoemann, A; Tod, M; Vidal, M1
Attwood, K; Burns, P; Cruz-Munoz, WR; Ebos, JM; Hudson, JM; Jedeszko, C; Kerbel, RS; Lee, CR; Mastri, M; Tracz, A1
Biziato, D; De Palma, M1
Alwan, WS; Bangalore, PK; Karpoormath, R; Naphade, SS; Palkar, MB; Patel, HM; Rane, RA; Shaikh, MS1
Campbell, KH; Henderson, CJ; MacLeod, AK; McLaughlin, LA; McMahon, M; Wolf, CR1
Borad, MJ; Bowles, DW; Calvo, E; Curtis, KK; Eckhardt, SG; Faessel, H; Gangolli, E; Goldman, J; Hidalgo, M; Parikh, A; Partyka, J; Rosen, LS; Ryan, DP; Stewart, S; Wirth, LJ1
Lee, M; Patil, PC; Satam, V1
Cass, CE; Damaraju, VL; Kuzma, M; Mowles, D; Sawyer, MB1
Binkhorst, L; Burger, H; Chaves, I; de Bruijn, P; de Wit, AS; Hamberg, P; Kloth, JS; Lam, MH; Mathijssen, RH; van der Horst, GT; Wiemer, EA1
Chotenimitkhun, R; D'Agostino, R; Hamilton, CA; Herrington, DM; Hundley, WG; Jordan, JH; Lash, TL; Lawrence, JA; Vasu, S; Yeboah, J1
Kamal, A; Nekkanti, S; Sathish, M; Shankaraiah, N; Sreekanth, K; Srinivasulu, V1
Belal, A1
Berndsen, RH; Bonvin, D; Dyson, PJ; Griffioen, AW; Nowak-Sliwinska, P; Scherrer, E; Weiss, A; Wong, TJ1
Iqbal, Y; Malik, MF; Riaz, SK1
Awuah, SG; Bio, M; Cantu, R; D'Souza, F; Das, SK; Gobeze, HB; Nesterov, VN; Watley, RL; You, Y1
Amir, E; Ethier, JL; Krzyzanowska, MK; Ocana, A; Seruga, B; Srikanthan, A1
Attanzio, A; Barraja, P; Carbone, A; Ciancimino, C; Cirrincione, G; Di Vita, G; Diana, P; Livrea, MA; Montalbano, A; Parrino, B; Spanò, V; Tesoriere, L1
Benda, B; Curtis, JR; Geier, J; Kaplan, IV; Kwok, K; Lee, EB; Riese, R; Soma, K; Wang, L1
Briley, LP; du Bois, A; Johnson, T; Parham, LR; Russo, M; Song, K; Spraggs, CF; Tada, H; Xu, CF1
Chen, HM; Chen, SH; Coakley, BA; Divino, C; Eisenstein, S; Ferris, R; Gildener-Leapman, N; Kao, J; Ko, EC; Ma, G; Mandeli, J; Ozao, J; Pan, PY; Schwartz, M; Sung, M; Wang, LH1
Barnhart, TE; Cai, W; Chakravarty, R; Chen, F; Goel, S; Hernandez, R; Hong, H; Valdovinos, HF1
Abonia, R; Acosta, P; Butassi, E; Insuasty, B; Ortiz, A; Quiroga, J; Zacchino, SA1
Cherrington, JM; Laird, AD; Mendel, DB1
Abonante, S; Cafeo, G; De Francesco, EM; De Marco, P; Dolce, V; Felli, L; Kohnke, FH; Lappano, R; Maggiolini, M; Pisano, A; Ponassi, M; Rosano, C; Santolla, MF1
Baldetorp, B; Döme, B; Fehniger, TE; Gustavsson, L; Kim, Y; Kwon, HJ; Malm, J; Marko-Varga, G; Nishimura, T; Sugihara, Y; Török, S; Végvári, Á; Watanabe, K; Welinder, C1
Cohen, EE; Fleming, GF; Harris, PJ; Janisch, L; Karovic, S; Karrison, TG; Levine, MR; Maitland, ML; O'Donnell, PH; Polite, BN; Ratain, MJ1
Kleibeuker, EA; Slotman, BJ; Ten Hooven, MA; Thijssen, VL; Verheul, HM1
Gemma, A; Miyanaga, A1
Aliper, A; Borisov, N; Buzdin, A; Kholodenko, R; Malakhova, G; Roumiantsev, S; Shepelin, D; Suntsova, M; Vasilov, R; Venkova, L; Zhavoronkov, A1
Li, R1
Crafter, C; D'Cruz, CM; Davies, BR; Dudley, P; Guan, N; Hanson, L; Jacobs, V; Jacques, K; James, N; Jenkins, EL; Kodaira, M; Ladd, B; Lindemann, J; Logie, A; Tamura, K; Zinda, M1
Demko, N; Federico, CA; Fergusson, D; Hakala, A; Henderson, VC; Kimmelman, J; MacKinnon, N1
Chen, S; Chen, X; Dong, B; Huang, Q; Li, A; Li, Q; Liu, Y; Miao, J; Wang, Z; Yao, M; Zhang, N; Zhou, C1
Dervan, PB; Kang, JS1
Carlisle, B; Demko, N; Freeman, G; Hakala, A; Hey, S; Kimmelman, J; London, AJ; MacKinnon, N; Ramsay, T1
Gardner, EE; Rudin, CM1
Brunelli, C; Carbone, F; Di Iorio, C; Gigli, L; Montecucco, F; Nencioni, A; Rosa, GM; Tagliasacchi, MI1
Varvounis, G1
Benedetto, P; Flores, A; Kovacs, K; Kwon, D; Merchan, JR; Montero, AJ; Rocha-Lima, C; Trent, JC1
Gong, P; Luo, R; Tang, Q; Tu, Q; Tu, Y; Wang, L; Wang, P; Wu, C; Zheng, P; Zhu, W1
Eckstein, N; Frötschl, R; Haas, B; Weber-Lassalle, K1
Arita, S; Chen, L; Esaki, T; Hashimoto, J; Hirai, F; Kawata, T; Kodaira, M; Lindemann, J; Seto, T; Tamura, K; Tanabe, Y; Toyokawa, G; Yamamoto, H; Yonemori, K1
Bergman, PJ; Merrick, CH; Pierro, J; Regan, RC; Schleis, SE; Siedlecki, CT; Sones, EA; Wright, ZM1
Cai, Y; Dong, X; Huang, W; Si, W; Tang, Q; Wu, X; Zhang, Q1
Devine, L; Kelly, WK; Kluger, H; Lee, JJ; Li, J; Rink, L; Saif, MW1
Boison, D; Chen, QY; Gao, J; Lu, NN; Weng, ZY; Xiao, XX1
Cannell, PK; Harrison, SJ; Mainwaring, P; Millward, MJ; Padrik, P; Price, T; Reich, SD; Spencer, A; Trikha, M; Underhill, CR1
Biller, BJ; Kurzman, ID; Pellin, MA; Robinson, K; Tsimbas, K; Vail, DM; Wouda, RM1
Markovic, LE; Stein, TJ; Stepien, RL; Tjostheim, SS1
Baracos, VE; Bathe, OF; Cervo, L; Giavazzi, R; Lecker, SH; Martinelli, GB; Olivari, D; Ottoboni, L; Piccirillo, R; Re Cecconi, AD; Resovi, A; Stretch, C; Talamini, L1
Kłoczko, J; Ołdziej, AE; Romaniuk, W; Zińczuk, J1
Bawn, RH; Bisset, LC; Blackburn, TJ; Cano, C; Clegg, W; Cottyn, B; Golding, BT; Griffin, RJ; Hammonds, T; Hardcastle, IR; Harrington, RW; Leung, H; Molyneux, L; Myers, SM; Newell, DR; Rigoreau, L; Vidot, S; Wong, AC1
Del Rosario, G; Dragovich, PS; Erickson, HK; He, J; Hop, CE; Khojasteh, SC; Liu, L; Ma, Y; Pei, Z; Pillow, TH; Sadowsky, JD; Xu, K; Yu, SF; Zhang, D1
Anisfeld, A; Chen, C; Chen, Y; Curtis, JR; Geier, J; Krishnaswami, S; Strengholt, S; Zhang, R1
Flanagan, KJ; Gräfe, S; Gutsche, CS; Kulak, N; Ortwerth, M; Reissig, HU; Senge, MO; Wiehe, A1
Abe, M; Andersson, P; Cao, R; Cao, Y; Chen, F; Chen, X; Fischer, C; Hosaka, K; Iwamoto, H; Lim, S; Lu, Y; Nakamura, M; Nie, G; Seki, T; Skov, PV; Yang, Y; Zhang, Y1
Lan, L; Mao, ZM; Qi, Q; Wang, S; Wang, YL; Xin, YX; Zhan, XP; Zhao, K1
Gibson, KR; Harrigan, JA; Jacq, X; Knights, C; McLellan, L; Stockley, M; Tate, EW; Ward, JA; Whitlock, GA1
Benoit, G; Benoudiba, F; Brizard, M; Caillet, V; Corréas, JM; David, P; Deveaux, S; Elaidi, R; Gaudric, A; Hammel, P; Joly, D; Le Rest, C; Méjean, A; Oudard, S; Richard, S; Timsit, MO1
Conrado, D; Cook, J; Dikranian, A; Dowty, ME; Furst, DE; Hutmacher, MM; Krishnaswami, S; Lamba, M; Nduaka, C; Stock, T1
Cohen, SB; Sivaraman, P1
Abdel-Aziz, AK; Bornaghi, V; Bossi, D; Colecchia, M; Elgendy, M; Fazio, N; Giandomenico, V; Kanesvaran, R; Lanfrancone, L; Lozano, MD; Mercurio, C; Minucci, S; Nole, F; Pallavicini, I; Perez-Gracia, JL; Procopio, G; Renne, G; Renne, SL; Teh, BT; Toh, CK1
Wang, M; Wang, X; Xu, C; Xu, K; Yang, C1
Atyabi, F; Bahrainian, S; Dinarvand, R; Saber, MM1
Abd-El Hameed, RH; Fatahala, SS; Mohamed, MS; Youns, M1
Bonsignore, R; Gentile, C; Lauria, A; Martorana, A1
Charles-Schoeman, C; Cohen, SB; Curtis, JR; DeMasi, R; Geier, J; Kwok, K; Lee, EB; Mariette, X; Nash, P; Riese, R; Tanaka, Y; Thirunavukkarasu, K; Wang, L; Winthrop, KL; Wollenhaupt, J1
Antón-Aparicio, LM; Leon, LA1
Barraja, P; Carbone, A; Cascioferro, S; Cilibrasi, V; Cirrincione, G; Diana, P; Doria, F; Frasson, I; Freccero, M; Giallombardo, D; Montalbano, A; Parrino, B; Richter, SN; Salvador, A; Spanò, V1
Chen, J; Del Rosario, G; Fang, F; Flygare, JA; Go, MAT; Gregson, SJ; Gunzner-Toste, J; He, J; Howard, PW; Junutula, JR; Kamath, AV; Kozak, KK; Lau, J; Leipold, DD; Liu, L; Masterson, L; Ng, C; Ohri, R; Pillow, TH; Polakis, P; Polson, AG; Poon, KA; Sadowsky, J; Schutten, M; Solis, W; Spencer, S; Xu, K; Yee, S; Yu, SF; Zhang, D; Zhong, F1
Winthrop, KL1
Bharathiraja, S; Manivasagan, P; Oh, J; Oh, YO; Quang Bui, N; Santha Moorthy, M; Seo, H; Song, K; Yoon, M1
Brullo, C; Fallacara, AL; Grossi, G; Musumeci, F; Sanna, M; Schenone, S1
Buchbinder, R; Hossain, A; Lopez-Olivo, MA; Maxwell, LJ; Mudano, AS; Singh, JA; Suarez-Almazor, ME; Tanjong Ghogomu, E; Tugwell, P; Wells, GA1
Gomez-Reino, JJ; Maneiro, JR; Souto, A1
Alivon, M; Boutouyrie, P; De Lepper, AG; Delhaas, T; Giroux, J; Goldwasser, F; Reesink, KD; Spronck, B1
Alves, F; Schmuck, K; Schuberth, I; Schuster, HJ; Tietze, LF1
Xiao, H; Yang, CS1
Del Conte, G; Guibal, A; Rüegg, C; Sessa, C1
Abrams, MT; Breslin, MJ; Buser, CA; Coleman, PJ; Cox, CD; Davide, JP; Diehl, RE; Fernandez-Metzler, C; Fraley, ME; Garbaccio, RM; Hamilton, K; Hartman, GD; Huber, HE; Kohl, NE; Kuo, LC; Li, C; Lobell, RB; Mahan, E; Prueksaritanont, T; Schaber, MD; Slaughter, DE; South, VJ; Tao, W; Torrent, M; Walsh, ES; Whitman, DB; Yan, Y1
Marzo, I; Naval, J1
Azmi, AS; Mohammad, RM1
Alexandrescu, DT; Anderson, RT; Atkins, MB; Dutcher, JP; Garbe, C; Guitart, J; Hauschild, A; Kong, HH; Lacouture, ME; Puzanov, I; Robert, C; Wood, L; Wu, S1
Davis, P; Garfield, DH; Hercbergs, A; Schöffski, P; Wolter, P1
Lenihan, DJ1
Messori, A; Trippoli, S1
Alves, F; Krewer, B; Major, F; Müller, M; Schuberth, I; Schuster, HJ; Tietze, LF; von Hof, JM1
Iwata, C; Kano, MR; Kataoka, K; Komuta, Y; Miyazono, K; Morishita, Y; Oka, M; Ouchi, Y; Shirai, YT1
De Nanteuil, G; Gloanec, P; Golsteyn, RM; Hickman, J; Parmentier, JG; Pierré, A; Portevin, B1
Sun, W; Wang, GS; Xu, LB; Xu, Y; Yang, XH1
Sun, Y; Wang, C1
Krewer, B; Schuberth, I; Schuster, HJ; Tietze, LF1
Goldstein, MR; Mascitelli, L; Pezzetta, F3
Awada, AH; Hatoum, HA; Ishak, RS; Otrock, ZK; Shamseddine, AI1
Kang, MH; Reynolds, CP1
Chen, ZS; Dai, CL; Fu, LW; Liang, YJ; Tiwari, AK; Tong, XZ; Wang, F; Wang, YS; Yan, YY1
Bjarnason, GA; Christensen, JG; Cruz-Munoz, W; Ebos, JM; Kerbel, RS; Lee, CR1
Amantea, M; Bello, CL; Houk, BE; Kang, D1
Begent, RH; Clingen, PH; Cobb, M; Gumbrell, L; Hartley, JA; Hochhauser, D; Jodrell, D; Loadman, P; Meyer, T; Spanswick, VJ; Wu, J1
Dreyer, C; Faivre, S; Raymond, E1
Barnabei, A; Corsello, SM; Gasparini, G; Longo, R; Torino, F1
Benichou, AS; Billemont, B; Blanchet, B; Dauphin, A; Goldwasser, F; Ropert, S; Saboureau, C; Taieb, F; Tod, M1
Maitland, ML; Snider, KL1
Chen, MH1
Tsukamoto, S; Yokosawa, H1
Billemont, B; Kelly, RJ; Rixe, O1
Gan, HK; Knox, JJ; Seruga, B1
Shibuya, M1
English, BC; Figg, WD; Price, DK1
Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B1
Brower, V1
Cortés-Funes, H1
Cesaretti, JA; Chen, SH; Huang, D; Kao, J; Lo, YC; Packer, S; Schwartz, ME; Stock, RG; Sung, MW; Vu, HL1
Bil, J; Golab, J; Jakobisiak, M; Nowis, D; Zapala, L1
Letai, A; Ni Chonghaile, T1
Krewer, B; Tietze, LF1
Schiff, D; van den Bent, MJ; Wen, PY1
Ivy, SP; Kaufman, BM; Wick, JY1
Beatty, K; Bokar, J; Borden, E; Budd, GT; Bukowski, RM; Chen, HX; Cooney, MM; Dolwati, A; Dreicer, R; Elson, P; Garcia, JA; Ivy, P; Mekhail, T; Rini, BI; Triozzi, P; Tyler, A1
Grover, RK; Rao, PN1
Papaetis, GS; Syrigos, KN1
Baum, C; Bello, CL; Dinolfo, M; Huang, X; Levine, S; Mulay, M; Patyna, S; Rosen, L; Toh, M; Van Vugt, A1
Bello, CL; Demetri, GD; Houk, BE; Motzer, RJ; Poland, B; Rosen, LS1
Gu, Y; Meng, F; Qu, B; Shu, Y; Sun, Y; Xu, Q; Zhao, W; Zhu, X1
Butler, S; Campiani, G; Fayne, D; Lawler, M; Lloyd, DG; McGovern, NN; Meegan, MJ; Nathwani, SM; Sarkadi, B; Williams, DC; Zisterer, DM1
Wang, ZY1
Bayer, M; Berdel, WE; Kessler, T; Liersch, R; Mesters, RM; Schwöppe, C1
Chao, R; Harper, K; Huang, X; Ilagan, J; Liu, G; Robert, F; Sandler, A; Schiller, JH; Traynor, AM; Tye, L; Verkh, L1
De Greve, J; Decoster, L; Fontaine, C; Schallier, D; Trullemans, F1
Fan, J; Ge, F; Liao, XJ; Liu, QY; Pang, HD; Xiong, S; Xu, SH; Yang, XX1
Heng, DY; Kollmannsberger, C1
Bando, T; Kashiwazaki, G; Minoshima, M; Nishijima, S; Shinohara, K; Sugiyama, H1
Canipari, C; De Amici, M; Imarisio, I; Paglino, C; Porta, C; Quaglini, S; Sacchi, L1
Minor, DR1
Bose, D; Ellis, LM; Flaherty, KT; Hofstetter, W; Meric-Bernstam, F; Reardon, DA1
Chen, SH; Eisenstein, S; Fu, S; Kao, J; Ko, EC; Sikora, AG1
Dalhaug, A; Nieder, C1
Devarajan, P1
Figulla, HR; Hannig, M; Sauer, H; Wartenberg, M1
Bertolotti, M; Bosotti, R; Brasca, MG; Calogero, R; Ciomei, M; De Baere, T; Fiorentini, F; Galvani, A; Isacchi, A; Lazar, V; Locatelli, G; Mercurio, C; Pesenti, E; Scaburri, A; Scacheri, E; Soria, JC1
Bergqvist, S; Christensen, JG; Dagostino, E; Guo, C; Karlicek, S; Kephart, SE; Knighton, D; Kraynov, E; Lamerdin, J; Loi, CM; Marakovits, J; Martinez, R; Murray, BW; Piraino, J; Popoff, I; Smeal, T; Westwick, JK; Zager, M; Zhang, C1
Corinaldesi, R; Morselli-Labate, AM; Pezzilli, R1
Kelleher, FC; McDermott, R1
Pérez-Tomás, R; Viñas, M1
Lam, KS; Potts, BC1
Airoldi, M; Barone, C; Caponigro, F; Comis, S; Crippa, S; Fiorentini, F; Fornari, G; Jannuzzo, MG; Lorusso, D; MacArthur, R; Merlano, M; Petroccione, A; Schena, M; Weitman, S1
Ashwell, MA; Chen, CR; France, DS; Hill, J; Jeay, S; Leggett, DS; Li, CJ; Li, Y; Moussa, MM; Munshi, N1
den Hollander, M; Gelderblom, H; Hamberg, P; Loos, WJ; Sleijfer, S; Steeghs, N; Tascilar, M; van de Biessen, D; Verweij, J1
Baker, SD; Chen, Z; den Hartigh, J; den Hollander, M; Gelderblom, H; Guchelaar, HJ; König-Quartel, JM; Ploeger, BA; van Erp, NP; Zandvliet, AS1
Billemont, B; Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Massault, PP; Mir, O; Ropert, S; Vignaux, O1
Saijo, N1
Sato, Y1
Berger, MS; Deeken, JF; Hwang, JJ; Kuruvilla, J; Marshall, JL; Mendelson, D; Pishvaian, MJ; Siu, LL; Viallet, J1
Brandes, AA; Franceschi, E; Girardi, F1
Billaud, M; Viollet, B1
Cho, CH; Kim, TY; Park, JW; Shin, HW1
Chang, MH; Cherian, C; Desmoulin, SK; Fulterer, A; Gangjee, A; Hou, Z; Matherly, LH; Romero, MF; Stout, M; Wang, Y; Wu, J1
Eames, T; Staehler, M; Wollenberg, A1
Bouattour, M; Colichi, C; Delbaldo, C; Dreyer, C; Faivre, S; Raymond, E; Sablin, MP1
Chen, Z; Coffils, M; Fegan, C; Gregson, SJ; Hamaguchi, A; Hartley, JA; Hartley, JM; Howard, PW; Lin, TT; Martin, CR; Masterson, LA; Pepper, C; Suggitt, M; Thurston, DE; Tiberghien, AC1
Fischer, BS; Gan, J; Ganapathi, R; Gong, J; Iyer, R; Masson, E; Mekhail, T; Patricia, D; Pursley, J; Williams, D1
Camacho, JR; Martínez, R; Osornio, YM; Ramírez-Apan, MT; Reyes-Gutiérrez, PE1
Vollmar, AM; von Schwarzenberg, K1
Arioka, H; Murakami, H; Shimoyama, T; Tamura, T; Ueda, Y; Yamada, Y; Yamamoto, N2
Belcastro, V; Bosotti, R; Brunetti-Pierri, N; di Bernardo, D; Ferriero, R; Iorio, F; Isacchi, A; Mithbaokar, P; Murino, L; Scacheri, E; Tagliaferri, R1
Agostino, NM; Chinchilli, VM; Drabick, JJ; Gingrich, R; Koszyk-Szewczyk, A; Lynch, CJ; Sivik, J1
Al-Tel, TH1
Ezell, SJ; Gurpinar, E; Li, H; Rayburn, ER; Sommers, CI; Velu, SE; Wang, W; Xu, H; Yang, X; Zhang, R; Zhang, X1
Armand, JP; Boven, E; Brega, NM; Countouriotis, AM; Hartog, V; Massard, C; Ruiz-Garcia, A; Soria, JC; Tillier, C1
Andrews, DW; Geng, F; Kale, J; Leber, B1
Bello, A; Burris, HA; Chao, R; Chiorean, EG; Jones, S; Lee, FC; Liau, KF; Royce, M; Sweeney, CJ; Tye, L; Verschraegen, CF1
Gulder, TA; Moore, BS1
Ardini, E; Galvani, A; Magnaghi, P; Menichincheri, M; Orsini, P1
Fumita, S; Hashimoto, J; Ichikawa, Y; Kimura, N; Miyazaki, M; Nakagawa, K; Ohki, E; Okamoto, I; Shimizu, T; Takeda, M; Terashima, M; Tsurutani, J1
Schmidt, C1
Chacko, AD; Crawford, N; Fennell, DA; Longley, DB; McCoy, F; Redmond, K; Savage, KI1
Dempke, WC; Zippel, R1
Bertolini, F; Braidotti, P; Calleri, A; Mancuso, P; Marighetti, P; Martin-Padura, I; Quarna, J; Rabascio, C1
Villabona, C1
Campiani, G; Forde, JC; Hollywood, D; Lawler, M; Lynch, TH; Maginn, EN; Marignol, L; Martin, LM; McElligott, AM; McNamara, G; Williams, DC; Zisterer, D1
Blumenschein, GR; Chao, RC; Cohen, RB; Heath, EI; Kim, ST; Loconte, NK; Lorusso, PM; Ruiz-Garcia, A; Wilding, G1
Chu, DT1
Aono, Y; Nishioka, Y; Sone, S1
Chen, P; Fink, BE; Gavai, AV; Goyal, B; Kim, SH; Lee, FY; Mastalerz, H; Norris, D; Oppenheimer, S; Tokarski, JS; Vite, GD; Wong, TW; Zhang, H; Zhao, Y1
Aherne, W; Caldwell, JJ; Collins, I; de Haven Brandon, A; Eccles, SA; Eve, PD; Garrett, MD; Heaton, SP; Henley, A; Hunter, LJ; Pickard, L; Raynaud, FI; Ruddle, R; Thompson, NT; Valenti, M; Vijayaraghavan, G; Walton, MI; Workman, P; Yap, TA1
Boulton, ME; Cai, J; Han, S; Law, B; Liao, D; Qing, R1
Bahleda, R; Chaput, N; Conforti, R; Flament, C; Gdoura, A; Kroemer, G; Litvinova, E; Soria, JC; Soumelis, V; Viaud, S; Zitvogel, L; Zoubir, M1
Cox, CD; Garbaccio, RM1
Greten, TF; Korangy, F; Manns, MP1
Albitar, MX; Anderson, KC; Baritaki, S; Berkers, C; Bonavida, B; Chandra, J; Chauhan, D; Cusack, JC; Fenical, W; Ghobrial, IM; Groll, M; Jensen, PR; Lam, KS; Lloyd, GK; McBride, W; McConkey, DJ; Miller, CP; Neuteboom, ST; Oki, Y; Ovaa, H; Pajonk, F; Palladino, MA; Potts, BC; Richardson, PG; Roccaro, AM; Sloss, CM; Spear, MA; Valashi, E; Younes, A1
Berlin, JD; Calcutt, MW; Chen, AP; Hachey, DL; Hartley, JA; Lee, W; Liao, CY; Puzanov, I; Rothenberg, ML; Spanswick, VJ; Vermeulen, WL1
Anthoney, DA; Armand, JP; Balheda, R; Kroemer, G; Laffranchi, B; Massard, C; Pacciarini, MA; Pellizzoni, C; Proctor, A; Scaburri, A; Soria, JC; Twelves, CJ1
Diaz-Padilla, I; Siu, LL1
Agrawal, N; Chen, C; DiPaola, R; Holen, K; Hsu, K; Liu, G; Rosenberg, E; Stein, M; Tan, AR; Wilding, G; Xue, L1
Cohen, EE; Fleming, GF; Gangadhar, TC; Geary, D; House, LK; Janisch, L; Kocherginsky, M; Maitland, ML; Ramirez, J; Ratain, MJ; Undevia, SD; Wu, K1
Emanuel, S; Fairchild, C; Fargnoli, J; Fink, B; Gavai, A; Hammell, A; Henley, B; Hilt, C; Hunt, JT; Krishnan, B; Kukral, D; Lee, FY; Lewin, A; Malone, H; Norris, D; Oppenheimer, S; Vite, G; Wong, TW; Yu, C1
Geoerger, B; Leblond, P1
Kay, LE; Ruschak, AM; Schimmer, AD; Slassi, M1
Chang, TT; Chen, TJ; Hsu, JC; Jen, YC; Li, WS; Lu, CK; Lu, IH; More, SV1
Adamson, PC; Ahern, CH; Baruchel, S; Blaney, SM; Dubois, SG; Glade-Bender, J; Grier, HE; Ingle, AM; Ivy, P; Reid, JM; Shusterman, S; Wu, B1
Bag, I; Juvekar, A; Kamal, A; Kumar, GB; Pal-Bhadra, M; Pushpavalli, SN; Ramaiah, MJ; Reddy, MK; Reddy, VS; Sen, S; Srikanth, YV; Zingde, SM1
Choi, Y; Kim, DE; Lee, DK; Park, JE; Schellingerhout, D; Shon, SM1
Li, Z; Lin, S; Wang, X; Wei, Y; Yang, H; Zhao, C; Zhao, Y1
Clark, BR; Fox, D; Leroy, J; Murphy, CD; O'Connor, S1
Budak, K; Pestalozzi, B; Weisshaupt, Ch1
Hollyfield, JG; Hong, L; Salomon, RG1
Assaraf, YG; Beerepoot, LV; Broxterman, HJ; de Haas, RR; Dekker, H; Gotink, KJ; Griffioen, AW; Honeywell, RJ; Jansen, G; Labots, M; Musters, RJ; Peters, GJ; Pili, R; Rudek, MA; Verheul, HM1
Bjørkøy, G; Fuglseth, E; Hoff, BH; Kaspersen, SJ; Kjøbli, E; Sundby, E; Sørum, C; Willassen, V1
Carmichael, L; Chao, B; Eickhoff, J; Harrison, M; Ivy, P; Jeraj, R; Kolesar, J; Liu, G; Marnocha, R; Perlman, S; Simoncic, U; Vanderhoek, M; Wilding, G1
Aparicio, LM; Gallego, GA; Pulido, EG1
Amiri-Kordestani, L; Bates, SE; Fojo, T1
Ghalali, A; Högberg, J; Stenius, U; Ye, ZW1
Reed, MW; Young, RJ1
Armes, SP; Au, KM; Lu, Z; Matcher, SJ1
Adamson, PC; Ahern, CH; Baruchel, S; Blaney, SM; DuBois, SG; Glade-Bender, J; Ingle, AM; Ivy, P; Reid, JM; Shusterman, S1
Chon, E; Kubicek, LN; McCartan, L; Vail, DM1
Alvarez, F; Beaver, L; Bryan, J; Carreras, J; Clifford, C; Ettinger, S; Fulton, L; Gauthier, M; Gill, V; Gillings, S; Haney, S; Henry, C; Hershey, B; Higginbotham, ML; Hillman, L; Jones, P; Kiselow, M; Klein, MK; Krick, E; Ladue, T; London, C; Mathie, T; McNeill, C; Novasad, A; Phillips, B; Stingle, N; Thamm, D; Vail, DM; Vaughan, A; Vickery, K1
Deeken, JF; He, P; Rais, R; Rudek, MA; Xu, L; Zhao, M1
Choueiri, TK; Je, Y; Richards, CJ; Schutz, FA1
Bareford, MD; Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Poklepovic, A1
Gangjee, A; Ihnat, MA; Raghavan, S; Thorpe, JE; Yang, J; Zaware, N1
Döme, B; Török, S1
Basaga, H; Bodur, C1
Conley, SJ; Wicha, MS1
Telli, M; Witteles, RM1
Hartley, JA; Hochhauser, D1
Budha, N; Buonarati, MH; Dean, B; Hop, CE; Jones, SA; Murakami, SC; Shin, YG; Ware, J; Wong, H1
Camidge, DR; Chan, E; Chow Maneval, E; Diab, S; Eckhardt, SG; Khosravan, R; Leong, S; Lin, X; Lockhart, AC; Messersmith, WA; Spratlin, J1
Davids, MS; Letai, A1
Cesaretti, JA; Chen, SH; Forsythe, K; Galsky, M; Genden, EM; Kao, J; Ko, EC; Lau, KH; Ozao-Choy, J; Packer, SH; Schwartz, M; Stock, RG; Sung, MW; Tong, CC1
Cao, J; Fan, L; Gao, Y; Liu, XF; Lu, XC; Yang, HY1
Davies, TG; de Haven Brandon, AK; Eccles, SA; Eve, PD; Feltell, RE; Garrett, MD; Grimshaw, KM; Heaton, SP; Heinzmann, K; Jones, PS; Lyons, JF; Martins, V; Raynaud, FI; Reule, M; Te Poele, RH; Thompson, NT; Valenti, MR; Walton, MI; Woodhead, SJ; Workman, P; Yap, TA; Zetterlund, A1
Chang, X; Liu, Y; Shen, X; Song, T; Zhang, Z1
Chen, M; Fang, X; Tang, S; Zheng, N1
Airley, R1
Bokar, JA; Brell, JM; Cooney, MM; Dowlati, A; Gibbons, J; Ivy, P; Krishnamurthi, SS; Meropol, NJ; Rath, L; Savvides, P1
Goto, Y; Hirata, T; Ikeda, Y; Nokihara, H; Tamura, T; Tanioka, M; Yamada, K; Yamada, Y; Yamamoto, N1
Argyle, DJ; Bavcar, S1
Cheng, L; Liu, Z; Sun, C; Wang, J; Xu, H; Yang, K1
Balakrishnar, B; Clements, A; Gao, B; Gurney, H; Wong, M; Yeap, S1
Krzemieniecki, K; Sowa-Staszczak, A; Zygulska, AL1
Bottai, G; Santarpia, L1
Erdem, L; Giovannetti, E; Honeywell, R; Leon, LG; Peters, GJ1
Bradley, JM; Cohen, PA; Dominguez, AL; Finke, JH; Gendler, SJ; Gorman, JE; Ko, JS; McCurry, DB; Pathangey, LB; Rayman, PA; Rini, BI; Spencer, CD; Storkus, WJ; Zorro-Manrique, S1
Chen, X; Diao, X; Gao, Z; Guo, Z; Jiang, H; Xie, C; Zhang, L; Zhong, D; Zhou, J1
Hensley, JR; Kulik, L; Lacouture, ME; Mulcahy, M; Nardone, B; Rademaker, A; West, DP1
Chang, X; Feng, Y; Li, X; Liang, X; Song, T; Su, P; Wu, G; Wu, Z; Xie, S; Zhang, Z; Zhao, Y1
Funakoshi, T; Shimada, YJ1
Asahi, S; Kogame, A; Kondo, T; Miyamoto, M; Prakash, S; Shibata, S; Shyu, WC; Tagawa, Y; Tohyama, K; Tojo, H1
Akintayo, A; Chen, Z; El-Rayes, B; Fanucchi, MP; Harvey, RD; Kauh, JS; Khuri, FR; Lewis, CM; Nadella, P; Owonikoko, TK; Ramalingam, SS; Rogatko, A; Shin, DM; Tighiouart, M1
Rose, S1
Cropp, G; Gosalia, R; Hannah, A; Sheldon, M; Stopeck, A; Vahedian, M1
Garber, K2
Curran, WJ1
Rosen, LS1
Barraja, P; Beall, HD; Bunderson, M; Moody, CJ; Newsome, JJ; Swann, E; Tooke, JE; Whatmore, JL1
Alileche, A1
Bailly, C; Lansiaux, A1
Traxler, P1
Kumar, R; Lown, JW1
Ravnskov, U1
Grünwald, V; Hidalgo, M1
Boucher, J; Cherrington, JM; Chien, MB; Downing, S; Hannah, AL; Kollias-Baker, C; London, CA; McMahon, G; Mendel, DB; Post, G; Rosenberg, M; Shenoy, N; Zadovoskaya, R1
Ledbetter, S; Pratt, BM; Teicher, BA; Walter-Yohrling, J1
Antonellini, A; De Jonge, MJ; Fiorentini, F; Fowst, C; Hartman, CM; Mantel, M; Planting, AS; Sparreboom, A; Stoter, G; Ten Tije, AJ; Tursi, J; Van Der Gaast, A; Verweij, J1
Bekele, BN; Bucana, CD; Doan, DD; Fidler, IJ; Greenberg, JS; Holsinger, FC; Jasser, SA; Myers, JN; Schiff, BA; Swan, EA; Younes, MN1
Kuenen, BC1
CAMPBELL, GW; DULANEY, EL; GITTERMAN, CO; HENDLIN, D; KACZKA, EA; WOODRUFF, HB1
MCAFEE, J; RUBENFELD, S; WINKELMAN, J1
MARKLE, V; PAZDER, LH; TAYLOR, JD1
Blake, RA; Chan, J; Harris, D; Howlett, AR; Kiewlich, D; Le, P; Liang, C; Lipson, KE; McMahon, G; Miller, T; Patel, N; Rice, A; Sun, L; Vasile, S; Wang, X1
Shiotsu, Y1
Erber, R; Groth, G; Hammes, HP; Katsen, AD; Kerger, H; Menger, MD; Thurnher, A; Ullrich, A; Vajkoczy, P1
Abdollahi, A; Bischof, M; Debus, J; Grone, HJ; Hahnfeldt, P; Han, X; Hlatky, L; Huber, PE; Klenke, F; Krix, M; Lipson, KE; Poerschke, D; Roth, A; Sckell, A; Zieher, H1
Berlin, JD; Campbell, A; Fiorentini, F; Fontana, E; Fowst, C; Hande, KR; Howard, M; Lankford, O; Lockhart, AC; Paty, VA; Roth, BJ; Rothenberg, ML; Vreeland, F1
Bando, T; Iwai, A; Kihara, K; Narita, A; Sugiyama, H1
Akiyama, M; Anderson, KC; Chauhan, D; García-Echeverría, C; Hideshima, T; Hofmann, F; Joseph, M; Kung, AL; Libermann, TA; McMullan, CJ; Mitsiades, CS; Mitsiades, NS; Pearson, MA; Poulaki, V; Shringarpure, R1
Broggini, M; Fontana, E; Fowst, C; Geroni, C; Marchini, S; Moneta, D1
Broxterman, HJ; Georgopapadakou, NH1
Dellian, M; Eichhorn, ME; Strieth, S1
Bailly, C1
Abbruzzese, JL; Charnsangavej, CA; Davis, D; Faria, SC; Herbst, R; Hess, K; Hicks, M; Jackson, EF; Madden, T; McConkey, D; Scholz, C; Xiong, HQ1
Abdollahi, A; Bischof, M; Debus, JU; Gong, P; Huber, PE; Lipson, KE; Stoffregen, C; Weber, KJ1
Bajgar, R; Huf, M; Kolárová, H; Macecek, J; Mosinger, J; Nevrelová, P; Strnad, M; Tomecka, M; Tomek, P1
Atteridge, CE; Biggs, WH; Carter, TA; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Grotzfeld, RM; Herrgard, S; Insko, DE; Lockhart, DJ; Mehta, SA; Milanov, ZV; Pao, W; Patel, HK; Sawyers, CL; Shah, NP; Treiber, DK; Varmus, H; Velasco, AM; Wodicka, LM; Zarrinkar, PP1
Rabindran, SK1
Giaccone, G; Hoekman, K; Kok, A; Kuenen, BC; Pinedo, HM; Ruijter, R; Schalkwijk, C1
Bucana, C; de Heus, G; Dumez, H; Eskens, FA; Fidler, IJ; Hoekstra, R; Planting, AS; Ravera, C; Sizer, KC; Vaidyanathan, S; van der Gaast, A; van Oosterom, AT; Verweij, J1
Aherne, W; Hannah, A; Hardcastle, A; Hayes, C; Judson, I; Kakkar, AJ; Leach, M; O'Donnell, A; Padhani, A; Phillips, S; Raynaud, F; Scurr, M; Trigo, JM; Workman, P1
Ambrus, K; Herrmann, R; Pless, M; Rochlitz, C; Salzberg, M; Scigalla, P1
Shore, GC; Viallet, J1
Stadler, WM1
Armand, JP; Bello, C; Brega, N; Delbaldo, C; Deprimo, S; Faivre, S; Lassau, N; Lozahic, S; Massimini, G; Raymond, E; Robert, C; Scigalla, P; Vera, K1
Veryard, C1
Fu, A; Hallahan, DE; Huamani, J; Kim, DW1
Gianni, L; Grasselli, G; Ielmini, N; Lladò, A; Locatelli, A; Marimon, I; Marsoni, S; Sessa, C; Trigo, J; Viganò, L1
Bando, T; Minoshima, M; Sakakibara, Y; Sasaki, S; Shinohara, K; Sugiyama, H1
Bello, CL; Christensen, JG; Hoosen, S; Motzer, RJ1
Gasparini, G; Longo, R; Sarmiento, R1
Cabebe, E; Wakelee, H1
Major, F; Schuberth, I; Tietze, LF1
Bando, T; Minoshima, M; Sasaki, S; Shimizu, T; Shinohara, K; Sugiyama, H; Takaoka, T1
Curtiss, FR1
Bernasconi, P; Calatroni, S; Crosetto, N; Dikic, I1
Mascitelli, L; Pezzetta, F1
Bae, Y; Fujii, T; Hirakawa, K; Iwata, C; Kaminishi, M; Kano, MR; Kataoka, K; Kiyono, K; Komuro, A; Miyazono, K; Morishita, Y; Nishiyama, N; Oka, M; Ouchi, Y; Yashiro, M1
Chow, LQ; Eckhardt, SG1
Heldin, CH; Ostman, A1
Force, T; Krause, DS; Van Etten, RA1
Angele, MK; Bruns, CJ; Eichhorn, ME; Jauch, KW; Kleespies, A1
Senan, S; Smit, EF1
Blay, JY1
Baum, C; Bello, CL; Britten, CD; Hecht, JR; Kabbinavar, F; Li, J; Slamon, D1
Kamba, T; McDonald, DM1
Di Lorenzo, L1
Chang, M; Chen, P; Fink, BE; Gavai, A; Han, WC; Johnson, W; Langley, D; Leavitt, K; Lee, FY; Marathe, P; Mastalerz, H; Norris, D; Oppenheimer, S; Sleczka, B; Tarrant, J; Tokarski, JS; Vite, GD; Vyas, DM; Wong, H; Wong, TW; Zhang, G; Zhang, H1
Kibble, A; Shumoogam, J1
Demetri, G; Faivre, S; Raymond, E; Sargent, W1
George, D; Verweij, J1
Bello, C; DePrimo, SE1
Christensen, JG1
Armand, JP; Mir, O; Ropert, S1
Rini, BI1
Alba, E; Medina, MA; Quesada, AR1
Christensen, JG; Ebos, JM; Kerbel, RS; Lee, CR; Mutsaers, AJ1
Davis, P; Garfield, D; Hercbergs, A1
Faivre, S; Le Tourneau, C; Raymond, E1
Campiani, G; Greene, LM; Lawler, M; Williams, DC; Zisterer, DM1
Auperin, A; Bourhis, J; Deutsch, E; Frascogna, V; Lecluse, Y; Tao, Y; Zhang, P1
Han, EK; McGonigal, T1
Joensuu, H1
Andraos, R; Cheong, R; Feinberg, AP; Iacobuzio-Donahue, CA; Kaneda, A; Ko, MS; Levchenko, A; Longo, DL; Ohlsson, R; Onyango, P; Pearson, MA; Sharov, AA; Timp, W; Wang, CJ; Wen, B1
Devaiah, V; Juvekar, A; Kamal, A; Kurian, N; Laxma Reddy, K; Sen, S; Shankaraiah, N; Zingde, S1
Goldstein, MR1
Giordano, S; Petrelli, A1
Abdollahi, A; Debus, J; Hauser, K; Huber, PE; Lipson, KE; Roth, A; Timke, C; Weber, KJ; Zieher, H1
Bickford, C; Champion, JC; Durand, JB; Halushka, M; Kassiotis, CM; Khakoo, AY; Lenihan, DJ; Plana, JC; Tannir, N; Trent, J1
Baritaki, S; Berenson, J; Bonavida, B; Daniels, TR; Jazirehi, AR; Palladino, M; Penichet, ML; Spandidos, DA; Suzuki, E; Umezawa, K1
Kapoor, S1
Anderson, WK1
Newmark, HL2
Heidrich, G; Houde, RW; Kaiko, RF; Rogers, A; Wallenstein, SL1
Stambaugh, JE; Tejada, F; Trudnowski, RJ1
Judd, KP; Reif, AE; Southwick, PL1
Gust, D; Jori, G; Moore, AL; Moore, TA; Reddi, E1
Becker, M; Buchdunger, E; Cozens, RM; Daniels, D; Lydon, NB; Mett, H; Mueller, M; Stover, D; Traxler, P1
Stephenson, J1
Kuwano, M; Ono, M1
Dimitroulakos, J; Minden, MD; Penn, LZ; Tan, MM; Wong, WW; Xia, Z1
Berger, NA; Berger, SJ; Dowlati, A; Gerson, SL; Haaga, J; Liu, L; Remick, SC; Spiro, TP; Willson, JK1
Fabbro, D; Manley, PW1
Cropp, GF; Giaccone, G; Hoekman, K; Huisman, H; Kedde, MA; Kuenen, BC; Levi, M; Noordhuis, P; Parson, MR; Peters, GJ; Pinedo, HM; Rosen, L; Ruijter, R; Scigalla, P; Smit, EF; van der Vijgh, WJ1
Blanke, CD; Corless, CL; Druker, BJ; Heinrich, MC1
Almerico, AM; Barraja, P; Cirrincione, G; Dattolo, G; Diana, P; Lauria, A; Montalbano, A1
Boger, DL; Coleman, RS; Invergo, BJ; Kitos, PA; Leong, T; McLaughlin, LW; Thompson, SC; Zarrinmayeh, H1
Phang, JM1
Animati, F; Arcamone, FM; Barbieri, B; Configliacchi, E; D'Alessio, R; Geroni, C; Giuliani, FC; Lazzari, E; Menozzi, M; Mongelli, N1
Lalezari, I; Schwartz, EL1
Hori, T; Murata, M; Takahashi, E1
Hori, T; Ishihara, T; Kaneko, Y; Minamihisamatsu, M; Murata, M; Takahashi, E1
Halbrecht, I; Hart, J; Klar, D; Shabtai, F1
Capretti, G; Frigerio, G1
Sporn, MB1
Chandra, P; Gericke, D; Thorbeck, R; Zunino, F1
Corrado, L; Felsenfeld, H; Kubilus, J1

Reviews

153 review(s) available for pyrroles and Neoplasms

ArticleYear
Immunogenic Cell Death Induction by Ionizing Radiation.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Alarmins; Animals; Antigens, Neoplasm; Biomarkers; Combined Modality Therapy; Cytokines; Dose-Response Relationship, Radiation; Ferroptosis; HMGB1 Protein; Humans; Hyperthermia, Induced; Immunogenic Cell Death; Mice; Morpholines; Necroptosis; Neoplasms; Piperazines; Pyrroles; Radiation Tolerance; Radiation, Ionizing

2021
Recent Advances of Diketopyrrolopyrrole Derivatives in Cancer Therapy and Imaging Applications.
    Molecules (Basel, Switzerland), 2023, May-15, Volume: 28, Issue:10

    Topics: Humans; Ketones; Nanoparticles; Neoplasms; Photochemotherapy; Phototherapy; Pyrroles

2023
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
    Science & sports, 2023, Apr-04

    Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide

2023
Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy.
    Expert opinion on biological therapy, 2021, Volume: 21, Issue:7

    Topics: Antineoplastic Agents; Benzodiazepines; Cell Line, Tumor; DNA; Humans; Immunoconjugates; Neoplasms; Pyrroles

2021
Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows.
    Molecular cancer therapeutics, 2020, Volume: 19, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Double-Blind Method; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; G1 Phase Cell Cycle Checkpoints; Humans; Immunotherapy; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Neoplastic Stem Cells; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic

2020
Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics.
    Expert opinion on investigational drugs, 2020, Volume: 29, Issue:12

    Topics: Animals; Antineoplastic Agents; Fibroblast Growth Factors; Humans; Molecular Targeted Therapy; Morpholines; Neoplasms; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptors, Fibroblast Growth Factor

2020
Polymeric immunosensors for tumor detection.
    Biomedical physics & engineering express, 2020, 05-06, Volume: 6, Issue:3

    Topics: Aniline Compounds; Biomarkers, Tumor; Biosensing Techniques; Electrochemical Techniques; Electrochemistry; Enzyme-Linked Immunosorbent Assay; Humans; Immunoassay; Ligands; Magnetics; Mutation; Neoplasms; Point-of-Care Systems; Polyhydroxyethyl Methacrylate; Polymers; Pyrroles; Surface Plasmon Resonance; Thermometry

2020
Application of DNA-Alkylating Pyrrole-Imidazole Polyamides for Cancer Treatment.
    Chembiochem : a European journal of chemical biology, 2021, 05-04, Volume: 22, Issue:9

    Topics: Animals; Antineoplastic Agents, Alkylating; DNA; Humans; Imidazoles; Neoplasms; Nylons; Proto-Oncogene Proteins p21(ras); Pyrroles; Telomere

2021
Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors.
    European journal of drug metabolism and pharmacokinetics, 2021, Volume: 46, Issue:3

    Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Infant; Male; Models, Biological; Neoplasms; Pyrroles; Sunitinib; Young Adult

2021
Small-Molecule Inhibitors Targeting Proteasome-Associated Deubiquitinases.
    International journal of molecular sciences, 2021, Jun-09, Volume: 22, Issue:12

    Topics: Enzyme Inhibitors; Humans; Neoplasm Proteins; Neoplasms; Proteasome Endopeptidase Complex; Proteolysis; Pyrroles; Pyrrolidines; Ubiquitin Thiolesterase

2021
Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling.
    The FEBS journal, 2017, Volume: 284, Issue:24

    Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bridged Bicyclo Compounds, Heterocyclic; Drug Screening Assays, Antitumor; Humans; Indoles; MAP Kinase Signaling System; Mitochondrial Dynamics; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Oncogene Addiction; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Sulfonamides

2017
Therapeutic Implications of Autophagy Inducers in Immunological Disorders, Infection, and Cancer.
    International journal of molecular sciences, 2017, Sep-12, Volume: 18, Issue:9

    Topics: Adaptive Immunity; Animals; Autoimmune Diseases; Autophagy; Benzylisoquinolines; Cholecalciferol; Humans; Immune System Diseases; Immunity, Innate; Indoles; Infections; Isoquinolines; Lysosomes; Maprotiline; Metformin; Neoplasms; Phenols; Pyrroles; Resveratrol; Sirolimus; Spermidine; Stilbenes; Tetrahydroisoquinolines; Trehalose

2017
Batzella, Crambe and Monanchora: Highly Prolific Marine Sponge Genera Yielding Compounds with Potential Applications for Cancer and Other Therapeutic Areas.
    Nutrients, 2018, Jan-02, Volume: 10, Issue:1

    Topics: Alkaloids; Animals; Antineoplastic Agents; Crambe Sponge; Guanidines; Humans; Molecular Mimicry; Molecular Structure; Neoplasms; Porifera; Pyrroles; Quinolines; Structure-Activity Relationship

2018
Pyrrolopyrimidine, A Multifaceted Scaffold in Cancer Targeted Therapy.
    Drug research, 2018, Volume: 68, Issue:9

    Topics: Antineoplastic Agents; Drug Design; Humans; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Structure-Activity Relationship

2018
Benzopyrroloxazines containing a bridgehead nitrogen atom as promising scaffolds for the achievement of biologically active agents.
    European journal of medicinal chemistry, 2018, May-10, Volume: 151

    Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Bacterial Infections; Chemistry Techniques, Synthetic; Drug Discovery; Humans; Inflammation; Neoplasms; Nitrogen; Oxazines; Pyrroles; Virus Diseases

2018
Managing Risks with Biologics.
    Current gastroenterology reports, 2019, Jan-11, Volume: 21, Issue:2

    Topics: Antibodies, Monoclonal, Humanized; Biological Products; Demyelinating Diseases; Deprescriptions; Drug Substitution; Gastrointestinal Agents; Humans; Infections; Inflammatory Bowel Diseases; Lymphoma; Melanoma; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk; Risk Assessment; Skin Neoplasms; Tumor Necrosis Factor-alpha; Ustekinumab

2019
Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
    Cancer treatment reviews, 2013, Volume: 39, Issue:7

    Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials as Topic; Hematologic Diseases; Humans; Incidence; Indoles; Neoplasms; Neutropenia; Publication Bias; Pyrroles; Risk; Sunitinib; Thrombocytopenia

2013
Clinical and marketed proteasome inhibitors for cancer treatment.
    Current medicinal chemistry, 2013, Volume: 20, Issue:20

    Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Lactones; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Threonine

2013
Body composition in chemotherapy: the promising role of CT scans.
    Current opinion in clinical nutrition and metabolic care, 2013, Volume: 16, Issue:5

    Topics: Anthracyclines; Body Composition; Body Weight; Chemotherapy, Adjuvant; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Muscle, Skeletal; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Reproducibility of Results; Sorafenib; Sunitinib; Tomography, X-Ray Computed

2013
A functional scaffold in marine alkaloid: an anticancer moiety for human.
    Current medicinal chemistry, 2013, Volume: 20, Issue:31

    Topics: Alkaloids; Animals; Antineoplastic Agents; Humans; Indoles; Neoplasms; Oxazoles; Pyridines; Pyrroles; Quinolines

2013
BH3 mimetics: status of the field and new developments.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:9

    Topics: Amino Acid Motifs; Aniline Compounds; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Drug Design; Drug Screening Assays, Antitumor; Gossypol; Humans; Indoles; Molecular Mimicry; Neoplasms; Peptide Fragments; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Sulfonamides

2013
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
    International journal of cancer, 2014, Aug-15, Volume: 135, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Incidence; Indazoles; Indoles; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vomiting

2014
Comparative pathophysiology, toxicology, and human cancer risk assessment of pharmaceutical-induced hibernoma.
    Toxicology and applied pharmacology, 2013, Dec-15, Volume: 273, Issue:3

    Topics: Animals; Benzazepines; Carcinogenicity Tests; Disease Models, Animal; Humans; Hydromorphone; Lipoma; Mutagenicity Tests; Neoplasms; Phentolamine; Piperidines; Pyrimidines; Pyrroles; Quinoxalines; Rats; Risk Assessment; Varenicline

2013
Tumor angiogenesis and anti-angiogenic therapies.
    Human antibodies, 2013, Volume: 22, Issue:1-2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Placenta Growth Factor; Pregnancy Proteins; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factors

2013
The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders.
    The journal of investigative dermatology. Symposium proceedings, 2013, Volume: 16, Issue:1

    Topics: Alopecia Areata; Animals; Antibodies, Monoclonal; Autoimmune Diseases; Humans; Interleukin-15; Leukemia-Lymphoma, Adult T-Cell; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Interleukin-15; Signal Transduction

2013
Sunitinib in the treatment of advanced solid tumors.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2014, Volume: 201

    Topics: Animals; Antineoplastic Agents; Humans; Indoles; Neoplasms; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib

2014
Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
    Critical reviews in oncology/hematology, 2014, Volume: 92, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Cardiovascular Diseases; Humans; Imidazoles; Incidence; Indazoles; Indoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk; Sunitinib

2014
Small molecule inhibitors in veterinary oncology practice.
    The Veterinary clinics of North America. Small animal practice, 2014, Volume: 44, Issue:5

    Topics: Animals; Benzamides; Cat Diseases; Cats; Dog Diseases; Dogs; Indoles; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Thiazoles

2014
A Short Review on the Synthetic Strategies of Duocarmycin Analogs that are Powerful DNA Alkylating Agents.
    Anti-cancer agents in medicinal chemistry, 2015, Volume: 15, Issue:5

    Topics: Animals; Antineoplastic Agents, Alkylating; Cell Proliferation; DNA Methylation; DNA, Neoplasm; Duocarmycins; Humans; Indoles; Molecular Structure; Neoplasms; Pyrroles

2015
Diagnostic and therapeutic implications of the vascular endothelial growth factor family in cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:5

    Topics: Angiogenesis Inhibitors; Bevacizumab; Humans; Indoles; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Neovascularization, Pathologic; Prognosis; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factors

2015
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
    Annals of the rheumatic diseases, 2016, Volume: 75, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Female; Humans; Incidence; Janus Kinase 3; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Young Adult

2016
Drug compound characterization by mass spectrometry imaging in cancer tissue.
    Archives of pharmacal research, 2015, Volume: 38, Issue:9

    Topics: Animals; Antineoplastic Agents; Drug Compounding; Humans; Indoles; Neoplasms; Precision Medicine; Protein Kinase Inhibitors; Pyrroles; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Sunitinib; Xenograft Model Antitumor Assays

2015
Combining radiotherapy with sunitinib: lessons (to be) learned.
    Angiogenesis, 2015, Volume: 18, Issue:4

    Topics: Animals; Chemoradiotherapy; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib

2015
[Anti-angiogenesis and molecular targeted therapies].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2015
Marinopyrroles: Unique Drug Discoveries Based on Marine Natural Products.
    Medicinal research reviews, 2016, Volume: 36, Issue:1

    Topics: Anti-Bacterial Agents; Antineoplastic Agents; Aquatic Organisms; Bacteria; Biological Products; Cosmetics; Drug Design; Drug Discovery; Europe; Humans; Marine Biology; Methicillin-Resistant Staphylococcus aureus; Neoplasms; Pharmaceutical Preparations; Pyrroles; Seawater; United States; United States Food and Drug Administration

2016
A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib.
    eLife, 2015, Oct-13, Volume: 4

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Indoles; Neoplasms; Pyrroles; Research Design; Sunitinib; Treatment Outcome

2015
A sequence-specific DNA binding small molecule triggers the release of immunogenic signals and phagocytosis in a model of B-cell lymphoma.
    Quarterly reviews of biophysics, 2015, Volume: 48, Issue:4

    Topics: Adenosine Triphosphate; Animals; Calreticulin; DNA; Enzyme-Linked Immunosorbent Assay; HMGB1 Protein; Humans; Imidazoles; Immunoblotting; Inflammation; K562 Cells; Luminescence; Lymphoma, B-Cell; Macrophages; Necrosis; Neoplasms; Nylons; Phagocytosis; Pyrroles; Signal Transduction; Telomere; Up-Regulation

2015
Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.
    Journal of the National Cancer Institute, 2016, Volume: 108, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Humans; Indoles; Neoplasms; Pyrroles; Risk Assessment; Sunitinib; United States; United States Food and Drug Administration

2016
Update on cardiotoxicity of anti-cancer treatments.
    European journal of clinical investigation, 2016, Volume: 46, Issue:3

    Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bevacizumab; Cardiotoxicity; Echocardiography; Humans; Indoles; Lapatinib; Magnetic Resonance Imaging; Neoplasms; Positron-Emission Tomography; Pyrroles; Quinazolines; Radiation Injuries; Radiotherapy; Sunitinib; Taxoids; Trastuzumab; Troponin; Vinca Alkaloids

2016
An Update on the Synthesis of Pyrrolo[1,4]benzodiazepines.
    Molecules (Basel, Switzerland), 2016, Jan-28, Volume: 21, Issue:2

    Topics: Anti-HIV Agents; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Cyclization; DNA; HIV Infections; Humans; Molecular Structure; Neoplasms; Pyrroles; Structure-Activity Relationship

2016
Is sunitinib a Narrow Therapeutic Index Drug? - A systematic review and in vitro toxicology-analysis of Sunitinib vs. Imatinib in cells from different tissues.
    Regulatory toxicology and pharmacology : RTP, 2016, Volume: 77

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug and Narcotic Control; Drugs, Generic; Humans; Imatinib Mesylate; Indoles; Inhibitory Concentration 50; Neoplasms; Organ Specificity; Phosphorylation; Protein Kinase Inhibitors; Pyrroles; Risk Assessment; Signal Transduction; Sunitinib; Toxicity Tests

2016
[Proteasome inhibitors in cancer therapy].
    Postepy higieny i medycyny doswiadczalnej (Online), 2015, Dec-31, Volume: 69

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Dipeptides; Humans; Lactones; Multiple Myeloma; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrroles; Thiazoles; Threonine

2015
Malignancy and Janus Kinase Inhibition.
    Rheumatic diseases clinics of North America, 2017, Volume: 43, Issue:1

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Incidence; Janus Kinases; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Neoplasms

2017
Kinase Inhibitors in Multitargeted Cancer Therapy.
    Current medicinal chemistry, 2017, Volume: 24, Issue:16

    Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib

2017
The emerging safety profile of JAK inhibitors in rheumatic disease.
    Nature reviews. Rheumatology, 2017, Volume: 13, Issue:4

    Topics: Azetidines; Humans; Infections; Janus Kinases; Neoplasms; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Rheumatic Diseases; Signal Transduction; Sulfonamides

2017
Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors.
    Current medicinal chemistry, 2017, Volume: 24, Issue:19

    Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Drug Design; Humans; Inflammation; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Structure-Activity Relationship

2017
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    The Cochrane database of systematic reviews, 2017, 03-10, Volume: 3

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Products; Disease Progression; Humans; Methotrexate; Neoplasms; Network Meta-Analysis; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Failure

2017
Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis.
    Seminars in arthritis and rheumatism, 2017, Volume: 47, Issue:2

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Humans; Neoplasms; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Risk

2017
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
    International journal of cancer, 2008, Sep-01, Volume: 123, Issue:5

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac

2008
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
    Nature clinical practice. Oncology, 2008, Volume: 5, Issue:7

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Clinical Trials as Topic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2008
Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.
    Journal of cellular physiology, 2009, Volume: 218, Issue:1

    Topics: Aniline Compounds; Animals; Apoptosis; Benzamides; Binding Sites; Biphenyl Compounds; Gossypol; Humans; Indoles; Lymphoma; Models, Molecular; Neoplasms; Nitrophenols; Piperazines; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Sulfonamides; Sulfones

2009
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    The oncologist, 2008, Volume: 13, Issue:9

    Topics: Benzenesulfonates; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quality of Life; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib

2008
[Progress in the studies on small molecule IGF-1R inhibitors].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2008, Volume: 43, Issue:10

    Topics: Animals; Apoptosis; Benzimidazoles; Catechin; Cell Line, Tumor; Humans; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyridones; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction

2008
[Advances in the study of small peptides in targeted drug delivery system].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2008, Volume: 43, Issue:10

    Topics: Animals; Antineoplastic Agents; Doxorubicin; Drug Delivery Systems; Humans; Neoplasms; Oligopeptides; Pyrroles; Receptors, Bombesin; Receptors, LHRH; Receptors, Somatostatin

2008
Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives.
    Critical reviews in oncology/hematology, 2009, Volume: 70, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Hypoxia; Enzyme Inhibitors; Humans; Hypoxia-Inducible Factor 1; Indoles; Intercellular Signaling Peptides and Proteins; Mustard Compounds; Neoplasms; Neovascularization, Pathologic; Phenylpropionates; Pyrroles; Sunitinib

2009
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-15, Volume: 15, Issue:4

    Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Gossypol; Humans; Indoles; Mitochondria; Neoplasms; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Sulfonamides; Thionucleotides

2009
A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Apr-01, Volume: 15, Issue:7

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Indoles; Male; Middle Aged; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib

2009
[Targeted therapies and their indications in solid neoplasias].
    La Revue de medecine interne, 2009, Volume: 30, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2009
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Therapy, Combination; Humans; Hypothyroidism; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib; Thyroid Function Tests; Treatment Outcome

2009
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
    Targeted oncology, 2009, Volume: 4, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Drug Administration Routes; Female; Hemorrhage; Humans; Hypertension; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A

2009
Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.
    Current cardiology reports, 2009, Volume: 11, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Heart; Heart Diseases; Heart Failure; Humans; Indoles; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Trastuzumab

2009
Targeting the proteasome pathway.
    Expert opinion on therapeutic targets, 2009, Volume: 13, Issue:5

    Topics: Acetylcysteine; Animals; Antineoplastic Agents; Biological Products; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Discovery; Humans; Lactones; Neoplasms; Peptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Ubiquitin; Ubiquitin-Activating Enzymes; Ubiquitins

2009
Renal toxicity of targeted therapies.
    Targeted oncology, 2009, Volume: 4, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hypertension; Indoles; Kidney; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proteinuria; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2009
Sunitinib in solid tumors.
    Expert opinion on investigational drugs, 2009, Volume: 18, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Molecular Structure; Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Sunitinib

2009
Angiogenesis regulated by VEGF and its receptors and its clinical application.
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Design; Humans; Indoles; Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2009
The role of antiangiogenesis therapy: bevacizumab and beyond.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2009, Volume: 11, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Combined Modality Therapy; Drug Delivery Systems; Forecasting; Humans; Indoles; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2009
Mimicking the BH3 domain to kill cancer cells.
    Oncogene, 2008, Volume: 27 Suppl 1

    Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Binding, Competitive; Biphenyl Compounds; Clinical Trials as Topic; Dimerization; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Indoles; Mice; Mitochondria; Multigene Family; Neoplasm Proteins; Neoplasms; Nitrophenols; Piperazines; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Structure-Activity Relationship; Sulfonamides; Sulfones; Thionucleotides

2008
Neurological adverse effects caused by cytotoxic and targeted therapies.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dacarbazine; Drug Approval; Epothilones; Humans; Imatinib Mesylate; Indoles; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Piperazines; Pyrazines; Pyrimidines; Pyrroles; Sunitinib; Temozolomide; Tubulin Modulators; United States; United States Food and Drug Administration

2009
An overview of small-molecule inhibitors of VEGFR signaling.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Cadherins; Clinical Trials, Phase III as Topic; Extracellular Matrix Proteins; Humans; Indoles; Integrins; Intercellular Signaling Peptides and Proteins; National Cancer Institute (U.S.); Neoplasms; Niacinamide; Peptide Hydrolases; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Structure-Activity Relationship; Sunitinib; Transcription Factors; United States

2009
Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2009, Volume: 23, Issue:6

    Topics: Animals; Drug Delivery Systems; Genetic Therapy; Humans; Indoles; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib

2009
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Blood Pressure; Carcinoma, Renal Cell; Endpoint Determination; Fatigue; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Leukocyte Count; Linear Models; Male; Middle Aged; Neoplasms; Neutrophils; Nonlinear Dynamics; Population; Pyrroles; Sunitinib

2010
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2009
Compounds in clinical Phase III and beyond.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2010, Volume: 180

    Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Clinical Trials, Phase III as Topic; Endostatins; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A

2010
Sunitinib.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2010, Volume: 184

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Interactions; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Neoplasms; Pyrroles; Sunitinib

2010
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
    The Lancet. Oncology, 2010, Volume: 11, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Chemotherapy, Adjuvant; Humans; Indoles; Neoadjuvant Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Wound Healing

2010
Targeting immune suppressing myeloid-derived suppressor cells in oncology.
    Critical reviews in oncology/hematology, 2011, Volume: 77, Issue:1

    Topics: Animals; Antineoplastic Agents; CD11b Antigen; Humans; Immune Tolerance; Immunotherapy; Indoles; Myeloid Cells; Neoplasms; Neovascularization, Pathologic; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib; Tumor Microenvironment; Vascular Endothelial Growth Factor A

2011
The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:13

    Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromosome Aberrations; Chromosomes, Human, Pair 2; Drug Synergism; Gene Amplification; Humans; Lung Neoplasms; Lymphoma, Large-Cell, Anaplastic; Mutation; Neoplasms; Neuroblastoma; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1

2010
New insights on the antitumoral properties of prodiginines.
    Current medicinal chemistry, 2010, Volume: 17, Issue:21

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; DNA Damage; Humans; Indoles; Neoplasms; Prodigiosin; Pyrroles; Serratia; Signal Transduction

2010
Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides.
    Marine drugs, 2010, Mar-25, Volume: 8, Issue:4

    Topics: Animals; Drug Design; Enzyme Inhibitors; Fermentation; Humans; Lactones; Neoplasms; Proteasome Inhibitors; Pyrroles; Technology, Pharmaceutical

2010
[Treatment with antiangiogenic drugs].
    Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Bevacizumab; Humans; Imatinib Mesylate; Indoles; Neoplasms; Piperazines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A

2010
[Anti-angiogenic drugs].
    Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Hypoxia-Inducible Factor 1; Indoles; Intracellular Signaling Peptides and Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2010
Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
    The oncologist, 2010, Volume: 15, Issue:7

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cardiovascular Diseases; Female; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2010
[Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2010, Volume: 61, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Delivery Systems; Drug Eruptions; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Structure-Activity Relationship; Sunitinib

2010
Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.
    Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:8

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Indoles; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome

2010
Targeting apoptosis pathways by natural compounds in cancer: marine compounds as lead structures and chemical tools for cancer therapy.
    Cancer letters, 2013, May-28, Volume: 332, Issue:2

    Topics: Alkaloids; Alkanes; Animals; Anti-Bacterial Agents; Antineoplastic Agents; Apoptosis; Aquatic Organisms; Biological Products; Bryostatins; Carbamates; Cell Proliferation; Depsipeptides; Dioxoles; Drug Screening Assays, Antitumor; Humans; Lactones; Macrolides; Microtubules; Models, Chemical; Neoplasms; Phenanthrolines; Phenazines; Proteasome Endopeptidase Complex; Pyrones; Pyrroles; Quinolines; Spiro Compounds; Steroids; Tetrahydroisoquinolines; Thiazoles; Trabectedin

2013
Drugs targeting Bcl-2 family members as an emerging strategy in cancer.
    Expert reviews in molecular medicine, 2010, Sep-08, Volume: 12

    Topics: Aniline Compounds; Antineoplastic Agents; Drug Delivery Systems; Humans; Indoles; Neoplasms; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Sulfonamides

2010
Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics.
    Angewandte Chemie (International ed. in English), 2010, Dec-03, Volume: 49, Issue:49

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Factors; Cysteine Proteinase Inhibitors; Humans; Lactones; Molecular Conformation; Neoplasms; Proteasome Inhibitors; Pyrroles

2010
Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy.
    Cancer letters, 2010, Dec-28, Volume: 299, Issue:2

    Topics: Anaplastic Lymphoma Kinase; Animals; Crizotinib; Genetic Predisposition to Disease; Humans; Molecular Structure; Mutation; Neoplasms; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases

2010
Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor.
    Anticancer research, 2010, Volume: 30, Issue:11

    Topics: Alanine; Clinical Trials as Topic; Humans; Neoplasms; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Triazines; Vascular Endothelial Growth Factor Receptor-2

2010
[Vasopressin receptor antagonists: the vaptans].
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2010, Volume: 57 Suppl 2

    Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzamides; Benzazepines; Calcium Signaling; Clinical Trials as Topic; Cyclic AMP; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney Tubules, Collecting; Liver Cirrhosis; Morpholines; Multicenter Studies as Topic; Neoplasms; Pituitary Gland, Anterior; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Second Messenger Systems; Spiro Compounds; Tolvaptan; Vasopressins

2010
[Clinical manifestation of targeted drugs in individualized therapy of malignant tumors].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:10

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Doxorubicin; Drug Delivery Systems; ErbB Receptors; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Mutation; Neoplasms; Piperazines; Prednisone; Pyrimidines; Pyrroles; Remission Induction; Rituximab; Sunitinib; Vincristine

2010
Role of tyrosine kinase inhibitors in tumor immunology.
    Immunotherapy, 2011, Volume: 3, Issue:1

    Topics: Animals; Antigen-Presenting Cells; Antineoplastic Agents; Dendritic Cells; Humans; Indoles; Mice; Myeloid Cells; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; T-Lymphocytes, Regulatory; Treatment Outcome

2011
In pursuit of new anti-angiogenic therapies for cancer treatment.
    Frontiers in bioscience (Landmark edition), 2011, 01-01, Volume: 16, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment

2011
Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs.
    Anti-cancer agents in medicinal chemistry, 2010, Nov-01, Volume: 10, Issue:9

    Topics: Allosteric Regulation; Antineoplastic Agents; Drug Discovery; Humans; Kinesins; Neoplasms; Piperidines; Pyrroles; Taxoids

2010
Myeloid derived suppressor cells in human diseases.
    International immunopharmacology, 2011, Volume: 11, Issue:7

    Topics: Animals; Biomarkers; Humans; Immunosuppression Therapy; Indoles; Inflammatory Bowel Diseases; Mice; Molecular Targeted Therapy; Myeloid Cells; Myelopoiesis; Neoplasms; Pyrroles; Sunitinib; Tretinoin

2011
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
    Current cancer drug targets, 2011, Volume: 11, Issue:3

    Topics: Animals; Antineoplastic Agents; Drug Evaluation, Preclinical; Humans; Lactones; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrroles

2011
Brivanib alaninate for cancer.
    Expert opinion on investigational drugs, 2011, Volume: 20, Issue:4

    Topics: Alanine; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Neoplasms; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Triazines; Vascular Endothelial Growth Factor Receptor-2

2011
The development of pyrrolobenzodiazepines as antitumour agents.
    Expert opinion on investigational drugs, 2011, Volume: 20, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzodiazepines; Benzodiazepinones; DNA Damage; Drug Delivery Systems; Drug Design; Humans; Neoplasms; Pyrroles; Structure-Activity Relationship

2011
[Indications and current development of new targeted therapies in pediatric oncology].
    Bulletin du cancer, 2011, Volume: 98, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases

2011
Novel proteasome inhibitors to overcome bortezomib resistance.
    Journal of the National Cancer Institute, 2011, Jul-06, Volume: 103, Issue:13

    Topics: Allosteric Site; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Chloroquine; Clioquinol; Drug Resistance, Neoplasm; Humans; Hydroxyquinolines; Lactones; Neoplasms; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Threonine; Ubiquitinated Proteins; Ubiquitination

2011
Discovery of carboxyethylpyrroles (CEPs): critical insights into AMD, autism, cancer, and wound healing from basic research on the chemistry of oxidized phospholipids.
    Chemical research in toxicology, 2011, Nov-21, Volume: 24, Issue:11

    Topics: Animals; Antibodies; Autistic Disorder; CD36 Antigens; Cornea; Corneal Neovascularization; Endothelial Cells; Humans; Macular Degeneration; Mice; Mice, Knockout; Neoplasms; Oxidation-Reduction; Phospholipids; Protein Processing, Post-Translational; Pyrroles; Retinal Rod Photoreceptor Cells; Toll-Like Receptor 2; Wound Healing

2011
Sunitinib-induced asthenia: from molecular basis to clinical relief.
    Cancer biology & therapy, 2011, Nov-01, Volume: 12, Issue:9

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Asthenia; Gene Expression Regulation; Humans; Incidence; Indoles; Neoplasms; Pyrroles; Severity of Illness Index; Signal Transduction; Sunitinib

2011
Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.
    Journal of the National Cancer Institute, 2011, Dec-07, Volume: 103, Issue:23

    Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Breast Neoplasms; Confounding Factors, Epidemiologic; Cross-Over Studies; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Interferon-gamma; Neoplasms; Patient Selection; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Sunitinib; Treatment Outcome

2011
Anti-angiogenic therapy: concept to clinic.
    Microcirculation (New York, N.Y. : 1994), 2012, Volume: 19, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2012
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Mar-10, Volume: 30, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib

2012
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
    Magyar onkologia, 2012, Volume: 56, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib

2012
Bcl-2 inhibitors: emerging drugs in cancer therapy.
    Current medicinal chemistry, 2012, Volume: 19, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Clinical Trials as Topic; Gossypol; Humans; Indoles; Models, Biological; Molecular Mimicry; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrroles

2012
Small molecule drugs - optimizing DNA damaging agent-based therapeutics.
    Current opinion in pharmacology, 2012, Volume: 12, Issue:4

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzodiazepinones; Dioxoles; DNA; DNA Damage; Humans; Neoplasms; Nitrogen Mustard Compounds; Pyrroles; Tetrahydroisoquinolines; Trabectedin

2012
Targeting the B-cell lymphoma/leukemia 2 family in cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Sep-01, Volume: 30, Issue:25

    Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Drug Resistance, Neoplasm; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Sulfonamides; Thionucleotides; Treatment Outcome

2012
Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.
    Veterinary and comparative oncology, 2012, Volume: 10, Issue:3

    Topics: Animals; Antineoplastic Agents; Benzamides; Drug Therapy, Combination; Humans; Indoles; Neoplasms; Piperidines; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Thiazoles

2012
Evidence for therapeutic drug monitoring of targeted anticancer therapies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-10, Volume: 30, Issue:32

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Area Under Curve; Benzamides; Benzenesulfonates; Cetuximab; Dasatinib; Drug Monitoring; Everolimus; Evidence-Based Medicine; Half-Life; Humans; Imatinib Mesylate; Indoles; Injections, Intravenous; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Rituximab; Sirolimus; Sorafenib; Sunitinib; Thiazoles

2012
Hypothyroidism during treatment with tyrosine kinase inhibitors.
    Endokrynologia Polska, 2012, Volume: 63, Issue:4

    Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland; Thyroid Neoplasms

2012
Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers.
    Current pharmaceutical design, 2013, Volume: 19, Issue:5

    Topics: Animals; Antineoplastic Agents; Drug Design; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib

2013
Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
    Current topics in medicinal chemistry, 2012, Volume: 12, Issue:15

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Germ-Line Mutation; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome

2012
Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.
    Immunological investigations, 2012, Volume: 41, Issue:6-7

    Topics: Animals; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immune Tolerance; Indoles; Mice; Myeloid Progenitor Cells; Neoplasms; Organ Specificity; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; STAT3 Transcription Factor; STAT5 Transcription Factor; Sunitinib; T-Lymphocytes; Tumor Escape

2012
Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis.
    Acta oncologica (Stockholm, Sweden), 2013, Volume: 52, Issue:4

    Topics: Algorithms; Antineoplastic Agents; Humans; Hypothyroidism; Incidence; Indoles; Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sunitinib

2013
New chemotherapeutic agents: update of major chemoradiation trials in solid tumors.
    Oncology, 2002, Volume: 63 Suppl 2

    Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Angiostatins; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose Fractionation, Radiation; Drugs, Investigational; Endothelial Growth Factors; Enzyme Inhibitors; Esophageal Neoplasms; Farnesyltranstransferase; Female; Head and Neck Neoplasms; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Isoenzymes; Laryngeal Neoplasms; Lung Neoplasms; Lymphokines; Male; Membrane Proteins; Neoplasms; Peptide Fragments; Plasminogen; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Pyrroles; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2002
Inhibitors of the vascular endothelial growth factor receptor.
    Hematology/oncology clinics of North America, 2002, Volume: 16, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Phthalazines; Piperidines; Pyridines; Pyrroles; Quinazolines; Recombinant Proteins; RNA, Catalytic; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors

2002
Tyrosine kinases as targets in cancer therapy - successes and failures.
    Expert opinion on therapeutic targets, 2003, Volume: 7, Issue:2

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Fusion Proteins, bcr-abl; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome

2003
Recent developments in novel pyrrolo[2,1-c][1,4]benzodiazepine conjugates: synthesis and biological evaluation.
    Mini reviews in medicinal chemistry, 2003, Volume: 3, Issue:4

    Topics: Animals; Antibiotics, Antineoplastic; Benzodiazepines; Chemical Phenomena; Chemistry, Physical; DNA; Drug Screening Assays, Antitumor; Humans; Magnetic Resonance Spectroscopy; Models, Molecular; Neoplasms; Pyrroles; RNA; Structure-Activity Relationship; Tumor Cells, Cultured

2003
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
    Journal of the National Cancer Institute, 2003, Jun-18, Volume: 95, Issue:12

    Topics: Aminoquinolines; Aniline Compounds; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Design; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Neoplasms; Organic Chemicals; Panitumumab; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Structure-Activity Relationship

2003
[Current screening for molecular target therapy of cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib

2003
Brostallicin: a new concept in minor groove DNA binder development.
    Anti-cancer drugs, 2004, Volume: 15, Issue:1

    Topics: Alkylating Agents; Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Distamycins; DNA; Drug Combinations; Drug Evaluation, Preclinical; Drug Synergism; Glutathione; Glutathione Transferase; Guanidines; Humans; Molecular Structure; Neoplasms; Pyrroles

2004
Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives.
    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2004, Volume: 7, Issue:2

    Topics: Animals; Anti-HIV Agents; Drug Delivery Systems; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib

2004
Lamellarins, from A to Z: a family of anticancer marine pyrrole alkaloids.
    Current medicinal chemistry. Anti-cancer agents, 2004, Volume: 4, Issue:4

    Topics: Alkaloids; Animals; Antimetabolites, Antineoplastic; Heterocyclic Compounds, 4 or More Rings; Humans; Neoplasms; Pyrroles

2004
Antitumor activity of HER-2 inhibitors.
    Cancer letters, 2005, Sep-08, Volume: 227, Issue:1

    Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Neoplasms; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2

2005
Sunitinib malate for the treatment of solid tumours: a review of current clinical data.
    Expert opinion on investigational drugs, 2006, Volume: 15, Issue:5

    Topics: Animals; Antineoplastic Agents; Humans; Indoles; Neoplasms; Pyrroles; Sunitinib

2006
Anti-angiogenic and anti-HER therapy.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2006, Volume: 60, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor

2006
Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.
    Drugs of today (Barcelona, Spain : 1998), 2006, Volume: 42, Issue:6

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Humans; In Vitro Techniques; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; United States; United States Food and Drug Administration

2006
Targeting ubiquitin in cancers.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:18

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Communication; Cell Cycle; Genetic Therapy; Heat-Shock Proteins; Humans; Lactones; Neoplasms; Pyrazines; Pyrroles; Ubiquitin

2006
Sunitinib: from rational design to clinical efficacy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Mar-01, Volume: 25, Issue:7

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Design; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Leukemia, Myeloid, Acute; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib

2007
PDGF receptors as targets in tumor treatment.
    Advances in cancer research, 2007, Volume: 97

    Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Extracellular Fluid; Fibroblasts; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Piperazines; Platelet-Derived Growth Factor; Pressure; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Sunitinib; Translocation, Genetic

2007
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.
    Nature reviews. Cancer, 2007, Volume: 7, Issue:5

    Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Drug Delivery Systems; Enzyme Inhibitors; Heart; Heart Diseases; Humans; Indoles; Lapatinib; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Trastuzumab

2007
Angiogenesis in cancer: molecular mechanisms, clinical impact.
    Langenbeck's archives of surgery, 2007, Volume: 392, Issue:3

    Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Benzenesulfonates; Carcinoma, Squamous Cell; Humans; Indoles; Microcirculation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2007
Design of clinical trials of radiation combined with antiangiogenic therapy.
    The oncologist, 2007, Volume: 12, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Combined Modality Therapy; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiation Dosage; raf Kinases; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2007
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
    British journal of cancer, 2007, Jun-18, Volume: 96, Issue:12

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Hemorrhage; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Thrombosis; Vascular Endothelial Growth Factor A; Wound Healing

2007
Molecular basis for sunitinib efficacy and future clinical development.
    Nature reviews. Drug discovery, 2007, Volume: 6, Issue:9

    Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Drug Design; Drug Resistance, Neoplasm; Humans; Indoles; Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A

2007
Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18 Suppl 10

    Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Endothelial Cells; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib

2007
A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18 Suppl 10

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib

2007
[Oral drugs inhibiting the VEGF pathway].
    Bulletin du cancer, 2007, Volume: 94 Spec No

    Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2007
Sunitinib.
    Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:14

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib

2007
Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
    BioEssays : news and reviews in molecular, cellular and developmental biology, 2007, Volume: 29, Issue:11

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Models, Biological; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2007
New developments in multitargeted therapy for patients with solid tumours.
    Cancer treatment reviews, 2008, Volume: 34, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles

2008
Role of focal adhesion kinase in human cancer: a potential target for drug discovery.
    Anti-cancer agents in medicinal chemistry, 2007, Volume: 7, Issue:6

    Topics: Animals; Drug Design; Focal Adhesion Protein-Tyrosine Kinases; Humans; Mice; Neoplasms; Pyrimidines; Pyrroles; RNA, Small Interfering

2007
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
    Current medicinal chemistry, 2008, Volume: 15, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab

2008
The photochemistry of carotenoids. Some photosynthetic and photomedical aspects.
    Annals of the New York Academy of Sciences, 1993, Dec-31, Volume: 691

    Topics: Carotenoids; Humans; Molecular Structure; Neoplasms; Photochemistry; Photosynthesis; Porphyrins; Pyrroles; Radiation Protection; Tetrapyrroles

1993
[Tumor angiogenesis and tumor angiogenesis inhibitors].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:5

    Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antigens, CD; Antineoplastic Agents; Cadherins; ErbB Receptors; Gefitinib; Humans; Indoles; Mice; Neoplasms; Oxindoles; Peptide Fragments; Plasminogen; Propionates; Pyrroles; Quinazolines; Vascular Cell Adhesion Molecule-1

2001
Su-6668. SUGEN.
    Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:8

    Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Humans; Indoles; Neoplasms; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles; Structure-Activity Relationship

2001
Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-15, Volume: 20, Issue:6

    Topics: Angiogenesis Inhibitors; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasms; Oxindoles; Piperazines; Propionates; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles

2002
A demonstration of the intrinsic importance of stabilizing hydrophobic binding and non-covalent van der Waals contacts dominant in the non-covalent CC-1065/B-DNA binding.
    Chemico-biological interactions, 1990, Volume: 73, Issue:1

    Topics: Animals; Antibiotics, Antineoplastic; Base Sequence; Carbamates; Chemical Phenomena; Chemistry, Physical; DNA; Duocarmycins; Humans; Indoles; Leucomycins; Macromolecular Substances; Molecular Conformation; Molecular Sequence Data; Molecular Structure; Neoplasms; Nucleic Acid Conformation; Pyrroles; Structure-Activity Relationship

1990
The regulatory functions of proline and pyrroline-5-carboxylic acid.
    Current topics in cellular regulation, 1985, Volume: 25

    Topics: Amino Acids; Animals; Biological Transport; Cell Communication; Cell Cycle; Charcoal; Glutamates; Glutamic Acid; Humans; Mitosis; NADP; Neoplasms; Ornithine; Oxidation-Reduction; Phosphoribosyl Pyrophosphate; Proline; Protein Biosynthesis; Purine Nucleotides; Pyrroles; Structure-Activity Relationship

1985
Plant phenolics as inhibitors of mutational and precarcinogenic events.
    Canadian journal of physiology and pharmacology, 1987, Volume: 65, Issue:3

    Topics: Animals; Carcinogens; Diet; Humans; Mutation; Neoplasms; Phenols; Plant Extracts; Plants, Edible; Porphyrins; Pyrroles

1987
[Molecular basis of viral induced tumors (author's transl)].
    Klinische Wochenschrift, 1973, Aug-15, Volume: 51, Issue:16

    Topics: Amidines; Animals; Anti-Bacterial Agents; Cell Transformation, Neoplastic; Daunorubicin; DNA Nucleotidyltransferases; DNA Viruses; Doxorubicin; Humans; Neoplasms; Oncogenic Viruses; Peptides; Pyrroles; RNA Viruses

1973

Trials

91 trial(s) available for pyrroles and Neoplasms

ArticleYear
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, Mar-01, Volume: 28, Issue:5

    Topics: Dose-Response Relationship, Drug; Hematologic Neoplasms; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Neoplasms; Pyrimidines; Pyrroles; Tumor Suppressor Protein p53

2022
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2022, Volume: 33, Issue:5

    Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Cholangiocarcinoma; Female; Fibroblast Growth Factors; Humans; Lung Neoplasms; Male; Morpholines; Neoplasm Recurrence, Local; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Fibroblast Growth Factor; Urinary Bladder Neoplasms

2022
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2022, Volume: 89, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Humans; Immune Checkpoint Inhibitors; Indoles; Lung Neoplasms; Neoplasms; Nivolumab; Pyrroles; Pyrrolidines

2022
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.
    Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:3

    Topics: Acetonitriles; Humans; Neoplasms; Oximes; Pyrazoles; Pyrimidines; Pyrroles; Pyrrolidines; Sulfonamides; Tumor Microenvironment

2022
First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors.
    Nature communications, 2022, 11-16, Volume: 13, Issue:1

    Topics: Class I Phosphatidylinositol 3-Kinases; Humans; Neoplasms; Piperazines; Pyrroles

2022
FIGHT-102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies.
    Cancer medicine, 2023, Volume: 12, Issue:9

    Topics: Adult; East Asian People; Humans; Morpholines; Neoplasms; Pyrimidines; Pyrroles; Young Adult

2023
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
    Science & sports, 2023, Apr-04

    Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide

2023
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 09-15, Volume: 29, Issue:18

    Topics: Adult; Carcinoma, Adenoid Cystic; Humans; Lymphoma, Non-Hodgkin; Neoplasms; Protein-Arginine N-Methyltransferases; Pyrimidines; Pyrroles

2023
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 06-15, Volume: 26, Issue:12

    Topics: Adult; Aged; Apoptosis Regulatory Proteins; Female; Follow-Up Studies; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Piperazines; Prognosis; Pyrroles

2020
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers.
    Investigational new drugs, 2021, Volume: 39, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Analgesics; Anti-Bacterial Agents; Antineoplastic Agents; Drug Eruptions; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Skin; Steroids; Young Adult

2021
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.
    Investigational new drugs, 2021, Volume: 39, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Everolimus; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; MTOR Inhibitors; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Pyrrolidines; Receptors, Colony-Stimulating Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor

2021
Concentration-QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations.
    British journal of clinical pharmacology, 2022, Volume: 88, Issue:2

    Topics: Dose-Response Relationship, Drug; Electrocardiography; Heart Rate; Humans; Long QT Syndrome; Neoplasms; Pyrimidines; Pyrroles

2022
Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
    Veterinary and comparative oncology, 2018, Volume: 16, Issue:1

    Topics: Animals; Carboplatin; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Indoles; Male; Neoplasms; Pyrroles

2018
A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.
    Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Biological Availability; Capsules; Cross-Over Studies; Fasting; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Neoplasms; Pyrimidines; Pyrroles; Tablets

2018
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies.
    Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:6

    Topics: Aged; Aminopyridines; Dose-Response Relationship, Drug; Electrocardiography, Ambulatory; Female; Heart Rate; Humans; Long QT Syndrome; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasms; Protein Kinase Inhibitors; Pyrroles

2018
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 05-01, Volume: 29, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Fatigue; Female; Gemcitabine; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Thrombocytopenia; Treatment Outcome

2018
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.
    Cancer research, 2018, 11-01, Volume: 78, Issue:21

    Topics: Animals; Antineoplastic Agents; Apoptosis; Area Under Curve; bcl-X Protein; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Screening Assays, Antitumor; Humans; Imidazoles; Kaplan-Meier Estimate; Maximum Tolerated Dose; Mice; Neoplasm Transplantation; Neoplasms; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Pyrroles; RNA, Small Interfering; Time Factors; Tumor Suppressor Protein p53

2018
Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors.
    The oncologist, 2019, Volume: 24, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Patient Safety; Prognosis; Protein Kinase Inhibitors; Pyrroles; Pyrrolidines; Survival Rate; Tissue Distribution

2019
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.
    Investigational new drugs, 2020, Volume: 38, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Biomarkers, Tumor; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Non-Randomized Controlled Trials as Topic; Prognosis; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Tissue Distribution; Young Adult

2020
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
    Arthritis research & therapy, 2019, 04-05, Volume: 21, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Herpes Zoster; Humans; Male; Middle Aged; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome

2019
A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperidines; Pyrroles; Treatment Outcome; Triazines

2013
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:8

    Topics: Administration, Oral; Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3

2013
Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.
    British journal of cancer, 2013, Apr-16, Volume: 108, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib

2013
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:5

    Topics: Adult; Aged; Angiogenesis Inhibitors; Biotransformation; Carcinoma, Renal Cell; China; Cohort Studies; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Hypertension; Incidence; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasms; Postprandial Period; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Sarcoma; Young Adult

2013
A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.
    Onkologie, 2013, Volume: 36, Issue:11

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Indoles; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Pyrroles; Thrombocytopenia; Treatment Outcome

2013
A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.
    Cancer, 2014, Apr-15, Volume: 120, Issue:8

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Female; HIV Infections; Humans; Indoles; Male; Middle Aged; Neoplasms; Pyrroles; Ritonavir; Sunitinib

2014
Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.
    Veterinary and comparative oncology, 2016, Volume: 14, Issue:2

    Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Combinations; Indoles; Lomustine; Neoplasms; Pyrroles

2016
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
    British journal of cancer, 2014, May-13, Volume: 110, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Fatigue; Feasibility Studies; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Indoles; Male; Middle Aged; Neoplasms; Nervous System Diseases; Pilot Projects; Protein Kinase Inhibitors; Pyrroles; Salvage Therapy; Sunitinib

2014
Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers.
    Cancer biology & therapy, 2014, Volume: 15, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Female; Gastrointestinal Hormones; Humans; Indoles; Male; Middle Aged; Neoplasms; Neuropeptides; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A

2014
Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Double-Blind Method; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Pilot Projects; Piperazines; Placebos; Protein Kinase Inhibitors; Purines; Pyrroles; Sildenafil Citrate; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A

2015
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.
    Investigational new drugs, 2015, Volume: 33, Issue:1

    Topics: Aged; Angiogenesis Inhibitors; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Body Weight; Constitutive Androstane Receptor; Cytochrome P-450 CYP3A; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Proteins; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Protein Kinase Inhibitors; Pyrroles; Receptors, Steroid; Sunitinib; Treatment Outcome

2015
Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Mar-01, Volume: 21, Issue:5

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Female; Gene Expression; Hedgehog Proteins; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms; Pyridines; Pyrroles; Retreatment; RNA, Messenger; Signal Transduction; Transcription Factors; Treatment Outcome; Zinc Finger Protein GLI1

2015
Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.
    Clinical pharmacokinetics, 2015, Volume: 54, Issue:8

    Topics: Administration, Oral; Aged; Animals; Antineoplastic Agents; Chronotherapy; Circadian Rhythm; Cross-Over Studies; Drug Evaluation, Preclinical; Female; Humans; Indoles; Male; Mice; Middle Aged; Neoplasms; Prospective Studies; Pyrroles; Sunitinib

2015
Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function.
    The Canadian journal of cardiology, 2015, Volume: 31, Issue:3

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Neoplasms; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left

2015
Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Sep-15, Volume: 21, Issue:18

    Topics: Antineoplastic Agents; CD11b Antigen; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Cell Survival; Disease Progression; Flow Cytometry; Humans; Immune System; Immunosuppressive Agents; Indoles; Leukocytes, Mononuclear; Monocytes; Myeloid Cells; Neoplasm Metastasis; Neoplasms; Phosphorylation; Pyrroles; Radiosurgery; Sialic Acid Binding Ig-like Lectin 3; STAT3 Transcription Factor; Sunitinib; Treatment Outcome

2015
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Nov-15, Volume: 21, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Collagen Type I; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Staging; Neoplasms; Neovascularization, Pathologic; Peptides; Pyrroles; Snake Venoms; Sunitinib; Vascular Endothelial Growth Factor Receptor-2

2015
Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Doxycycline; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Mice, Nude; Mutation, Missense; Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Signal Transduction; Xenograft Model Antitumor Assays

2015
A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 07-01, Volume: 22, Issue:13

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Administration Schedule; Epothilones; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; Tubulin Modulators

2016
Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:4

    Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Mutation; Neoplasms; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles

2016
Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult

2016
Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Sep-15, Volume: 22, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Lactones; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplasms; Proteasome Inhibitors; Pyrroles; Recurrence; Retreatment; Treatment Outcome; Young Adult

2016
Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
    Veterinary and comparative oncology, 2017, Volume: 15, Issue:3

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Dog Diseases; Dogs; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Flow Cytometry; Indoles; Male; Neoplasms; Neutropenia; Pyrroles

2017
Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
    Oncotarget, 2016, Dec-20, Volume: 7, Issue:51

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Prospective Studies; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome; von Hippel-Lindau Disease

2016
Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Mar-15, Volume: 15, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Benzodiazepinones; DNA; Histones; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles

2009
Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response.
    Cancer, 2009, Aug-01, Volume: 115, Issue:15

    Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Patient Compliance; Pyrroles; Radiation Dosage; Sunitinib

2009
A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Oct-01, Volume: 15, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; Tumor Burden

2009
Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Nov-15, Volume: 15, Issue:22

    Topics: Antineoplastic Agents; Arrhythmias, Cardiac; Aza Compounds; Dose-Response Relationship, Drug; Electrocardiography; Fluoroquinolones; Granisetron; Heart Ventricles; Humans; Indoles; Moxifloxacin; Neoplasms; Placebos; Protein-Tyrosine Kinases; Pyrroles; Quinolines; Risk; Sunitinib; Time Factors

2009
Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:4

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Half-Life; Humans; Indoles; Male; Middle Aged; Neoplasms; Pyrroles; Sunitinib; Taxoids

2010
Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:2

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Female; Guanidines; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Pyrroles; Sex Characteristics

2010
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.
    British journal of cancer, 2010, Jun-08, Volume: 102, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Interactions; Female; Humans; Ifosfamide; Indoles; Male; Maximum Tolerated Dose; Neoplasms; Pyrroles; Sunitinib

2010
Marginal increase of sunitinib exposure by grapefruit juice.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Beverages; Biological Availability; Citrus paradisi; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Labeling; Female; Food-Drug Interactions; Humans; Indoles; Male; Midazolam; Middle Aged; Neoplasms; Pyrroles; Sunitinib

2011
Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Aug-01, Volume: 16, Issue:15

    Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Female; Humans; Indoles; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Remission Induction

2010
Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:11

    Topics: Administration, Oral; Aged; Alanine; Antineoplastic Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Feces; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Pyrroles; Triazines

2010
Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:5

    Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Oxindoles; Plasminogen Activator Inhibitor 1; Postprandial Period; Propionates; Protein-Tyrosine Kinases; Pyrroles; Vascular Endothelial Growth Factor A

2011
Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:5

    Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Oxindoles; Postprandial Period; Propionates; Protein-Tyrosine Kinases; Pyrroles

2011
A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.
    British journal of cancer, 2010, Sep-28, Volume: 103, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Humans; Indoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome

2010
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-10, Volume: 28, Issue:29

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; Vomiting; Young Adult

2010
Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.
    Investigational new drugs, 2012, Volume: 30, Issue:2

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Feasibility Studies; Female; Glutamates; Guanine; Humans; Indoles; Japan; Male; Middle Aged; Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome

2012
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Endpoint Determination; Female; Half-Life; Hematologic Diseases; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome

2011
An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae.
    Cell cycle (Georgetown, Tex.), 2011, Jan-01, Volume: 10, Issue:1

    Topics: Adult; Aged; Cells, Cultured; Cyclin-Dependent Kinases; Disease Susceptibility; Female; Herpesviridae; Herpesviridae Infections; Humans; Immunosuppressive Agents; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasms; Pyrazoles; Pyrroles; Signal Transduction; Toll-Like Receptors

2011
Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jun-01, Volume: 17, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Benzodiazepinones; Dexamethasone; Dyspnea; Edema; Fatigue; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles

2011
A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors.
    Cell cycle (Georgetown, Tex.), 2011, Mar-15, Volume: 10, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; CDC2 Protein Kinase; Chemical and Drug Induced Liver Injury; Cohort Studies; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrroles

2011
A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.
    Investigational new drugs, 2012, Volume: 30, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Female; Humans; Infusions, Intravenous; Kinesins; Leukocyte Count; Male; Middle Aged; Neoplasms; Piperidines; Pyrroles; Young Adult

2012
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-01, Volume: 17, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Drug Interactions; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult

2011
Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Aug-01, Volume: 17, Issue:15

    Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Heart; Humans; Indoles; Male; Maximum Tolerated Dose; Neoplasms; Neutropenia; Pyrroles; Sunitinib

2011
Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Dec-15, Volume: 17, Issue:24

    Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Dideoxynucleosides; Drug Administration Schedule; Female; Fluorine Radioisotopes; Humans; Indoles; Kidney; Liver Neoplasms; Male; Middle Aged; Multimodal Imaging; Multivariate Analysis; Neoplasms; Positron-Emission Tomography; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A

2011
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:4

    Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Humans; Indoles; Neoplasms; Powders; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Young Adult

2012
Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
    Veterinary and comparative oncology, 2012, Volume: 10, Issue:3

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Indoles; Male; Neoplasms; Piroxicam; Protein-Tyrosine Kinases; Pyrroles

2012
Validation and application of a liquid chromatography-tandem mass spectrometric method for the determination of GDC-0152 in human plasma using solid-phase extraction.
    Biomedical chromatography : BMC, 2013, Volume: 27, Issue:1

    Topics: Chromatography, Liquid; Cyclohexanes; Dose-Response Relationship, Drug; Drug Stability; Humans; Linear Models; Neoplasms; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry

2013
A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome

2012
Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases.
    PloS one, 2012, Volume: 7, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Dose Fractionation, Radiation; Female; Follow-Up Studies; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Prognosis; Pyrroles; Radiotherapy, Image-Guided; Sunitinib; Survival Rate

2012
Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib

2012
A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Piperidines; Positron-Emission Tomography; Pyrroles; Triazines

2012
The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
    Journal of drugs in dermatology : JDD, 2012, Volume: 11, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Severity of Illness Index; Sorafenib; Sunitinib

2012
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
    British journal of cancer, 2013, Mar-05, Volume: 108, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines; Pyrroles; Sunitinib; Thyroid Neoplasms

2013
Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:9

    Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Endothelial Growth Factors; Fatigue; Female; Fibroblast Growth Factor 2; Headache; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Middle Aged; Molecular Structure; Nausea; Neoplasms; Pyrroles; Salvage Therapy; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vomiting

2002
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:7

    Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Indoles; Inhibitory Concentration 50; Male; Models, Chemical; Mutation; Neoplasms; Proto-Oncogene Proteins c-kit; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Time Factors; Tomography, X-Ray Computed

2003
Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Aug-01, Volume: 9, Issue:8

    Topics: Adult; Aged; Area Under Curve; DNA-Binding Proteins; Female; Guanidines; Humans; Infusions, Intravenous; Intercalating Agents; Male; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Neoplasms; Pyrroles

2003
A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-15, Volume: 10, Issue:2

    Topics: Aged; Antineoplastic Agents; Area Under Curve; Calibration; DNA Damage; Female; Guanidines; Humans; Kinetics; Male; Middle Aged; Models, Chemical; Neoplasms; Pyrroles; Time Factors

2004
A phase I surrogate endpoint study of SU6668 in patients with solid tumors.
    Investigational new drugs, 2004, Volume: 22, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Area Under Curve; Biomarkers, Tumor; Dose-Response Relationship, Drug; Endpoint Determination; Female; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Oxindoles; Propionates; Pyrroles; Time Factors; Tomography, X-Ray Computed

2004
Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles

2005
Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 1

    Topics: Absorption; Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; ErbB Receptors; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Software; Time Factors; Vascular Endothelial Growth Factor A

2005
A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.
    British journal of cancer, 2005, Oct-17, Volume: 93, Issue:8

    Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Drug Administration Schedule; Endpoint Determination; Female; Humans; Indoles; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles

2005
A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance.
    Investigational new drugs, 2006, Volume: 24, Issue:4

    Topics: Administration, Oral; Adult; Drug Administration Schedule; Female; Humans; Indoles; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Pyrroles

2006
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-01, Volume: 24, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Female; Humans; Hypertension; Indoles; Male; Middle Aged; Neoplasms; Pigmentation; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Skin; Sunitinib

2006
Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Humans; Indoles; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasms; Oxindoles; Propionates; Protein Binding; Pyrroles

2006
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Blood Pressure; Dose-Response Relationship, Drug; Fatigue; Female; Follow-Up Studies; Heart Rate; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Pancreas; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Failure

2008
Relative analgesic potency of oral zomepirac and intramuscular morphine in cancer patients with postoperative pain.
    Journal of clinical pharmacology, 1980, Volume: 20, Issue:4

    Topics: Administration, Oral; Adult; Analgesics; Clinical Trials as Topic; Female; Humans; Injections, Intramuscular; Male; Morphine; Neoplasms; Pain, Postoperative; Pyrroles; Tolmetin

1980
Double-blind comparisons of zomepirac and oxycodone with APC in cancer pain.
    Journal of clinical pharmacology, 1980, Volume: 20, Issue:4

    Topics: Adult; Analgesics; Aspirin; Caffeine; Clinical Trials as Topic; Codeine; Double-Blind Method; Drug Combinations; Female; Humans; Male; Neoplasms; Oxycodone; Pain; Phenacetin; Pyrroles; Tolmetin

1980
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-15, Volume: 20, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Indoles; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Pyrroles; Thromboembolism; Treatment Outcome

2002
[Controlled clinical study of the analgesic activity of a new drug (Z. 424) in pain caused by neoplasms].
    La Clinica terapeutica, 1970, Feb-28, Volume: 52, Issue:4

    Topics: Adult; Aged; Analgesics; Benzyl Compounds; Blood Pressure; Butylamines; Codeine; Digestive System; Ethanolamines; Female; Heart Rate; Humans; Middle Aged; Neoplasms; Palliative Care; Placebos; Pyrroles

1970

Other Studies

352 other study(ies) available for pyrroles and Neoplasms

ArticleYear
Systemic study of selected histone deacetylase inhibitors in cardiac complications associated with cancer cachexia.
    Canadian journal of physiology and pharmacology, 2022, Volume: 100, Issue:3

    Topics: Animals; Benzamides; Butyric Acid; Cachexia; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Female; Heart Diseases; Histone Deacetylase Inhibitors; Hydroxamic Acids; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Pyridines; Pyrroles

2022
Polypyrrole-based nanotheranostic agent for MRI guided photothermal-chemodynamic synergistic cancer therapy.
    Nanoscale, 2021, Nov-25, Volume: 13, Issue:45

    Topics: Animals; Hydrogen Peroxide; Magnetic Resonance Imaging; Manganese Compounds; Mice; Neoplasms; Oxides; Polymers; Pyrroles; Theranostic Nanomedicine

2021
Combination vinblastine and palladia for high-grade and metastatic mast cell tumors in dogs.
    The Canadian veterinary journal = La revue veterinaire canadienne, 2021, Volume: 62, Issue:12

    Topics: Animals; Dog Diseases; Dogs; Indoles; Mast Cells; Neoplasms; Pyrroles; Retrospective Studies; Vinblastine

2021
Gold nanorod@void@polypyrrole yolk@shell nanostructures: Synchronous regulation of photothermal and drug delivery performance for synergistic cancer therapy.
    Journal of colloid and interface science, 2022, Mar-15, Volume: 610

    Topics: Cell Line, Tumor; Doxorubicin; Gold; Humans; Nanotubes; Neoplasms; Pharmaceutical Preparations; Phototherapy; Polymers; Pyrroles; Tumor Microenvironment

2022
Dual-template rectangular nanotube molecularly imprinted polypyrrole for label-free impedimetric sensing of AFP and CEA as lung cancer biomarkers.
    Talanta, 2022, Mar-01, Volume: 239

    Topics: alpha-Fetoproteins; Biomarkers, Tumor; Biosensing Techniques; Carcinoembryonic Antigen; Electrochemical Techniques; Electrodes; Humans; Limit of Detection; Lung; Molecular Imprinting; Nanotubes; Neoplasms; Polymers; Pyrroles

2022
USP14 Regulates Cancer Cell Growth in a Fatty Acid Synthase-Independent Manner.
    International journal of molecular sciences, 2021, Dec-14, Volume: 22, Issue:24

    Topics: A549 Cells; Cell Proliferation; Fatty Acid Synthase, Type I; HEK293 Cells; Humans; MCF-7 Cells; Neoplasm Proteins; Neoplasms; Pyrroles; Pyrrolidines; Ubiquitin Thiolesterase; Ubiquitination

2021
Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies.
    Pharmacology research & perspectives, 2022, Volume: 10, Issue:1

    Topics: Adult; Aged; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Male; Middle Aged; Morpholines; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles

2022
Tumor acidity-activatable photothermal/Fenton nanoagent for synergistic therapy.
    Journal of colloid and interface science, 2022, Apr-15, Volume: 612

    Topics: Cell Line, Tumor; Humans; Hydroxyl Radical; Nanoparticles; Neoplasms; Polymers; Pyrroles; Theranostic Nanomedicine

2022
Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers.
    Molecular cancer therapeutics, 2022, 04-01, Volume: 21, Issue:4

    Topics: Animals; Antineoplastic Agents; Benzodiazepines; Cell Line, Tumor; Humans; Immunoconjugates; Mice; Neoplasms; Pyrroles; Xenograft Model Antitumor Assays

2022
Effect of Mild and Moderate Hepatic Impairment (Defined by Child-Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics.
    Journal of clinical pharmacology, 2022, Volume: 62, Issue:8

    Topics: Aminopyridines; Area Under Curve; Humans; Liver Diseases; Multiple Organ Failure; National Cancer Institute (U.S.); Neoplasms; Pyrroles; United States

2022
Synthesis Strategies and Medicinal Value of Pyrrole and its Fused Heterocyclic Compounds.
    Medicinal chemistry (Shariqah (United Arab Emirates)), 2022, Volume: 18, Issue:10

    Topics: Antiviral Agents; COVID-19; Heterocyclic Compounds; Humans; Neoplasms; Pyrroles

2022
Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study.
    Rheumatology (Oxford, England), 2022, 08-30, Volume: 61, Issue:9

    Topics: Etanercept; Herpes Zoster; Herpesvirus 3, Human; Humans; Neoplasms; Piperidines; Pyrimidines; Pyrroles

2022
Chidamide stacked in magnetic polypyrrole nano-composites counter thermotolerance and metastasis for visualized cancer photothermal therapy.
    Drug delivery, 2022, Volume: 29, Issue:1

    Topics: Aminopyridines; Animals; Benzamides; Magnetic Resonance Imaging; Mice; Neoplasms; Phototherapy; Photothermal Therapy; Polymers; Pyrroles; Thermotolerance

2022
Boosting nutrient starvation-dominated cancer therapy through curcumin-augmented mitochondrial Ca
    Journal of nanobiotechnology, 2022, May-12, Volume: 20, Issue:1

    Topics: Apoptosis; Autophagy; Cell Line, Tumor; Curcumin; Glucose; Humans; Indoles; Neoplasms; Nutrients; Pyrroles; Starvation

2022
Magnetic-targeted capacitive heterostructure of polypyrrole for hypoxia-tolerant synergistic photodynamic/photothermal therapy under near infrared excitation.
    Colloids and surfaces. B, Biointerfaces, 2022, Volume: 216

    Topics: Animals; Cell Line, Tumor; Hydrogen Peroxide; Hypoxia; Magnetic Phenomena; Mice; Mice, Nude; Nanoparticles; Neoplasms; Photochemotherapy; Photosensitizing Agents; Photothermal Therapy; Polymers; Pyrroles; Silicon Dioxide

2022
Polypyrrole Nanoenzymes as Tumor Microenvironment Modulators to Reprogram Macrophage and Potentiate Immunotherapy.
    Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022, Volume: 9, Issue:23

    Topics: Glutathione; Humans; Hyperthermia, Induced; Immunologic Factors; Immunotherapy; Macrophages; Neoplasms; Polymers; Pyrroles; Tumor Microenvironment

2022
Discovery and Optimization of Pyrrolopyrimidine Derivatives as Selective Disruptors of the Perinucleolar Compartment, a Marker of Tumor Progression toward Metastasis.
    Journal of medicinal chemistry, 2022, 06-23, Volume: 65, Issue:12

    Topics: Biomarkers; Cell Nucleolus; Cell Nucleus; Humans; Neoplasms; Pyrimidines; Pyrroles

2022
Fabrication of methylene blue-loaded ovalbumin/polypyrrole nanoparticles for enhanced phototherapy-triggered antitumour immune activation.
    Journal of nanobiotechnology, 2022, Jun-22, Volume: 20, Issue:1

    Topics: Humans; Methylene Blue; Nanoparticles; Neoplasms; Ovalbumin; Phototherapy; Polymers; Pyrroles

2022
2-Amino-Pyrrole-Carboxylate Attenuates Homology-Mediated DNA Repair and Sensitizes Cancer Cells to Doxorubicin.
    Biochemistry. Biokhimiia, 2022, Volume: 87, Issue:5

    Topics: Antineoplastic Agents; DNA Damage; DNA Repair; Doxorubicin; Humans; Neoplasms; Paclitaxel; Pyrroles

2022
Novel Donor-Acceptor Conjugated Polymer-Based Nanomicelles for Photothermal Therapy in the NIR Window.
    Biomacromolecules, 2022, 08-08, Volume: 23, Issue:8

    Topics: Animals; Humans; Mice; Micelles; Nanoparticles; Neoplasms; Phototherapy; Photothermal Therapy; Polymers; Pyrroles

2022
    Nanoscale, 2022, Aug-25, Volume: 14, Issue:33

    Topics: Copper; Humans; Nanoparticles; Neoplasms; Photoacoustic Techniques; Phototherapy; Photothermal Therapy; Polymers; Pyrroles; Temperature; Theranostic Nanomedicine

2022
Constructing Hypoxia-Tolerant and Host Tumor-Enriched Aggregation-Induced Emission Photosensitizer for Suppressing Malignant Tumors Relapse and Metastasis.
    Small (Weinheim an der Bergstrasse, Germany), 2022, Volume: 18, Issue:40

    Topics: Humans; Hypoxia; Neoplasms; Photochemotherapy; Photosensitizing Agents; Pyrroles; Reactive Oxygen Species; Recurrence

2022
A Water-Stable and Red-Emissive Radical Cation for Mutp53 Cancer Therapy.
    Angewandte Chemie (International ed. in English), 2022, 11-14, Volume: 61, Issue:46

    Topics: Cations; Humans; Mutant Proteins; Neoplasms; Pyrroles; Tumor Suppressor Protein p53; Water

2022
Green synthesis of gold nanoparticles using plant products and plants extracts aiming for cancer therapy: helping the beauty to beat 'cure' the beast.
    Artificial cells, nanomedicine, and biotechnology, 2022, Volume: 50, Issue:1

    Topics: Gold; Green Chemistry Technology; Humans; Metal Nanoparticles; Neoplasms; Plant Extracts; Polymers; Pyrroles

2022
Targeted Wolfram-Doped Polypyrrole for Photonic Hyperthermia-Synergized Radiotherapy.
    ACS applied materials & interfaces, 2022, Nov-16, Volume: 14, Issue:45

    Topics: Cell Line, Tumor; Humans; Hyperthermia; Hyperthermia, Induced; Neoplasms; Polymers; Pyrroles; Radiation-Sensitizing Agents; Tungsten

2022
Differential effects of proton pump inhibitors and vonoprazan on vascular endothelial growth factor expression in cancer cells.
    Drug development research, 2023, Volume: 84, Issue:1

    Topics: Endothelial Growth Factors; Humans; Molecular Docking Simulation; Neoplasms; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles

2023
Smart Chemical Oxidative Polymerization Strategy To Construct Au@PPy Core-Shell Nanoparticles for Cancer Diagnosis and Imaging-Guided Photothermal Therapy.
    Bioconjugate chemistry, 2023, 01-18, Volume: 34, Issue:1

    Topics: Gold; Humans; Nanoparticles; Neoplasms; Oxidative Stress; Phototherapy; Photothermal Therapy; Polymerization; Polymers; Pyrroles; Theranostic Nanomedicine

2023
Photonic Hyperthermia Synergizes with Immune-Activators to Augment Tumor-Localized Immunotherapy.
    Small methods, 2023, Volume: 7, Issue:5

    Topics: Humans; Hyperthermia; Hyperthermia, Induced; Immunotherapy; Neoplasms; Phototherapy; Polymers; Pyrroles; Tumor Microenvironment

2023
Hybrid Polypyrrole and Polydopamine Nanosheets for Precise Raman/Photoacoustic Imaging and Photothermal Therapy.
    Advanced healthcare materials, 2023, Volume: 12, Issue:27

    Topics: Humans; Nanoparticles; Neoplasms; Photoacoustic Techniques; Phototherapy; Photothermal Therapy; Polymers; Pyrroles; Theranostic Nanomedicine

2023
Multiple therapeutic mechanisms of pyrrolic N-rich g-C
    Journal of colloid and interface science, 2023, Nov-15, Volume: 650, Issue:Pt B

    Topics: Cell Line, Tumor; Copper; Humans; Hydrogen Peroxide; Nanoparticles; Neoplasms; Oxygen; Photochemotherapy; Photosensitizing Agents; Pyrroles; Reactive Oxygen Species; Tumor Microenvironment

2023
Covalent Organic Framework-Based Nanomotor for Multimodal Cancer Photo-Theranostics.
    Advanced healthcare materials, 2023, Volume: 12, Issue:30

    Topics: Cell Line, Tumor; Humans; Metal-Organic Frameworks; Neoplasms; Polymers; Precision Medicine; Pyrroles

2023
A new screening tool for FGFR inhibitor treatment?
    The Lancet. Oncology, 2019, Volume: 20, Issue:10

    Topics: Early Detection of Cancer; Humans; Neoplasms; Piperazines; Pyrroles; RNA, Messenger; Thiophenes

2019
Rational Design of BODIPY-Diketopyrrolopyrrole Conjugated Polymers for Photothermal Tumor Ablation.
    ACS applied materials & interfaces, 2019, Sep-11, Volume: 11, Issue:36

    Topics: Animals; Boron Compounds; Density Functional Theory; HeLa Cells; Humans; Hyperthermia, Induced; Ketones; Mice; Nanoparticles; Neoplasms; Phototherapy; Polymers; Pyrroles; Tumor Burden

2019
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor.
    Journal of medicinal chemistry, 2019, 09-26, Volume: 62, Issue:18

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Dogs; Drug Design; Humans; Inhibitory Concentration 50; Kinetics; Male; Mice; Molecular Conformation; Neoplasms; Oxazines; Protein Kinase Inhibitors; Pyrimidinones; Pyrroles; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; TOR Serine-Threonine Kinases

2019
NIR- and thermo-responsive semi-interpenetrated polypyrrole nanogels for imaging guided combinational photothermal and chemotherapy.
    Journal of controlled release : official journal of the Controlled Release Society, 2019, Volume: 311-312

    Topics: A549 Cells; Animals; Antineoplastic Agents; Contrast Media; Diagnostic Imaging; Drug Delivery Systems; Female; Hot Temperature; Humans; Methotrexate; Mice, Nude; Nanogels; Neoplasms; Photoacoustic Techniques; Phototherapy; Polymers; Pyrroles

2019
Polymeric Bis(dipyrrinato) Zinc(II) Nanoparticles as Selective Imaging Probes for Lysosomes of Cancer Cells.
    Inorganic chemistry, 2019, Sep-16, Volume: 58, Issue:18

    Topics: A549 Cells; Cell Line; Coordination Complexes; Fluorescent Dyes; HeLa Cells; Humans; Lysosomes; Microscopy, Confocal; Nanoparticles; Neoplasms; Optical Imaging; Polymers; Pyrroles; Zinc

2019
Investigation of thyroid function in dogs treated with the tyrosine kinase inhibitor toceranib.
    Veterinary and comparative oncology, 2020, Volume: 18, Issue:3

    Topics: Animals; Dog Diseases; Dogs; Female; Hypothyroidism; Indoles; Male; Neoplasms; Prospective Studies; Pyrroles; Thyroid Gland; Thyrotropin; Thyroxine; United Kingdom

2020
Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice.
    BMC cancer, 2019, Sep-14, Volume: 19, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclohexanes; Disease Models, Animal; Humans; Magnetic Resonance Imaging; Mice; Neoplasms; Positron-Emission Tomography; Pyrroles; Thiazoles; Xenograft Model Antitumor Assays

2019
NIR-II-Excited Intravital Two-Photon Microscopy Distinguishes Deep Cerebral and Tumor Vasculatures with an Ultrabright NIR-I AIE Luminogen.
    Advanced materials (Deerfield Beach, Fla.), 2019, Volume: 31, Issue:44

    Topics: Animals; Blood Vessels; Brain; Cell Survival; Fluorescent Dyes; HeLa Cells; Humans; Mice, Inbred BALB C; Microscopy, Fluorescence, Multiphoton; Neoplasms; Pyrroles; Quantum Dots; Spectroscopy, Near-Infrared; Thiadiazoles; Tissue Distribution

2019
Discovery of amide-bridged pyrrolo[2,3-d]pyrimidines as tumor targeted classical antifolates with selective uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
    Bioorganic & medicinal chemistry, 2019, 12-01, Volume: 27, Issue:23

    Topics: Amides; Animals; Antineoplastic Agents; Biosynthetic Pathways; Cell Line, Tumor; CHO Cells; Cricetulus; Folate Receptor 1; Folic Acid Antagonists; Humans; Models, Molecular; Neoplasms; Purine Nucleotides; Pyridines; Pyrroles

2019
TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
    Molecular oncology, 2020, Volume: 14, Issue:1

    Topics: Animals; Antineoplastic Agents; Benzodiazepines; Biliary Tract Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Immunoconjugates; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oncogenes; Proto-Oncogene Proteins c-met; Pyrroles; Rats; Rats, Sprague-Dawley; Stomach Neoplasms; Tissue Array Analysis; Xenograft Model Antitumor Assays

2020
Pyrrole derivatives as potential anti-cancer therapeutics: synthesis, mechanisms of action, safety.
    Journal of drug targeting, 2020, Volume: 28, Issue:5

    Topics: Animals; Antineoplastic Agents; Antioxidants; Blood Platelets; Cell Line, Tumor; Cell Membrane; ErbB Receptors; Hemoglobins; Humans; Male; Monocytes; Neoplasms; Pyrroles; Rats; Rats, Wistar; Receptors, Vascular Endothelial Growth Factor; Superoxide Dismutase

2020
Deciphering the molecular mechanism of FLT3 resistance mutations.
    The FEBS journal, 2020, Volume: 287, Issue:15

    Topics: Aminopyridines; Benzothiazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Mutation; Neoplasms; Phenylurea Compounds; Protein Conformation; Protein Kinase Inhibitors; Pyrroles

2020
Design and synthesis of a folate-receptor targeted diazepine-ring-opened pyrrolobenzodiazepine prodrug conjugate.
    Bioorganic & medicinal chemistry letters, 2020, 04-01, Volume: 30, Issue:7

    Topics: Animals; Antibiotics, Antineoplastic; Benzodiazepines; Drug Design; Female; Folate Receptors, GPI-Anchored; HeLa Cells; Humans; Mice, Nude; Neoplasms; Prodrugs; Pyrroles; Xenograft Model Antitumor Assays

2020
Potential 2,4-dimethyl-1H-pyrrole-3-carboxamide bearing benzimidazole template: Design, synthesis, in vitro anticancer and in silico ADME study.
    Bioorganic chemistry, 2020, Volume: 97

    Topics: Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Methylation; Models, Molecular; Neoplasms; Pyrroles; Structure-Activity Relationship

2020
Assessment of tumor enhancement by contrast-enhanced CT in solid tumor-bearing dogs treated with toceranib phosphate.
    Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association, 2020, Volume: 61, Issue:4

    Topics: Animals; Antineoplastic Agents; Contrast Media; Cross-Sectional Studies; Dog Diseases; Dogs; Female; Humans; Indoles; Male; Neoplasms; Pyrroles; Retrospective Studies; Tomography, X-Ray Computed

2020
Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs.
    Journal of veterinary internal medicine, 2020, Volume: 34, Issue:3

    Topics: Adenocarcinoma; Animals; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Dog Diseases; Dogs; Female; Indoles; Male; Neoplasm Recurrence, Local; Neoplasms; Pyrroles; Retrospective Studies; Treatment Outcome; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-2

2020
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.
    PloS one, 2020, Volume: 15, Issue:4

    Topics: Administration, Oral; Animals; Cell Line, Tumor; Female; Half-Life; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, SCID; Morpholines; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Nude; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Xenograft Model Antitumor Assays

2020
Precisely Tuning Photothermal and Photodynamic Effects of Polymeric Nanoparticles by Controlled Copolymerization.
    Angewandte Chemie (International ed. in English), 2020, 07-27, Volume: 59, Issue:31

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Infrared Rays; Mice; Nanoparticles; Neoplasms; Photochemotherapy; Photosensitizing Agents; Photothermal Therapy; Polymerization; Polymers; Pyrroles; Reactive Oxygen Species

2020
Scalable dextran-polypyrrole nano-assemblies with photothermal/photoacoustic dual capabilities and enhanced biocompatibility.
    Carbohydrate polymers, 2020, Aug-01, Volume: 241

    Topics: Animals; Biocompatible Materials; Cell Line, Tumor; Cell Survival; Dextrans; Human Umbilical Vein Endothelial Cells; Humans; Mice, Inbred BALB C; Nanostructures; Neoplasms; Photoacoustic Techniques; Phototherapy; Polymers; Pyrroles

2020
Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
    Inflammatory bowel diseases, 2021, 05-17, Volume: 27, Issue:6

    Topics: Clinical Trials, Phase III as Topic; Colitis, Ulcerative; Humans; Janus Kinase Inhibitors; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Neoplasms; Treatment Outcome

2021
Synthesis and biological evaluation of substituted pyrrolidines and pyrroles as potential anticancer agents.
    Archiv der Pharmazie, 2020, Volume: 353, Issue:12

    Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HCT116 Cells; HeLa Cells; HL-60 Cells; Humans; Inhibitory Concentration 50; Jurkat Cells; Molecular Structure; Neoplasms; PC-3 Cells; Pyrroles; Pyrrolidines; Structure-Activity Relationship; Time Factors

2020
Synthesis of novel 4,5-dihydropyrrolo[1,2-a]quinoxalines, pyrrolo[1,2-a]quinoxalin]-2-ones and their antituberculosis and anticancer activity.
    Archiv der Pharmazie, 2020, Volume: 353, Issue:12

    Topics: A549 Cells; Antineoplastic Agents; Antitubercular Agents; Cell Survival; Dose-Response Relationship, Drug; Drug Design; HeLa Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Melanoma, Experimental; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Neoplasms; Pyrroles; Quinoxalines; Structure-Activity Relationship

2020
Design, synthesis and anti-cancer activity of pyrrole-imidazole polyamides through target-downregulation of c-kit gene expression.
    European journal of medicinal chemistry, 2020, Dec-01, Volume: 207

    Topics: A549 Cells; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Design; Humans; Imidazoles; Neoplasms; Nylons; Promoter Regions, Genetic; Proto-Oncogene Proteins c-kit; Pyrroles

2020
A Hybrid Organo-Nanotheranostic Platform of Superlative Biocompatibility for Near-Infrared-Triggered Fluorescence Imaging and Synergistically Enhanced Ablation of Tumors.
    Small (Weinheim an der Bergstrasse, Germany), 2020, Volume: 16, Issue:41

    Topics: Animals; Cell Line, Tumor; Indocyanine Green; Mice; Nanoparticles; Neoplasms; Optical Imaging; Phototherapy; Polymers; Pyrroles; Theranostic Nanomedicine

2020
Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
    European journal of medicinal chemistry, 2021, Jan-01, Volume: 209

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Drug Design; Drug Discovery; Drug Screening Assays, Antitumor; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Models, Molecular; Neoplasms; Pyridines; Pyridones; Pyrroles; Transcription Factors

2021
Fabrication of electrochemical immunosensor based on acid-substituted poly(pyrrole) polymer modified disposable ITO electrode for sensitive detection of CCR4 cancer biomarker in human serum.
    Talanta, 2021, Jan-15, Volume: 222

    Topics: Antibodies, Immobilized; Biomarkers, Tumor; Biosensing Techniques; Electrochemical Techniques; Electrodes; Humans; Immunoassay; Limit of Detection; Neoplasms; Polymers; Pyrroles; Receptors, CCR4; Reproducibility of Results; Tin Compounds

2021
BF
    ACS applied materials & interfaces, 2020, Nov-25, Volume: 12, Issue:47

    Topics: Animals; Biocompatible Materials; Cell Line, Tumor; Cell Survival; Fluorescent Dyes; Mice; Mice, Nude; Nanoparticles; Neoplasms; Particle Size; Photothermal Therapy; Pyrroles; Spectroscopy, Near-Infrared; Theranostic Nanomedicine; Tissue Distribution; Transplantation, Homologous

2020
The challenge of drug approval in rare cancers.
    Cancer, 2021, 03-15, Volume: 127, Issue:6

    Topics: Drug Approval; Humans; Neoplasms; Pyrroles

2021
Heavy-Atom-Free Photosensitizers: From Molecular Design to Applications in the Photodynamic Therapy of Cancer.
    Accounts of chemical research, 2021, 01-05, Volume: 54, Issue:1

    Topics: Boron; Boron Compounds; Drug Design; Humans; Light; Naphthalimides; Neoplasms; Photochemotherapy; Photosensitizing Agents; Pyrroles; Quantum Theory; Singlet Oxygen

2021
Metal-Free Organo-Theranostic Nanosystem with High Nitroxide Stability and Loading for Image-Guided Targeted Tumor Therapy.
    ACS nano, 2021, 02-23, Volume: 15, Issue:2

    Topics: Cell Line, Tumor; Humans; Hyperthermia, Induced; Magnetic Resonance Imaging; Nanoparticles; Neoplasms; Nitrogen Oxides; Phototherapy; Polymers; Pyrroles; Theranostic Nanomedicine

2021
A PI polyamide-TPP conjugate targeting a mtDNA mutation induces cell death of cancer cells with the mutation.
    Cancer science, 2021, Volume: 112, Issue:6

    Topics: Cell Survival; DNA, Mitochondrial; HeLa Cells; Humans; Imidazoles; Mitochondria; Mitophagy; Mutation; Neoplasms; Nylons; Pyrroles; Reactive Oxygen Species; Sulfonium Compounds; Surface Plasmon Resonance

2021
A Highly Efficient One-for-All Nanodroplet for Ultrasound Imaging-Guided and Cavitation-Enhanced Photothermal Therapy.
    International journal of nanomedicine, 2021, Volume: 16

    Topics: Animals; Contrast Media; Female; Fluorocarbons; HeLa Cells; Humans; Mice, Inbred BALB C; Microbubbles; Nanostructures; Neoplasms; Neoplasms, Experimental; Phase Transition; Photoacoustic Techniques; Photothermal Therapy; Polymers; Pyrroles; Ultrasonography; Xenograft Model Antitumor Assays

2021
    The Lancet. Microbe, 2021, Volume: 2, Issue:6

    Topics: Cross-Sectional Studies; DNA; Ethiopia; HeLa Cells; HIV Infections; Humans; Hydrogen Peroxide; Isoniazid; Latent Tuberculosis; Leukocytes, Mononuclear; Manganese Compounds; Methylene Blue; Microscopy, Confocal; Mycobacterium tuberculosis; Nanocomposites; Nanoparticles; Neoplasms; Oxides; Photochemotherapy; Photosensitizing Agents; Photothermal Therapy; Polyethylene Glycols; Polymers; Prospective Studies; Pyrroles; Tuberculin Test; Tuberculosis; Tumor Microenvironment

2021
Iron Self-Boosting Polymer Nanoenzyme for Low-Temperature Photothermal-Enhanced Ferrotherapy.
    ACS applied materials & interfaces, 2021, Jul-07, Volume: 13, Issue:26

    Topics: Animals; Antineoplastic Agents; Carboxylic Acids; Catalysis; Female; Ferroptosis; HeLa Cells; Humans; Hydrogen Peroxide; Hydroxyl Radical; Iron; Light; Mice, Inbred BALB C; Mice, Nude; Nanostructures; Neoplasms; Photosensitizing Agents; Photothermal Therapy; Polymers; Pyrroles; Temperature

2021
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.
    Cell, 2021, 07-22, Volume: 184, Issue:15

    Topics: Animals; Antigen Presentation; Antigens, Neoplasm; Cell Line, Tumor; Cell Proliferation; Epitopes; Ethylenediamines; Gene Expression Regulation, Neoplastic; Hematopoiesis; Histocompatibility Antigens Class I; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Inflammation; Mice, Inbred C57BL; Neoplasms; Peptides; Protein Isoforms; Pyrroles; RNA Splicing; Sulfonamides; T-Lymphocytes

2021
Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes.
    Cancer research, 2021, 08-15, Volume: 81, Issue:16

    Topics: Active Transport, Cell Nucleus; Animals; Biomarkers, Tumor; Carrier Proteins; Cell Line, Tumor; Collagen; Cyclic N-Oxides; Drug Combinations; Genome, Human; Humans; Indolizines; Laminin; MCF-7 Cells; Membrane Proteins; Mice; Neoplasm Invasiveness; Neoplasm Transplantation; Neoplasms; Oxidation-Reduction; Phenotype; Phosphorylation; Protein Isoforms; Proteoglycans; Proteomics; Pyridazines; Pyridinium Compounds; Pyrroles; Pyruvate Kinase; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Triple Negative Breast Neoplasms

2021
Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19.
    International journal of biological sciences, 2021, Volume: 17, Issue:9

    Topics: Animals; Chlorocebus aethiops; Computer Simulation; COVID-19; COVID-19 Drug Treatment; Humans; Neoplasms; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor Cross-Talk; SARS-CoV-2; Vero Cells; Virus Internalization

2021
Singlet Oxygen-Responsive Polymeric Nanomedicine for Light-Controlled Drug Release and Image-Guided Photodynamic-Chemo Combination Therapy.
    ACS applied materials & interfaces, 2021, Jul-28, Volume: 13, Issue:29

    Topics: Acrylates; Animals; Antineoplastic Agents; Boron Compounds; Cell Line, Tumor; Drug Carriers; Drug Liberation; Female; Humans; Mice; Nanoparticles; Neoplasms; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Polyesters; Polyethylene Glycols; Pyrroles; Singlet Oxygen

2021
Increased incidence of gastrointestinal toxicity in canine cancer patients treated with concurrent abdominal radiation therapy and toceranib phosphate.
    Veterinary and comparative oncology, 2022, Volume: 20, Issue:1

    Topics: Abdomen; Animals; Dog Diseases; Dogs; Humans; Incidence; Indoles; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies

2022
Fluorescence/photoacoustic imaging-guided nanomaterials for highly efficient cancer theragnostic agent.
    Scientific reports, 2021, 08-05, Volume: 11, Issue:1

    Topics: Animals; Cell Line, Tumor; Chitosan; Fluorescence; Humans; Nanocomposites; Neoplasms; Optical Imaging; Photoacoustic Techniques; Phototherapy; Polymers; Pyrroles; Theranostic Nanomedicine

2021
Dihydropyrazole and dihydropyrrole structures based design of Kif15 inhibitors as novel therapeutic agents for cancer.
    Computational biology and chemistry, 2017, Volume: 68

    Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Kinesins; Molecular Docking Simulation; Molecular Structure; Neoplasms; Pyrazoles; Pyrroles; Quantitative Structure-Activity Relationship

2017
Tyrosine kinase-targeting drugs-associated heart failure.
    British journal of cancer, 2017, May-09, Volume: 116, Issue:10

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Case-Control Studies; Cetuximab; Cohort Studies; Heart Failure; Humans; Incidence; Indoles; Israel; Middle Aged; Neoplasms; Odds Ratio; Panitumumab; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sunitinib; Trastuzumab

2017
Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.
    Cancer cell, 2017, 04-10, Volume: 31, Issue:4

    Topics: Animals; Antineoplastic Agents; B7 Antigens; Benzodiazepines; Blood Vessels; Cell Line, Tumor; Endothelium, Vascular; Female; Humans; Immunoconjugates; Male; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Molecular Targeted Therapy; Neoplasms; Oligopeptides; Pyrroles; Rabbits

2017
Ortho group activation of a bromopyrrole ester in Suzuki-Miyaura cross-coupling reactions: Application to the synthesis of new microtubule depolymerizing agents with potent cytotoxic activities.
    Bioorganic & medicinal chemistry, 2017, 06-15, Volume: 25, Issue:12

    Topics: Animals; Antineoplastic Agents; Cattle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Halogenation; Humans; Microtubules; Molecular Docking Simulation; Neoplasms; Pyrroles; Rats

2017
Molecular docking studies of 3-bromopyruvate and its derivatives to metabolic regulatory enzymes: Implication in designing of novel anticancer therapeutic strategies.
    PloS one, 2017, Volume: 12, Issue:5

    Topics: Antineoplastic Agents; Citric Acid Cycle; Computer Simulation; Enzyme Inhibitors; Glycolysis; Humans; Ligands; Molecular Docking Simulation; Neoplasms; Propionates; Pyrroles; Pyruvates; Succinate Dehydrogenase

2017
AKT Inhibition in Solid Tumors With AKT1 Mutations.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Jul-10, Volume: 35, Issue:20

    Topics: Adult; Aged; Alleles; Antineoplastic Agents; Biomarkers, Tumor; Diarrhea; Disease-Free Survival; DNA, Neoplasm; Drug Eruptions; Exanthema; Female; Humans; Hyperglycemia; Loss of Heterozygosity; Male; Middle Aged; Mutation; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Signal Transduction

2017
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
    British journal of clinical pharmacology, 2017, Volume: 83, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chromatography, High Pressure Liquid; Drug Monitoring; Feasibility Studies; Female; Humans; Imatinib Mesylate; Indazoles; Indoles; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Tandem Mass Spectrometry; Treatment Outcome; Young Adult

2017
DNA-assisted upconversion nanoplatform for imaging-guided synergistic therapy and laser-switchable drug detoxification.
    Biomaterials, 2017, Volume: 136

    Topics: Animals; Antineoplastic Agents; Delayed-Action Preparations; DNA; Female; HEK293 Cells; HeLa Cells; Humans; Hyperthermia, Induced; Luminescent Agents; Lutetium; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Optical Imaging; Phototherapy; Polymers; Pyrroles; Sodium Fluoride

2017
A pyrrole-based natural small molecule mitigates HSP90 expression in MDA-MB-231 cells and inhibits tumor angiogenesis in mice by inactivating HSF-1.
    Cell stress & chaperones, 2017, Volume: 22, Issue:5

    Topics: Animals; Cell Line, Tumor; Cell Movement; Cornea; Down-Regulation; Female; Heat Shock Transcription Factors; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Mice; Mitogen-Activated Protein Kinase 3; Neoplasms; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Phosphorylation; Plant Leaves; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Wistar; Tinospora; Transplantation, Heterologous

2017
Highly absorbing multispectral near-infrared polymer nanoparticles from one conjugated backbone for photoacoustic imaging and photothermal therapy.
    Biomaterials, 2017, Volume: 144

    Topics: Animals; Female; HeLa Cells; Humans; Hyperthermia, Induced; Infrared Rays; Ketones; MCF-7 Cells; Mice, Inbred ICR; Nanoparticles; Neoplasms; Optical Imaging; Photoacoustic Techniques; Phototherapy; Pyrroles; Theranostic Nanomedicine; Thiophenes

2017
Diketopyrrolopyrrole-Based Photosensitizers Conjugated with Chemotherapeutic Agents for Multimodal Tumor Therapy.
    ACS applied materials & interfaces, 2017, Sep-13, Volume: 9, Issue:36

    Topics: Antineoplastic Agents; Combined Modality Therapy; Humans; Neoplasms; Photochemotherapy; Photosensitizing Agents; Pyrroles

2017
Synthesis of Size-Tunable Hollow Polypyrrole Nanostructures and Their Assembly into Folate-Targeting and pH-Responsive Anticancer Drug-Delivery Agents.
    Chemistry (Weinheim an der Bergstrasse, Germany), 2017, Dec-06, Volume: 23, Issue:68

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Carriers; HEK293 Cells; Humans; Hydrogen-Ion Concentration; Mice; Mice, Nude; MicroRNAs; Nanostructures; Neoplasms; Optical Imaging; Photoelectron Spectroscopy; Polyethylene Glycols; Polymers; Pyrroles; Spectroscopy, Fourier Transform Infrared; Tissue Distribution; Titanium; Transplantation, Heterologous

2017
Facile Preparation of Doxorubicin-Loaded and Folic Acid-Conjugated Carbon Nanotubes@Poly(N-vinyl pyrrole) for Targeted Synergistic Chemo-Photothermal Cancer Treatment.
    Bioconjugate chemistry, 2017, 11-15, Volume: 28, Issue:11

    Topics: Antibiotics, Antineoplastic; Doxorubicin; Drug Carriers; Drug Delivery Systems; Folic Acid; HeLa Cells; Humans; Hyperthermia, Induced; Nanotubes, Carbon; Neoplasms; Phototherapy; Polyvinyls; Pyrroles

2017
Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers.
    Journal of medicinal chemistry, 2017, 12-14, Volume: 60, Issue:23

    Topics: Animals; Antineoplastic Agents; Benzodiazepines; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dimerization; Female; Humans; Immunoconjugates; Mice; Models, Molecular; Neoplasms; Pyrroles; Receptor, ErbB-2; Sialic Acid Binding Ig-like Lectin 2

2017
Pyrrolidinyl PNA polypyrrole/silver nanofoam electrode as a novel label-free electrochemical miRNA-21 biosensor.
    Biosensors & bioelectronics, 2018, Apr-15, Volume: 102

    Topics: Biosensing Techniques; Dielectric Spectroscopy; Electrochemical Techniques; Gold; Humans; Limit of Detection; MicroRNAs; Neoplasms; Nucleic Acid Hybridization; Polymers; Pyrroles; Pyrrolidines; Silver

2018
Photo-based PDT/PTT dual model killing and imaging of cancer cells using phycocyanin-polypyrrole nanoparticles.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2018, Volume: 123

    Topics: Cell Line; Cell Line, Tumor; Chemistry, Pharmaceutical; HEK293 Cells; Humans; Nanoparticles; Neoplasms; Photochemotherapy; Photosensitizing Agents; Phycocyanin; Polymers; Pyrroles; Reactive Oxygen Species; Serum Albumin, Bovine

2018
Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia.
    Journal of feline medicine and surgery, 2018, Volume: 20, Issue:2

    Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Female; Indoles; Male; Mast Cells; Neoplasms; Pyrroles; Retrospective Studies; Treatment Outcome

2018
Near infrared imaging of Mer tyrosine kinase (MERTK) using MERi-SiR reveals tumor associated macrophage uptake in metastatic disease.
    Chemical communications (Cambridge, England), 2017, Dec-19, Volume: 54, Issue:1

    Topics: Animals; Binding Sites; c-Mer Tyrosine Kinase; Cell Line, Tumor; Cell Proliferation; Fluorescent Dyes; Macrophages; Mice; Microscopy, Confocal; Molecular Docking Simulation; Neoplasm Metastasis; Neoplasms; Protein Structure, Tertiary; Pyrimidines; Pyrroles; RNA Interference; RNA, Small Interfering; Signal Transduction; Spectroscopy, Near-Infrared; Structure-Activity Relationship

2017
Effects of Toceranib Phosphate on the Hypothalamic-Pituitary-Thyroid Axis in Tumor-Bearing Dogs.
    Journal of veterinary internal medicine, 2018, Volume: 32, Issue:1

    Topics: Animals; Autoantibodies; Dog Diseases; Dogs; Female; Hypothalamus; Hypothyroidism; Indoles; Male; Neoplasms; Pituitary Gland; Prospective Studies; Pyrroles; Thyroglobulin; Thyroid Gland; Thyrotropin; Thyroxine; Triiodothyronine

2018
pH Switchable Nanoassembly for Imaging a Broad Range of Malignant Tumors.
    ACS nano, 2017, 12-26, Volume: 11, Issue:12

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Cells, Cultured; Drug Screening Assays, Antitumor; HeLa Cells; Human Umbilical Vein Endothelial Cells; Humans; Hydrogen-Ion Concentration; Ketones; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Neoplasms, Experimental; Pyrroles; Thiophenes; Tumor Microenvironment

2017
Latent Warheads for Targeted Cancer Therapy: Design and Synthesis of pro-Pyrrolobenzodiazepines and Conjugates.
    Bioconjugate chemistry, 2017, Dec-20, Volume: 28, Issue:12

    Topics: Antineoplastic Agents; Benzodiazepines; Chemistry Techniques, Synthetic; Drug Design; Humans; KB Cells; Molecular Targeted Therapy; Neoplasms; Prodrugs; Pyrroles

2017
Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort.
    Oral surgery, oral medicine, oral pathology and oral radiology, 2018, Volume: 125, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Dasatinib; Denmark; Everolimus; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Pyrroles; Retrospective Studies; Sunitinib

2018
Intratumoral Payload Concentration Correlates with the Activity of Antibody-Drug Conjugates.
    Molecular cancer therapeutics, 2018, Volume: 17, Issue:3

    Topics: Animals; Antibodies; Benzodiazepines; Cell Line, Tumor; Drug Liberation; Humans; Immunoconjugates; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasms; Pyrroles; Receptor, ErbB-2; Tumor Burden; Xenograft Model Antitumor Assays

2018
Tumor-Targeting Nanoparticles of Small-Molecule Diketopyrrolopyrrole Derivative for Photothermal Therapy.
    Journal of nanoscience and nanotechnology, 2018, Apr-01, Volume: 18, Issue:4

    Topics: Animals; Ketones; Lasers; Mice; Nanoparticles; Neoplasms; Phototherapy; Pyrroles

2018
Restoration of conformation of mutant p53.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 05-01, Volume: 29, Issue:5

    Topics: Alkylation; Aminoquinolines; Antineoplastic Agents; Apoptosis; Clinical Trials as Topic; Ellipticines; Humans; Mutation; Neoplasms; Protein Binding; Protein Interaction Domains and Motifs; Pyrazoles; Pyrroles; Quinuclidines; Structure-Activity Relationship; Thiosemicarbazones; Tumor Suppressor Protein p53

2018
Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide-Hoechst Conjugate Suppresses Tumor Growth
    Molecular cancer therapeutics, 2018, Volume: 17, Issue:5

    Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Female; Fluorescent Dyes; HeLa Cells; Humans; Imidazoles; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Nylons; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrroles; Xenograft Model Antitumor Assays

2018
Functionalized poly(pyrrole-3-carboxylic acid) nanoneedles for dual-imaging guided PDT/PTT combination therapy.
    Biomaterials, 2018, Volume: 167

    Topics: Animals; Carboxylic Acids; Combined Modality Therapy; Female; HeLa Cells; Humans; Hyperthermia, Induced; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Nanostructures; Neoplasms; Optical Imaging; Organometallic Compounds; Photochemotherapy; Photosensitizing Agents; Polymers; Pyrroles; RAW 264.7 Cells; Theranostic Nanomedicine; Thermography

2018
Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
    Oral surgery, oral medicine, oral pathology and oral radiology, 2018, Volume: 125, Issue:5

    Topics: Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Incidence; Indoles; Ipilimumab; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Pamidronate; Pyrroles; Retrospective Studies; Sunitinib; Zoledronic Acid

2018
Hydrophobic structure of hairpin ten-ring pyrrole-imidazole polyamides enhances tumor tissue accumulation/retention in vivo.
    Bioorganic & medicinal chemistry, 2018, 05-15, Volume: 26, Issue:9

    Topics: Animals; Cell Line, Tumor; Cell Nucleus; Female; Fluoresceins; Fluorescence; Fluorescent Dyes; Humans; Hydrophobic and Hydrophilic Interactions; Imidazoles; Mice, Inbred BALB C; Molecular Structure; Neoplasms; Nylons; Pyrroles; Tissue Distribution

2018
Quinonoid compounds via reactions of lawsone and 2-aminonaphthoquinone with α-bromonitroalkenes and nitroallylic acetates: Structural diversity by C-ring modification and cytotoxic evaluation against cancer cells.
    European journal of medicinal chemistry, 2018, May-10, Volume: 151

    Topics: Acetates; Alkenes; Amination; Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Furans; Halogenation; Humans; Models, Molecular; Naphthoquinones; Neoplasms; Pyrroles; Quinones; Structure-Activity Relationship

2018
A theranostic nanocomposite system based on iron oxide-drug nanocages for targeted magnetic field responsive chemotherapy.
    Nanomedicine : nanotechnology, biology, and medicine, 2018, Volume: 14, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Drug Delivery Systems; Ferric Compounds; HeLa Cells; Humans; Magnetic Fields; MCF-7 Cells; Nanocomposites; Neoplasms; Pyrroles; Quinones; Theranostic Nanomedicine

2018
pH/NIR-Responsive Polypyrrole-Functionalized Fibrous Localized Drug-Delivery Platform for Synergistic Cancer Therapy.
    ACS applied materials & interfaces, 2018, Jun-20, Volume: 10, Issue:24

    Topics: Drug Delivery Systems; Humans; Hydrogen-Ion Concentration; Infrared Rays; Neoplasms; Polymers; Pyrroles

2018
NIR-controlled morphology transformation and pulsatile drug delivery based on multifunctional phototheranostic nanoparticles for photoacoustic imaging-guided photothermal-chemotherapy.
    Biomaterials, 2018, Volume: 176

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Combined Modality Therapy; Doxorubicin; Drug Liberation; Fluorescent Dyes; Heterografts; Humans; Hypothermia, Induced; Infrared Rays; Lasers; Mice; Nanocapsules; Neoplasms; Photoacoustic Techniques; Photochemotherapy; Polyhydroxyethyl Methacrylate; Polymers; Prodrugs; Pyrroles; Theranostic Nanomedicine

2018
Cytotoxic and Apoptotic Effects of Novel Pyrrolo[2,3-d]Pyrimidine Derivatives Containing Urea Moieties on Cancer Cell Lines.
    Anti-cancer agents in medicinal chemistry, 2018, Volume: 18, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Neoplasms; Pyrimidines; Pyrroles; Structure-Activity Relationship; Urea

2018
Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
    JCI insight, 2018, 06-07, Volume: 3, Issue:11

    Topics: Aminopyridines; Animals; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Diphtheria Toxin; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Forkhead Transcription Factors; Gene Knockout Techniques; Humans; Lymphocyte Depletion; Macrophages; Male; Mice; Mice, Transgenic; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Primary Cell Culture; Purines; Pyrroles; Quinazolinones; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; T-Lymphocytes, Regulatory; Tumor Microenvironment

2018
A retrospective study of proteinuria in dogs receiving toceranib phosphate.
    The Canadian veterinary journal = La revue veterinaire canadienne, 2018, Volume: 59, Issue:6

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Dog Diseases; Dogs; Female; Glucocorticoids; Incidence; Indoles; Male; Neoplasms; Proteinuria; Pyrroles; Retrospective Studies

2018
Purin-6-one and pyrrolo[2,3-d]pyrimidin-4-one derivatives as potentiating agents of doxorubicin cytotoxicity.
    Future medicinal chemistry, 2018, Sep-01, Volume: 10, Issue:17

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Humans; Neoplasms; Purinones; Pyrimidinones; Pyrroles

2018
Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class.
    Angewandte Chemie (International ed. in English), 2018, 11-12, Volume: 57, Issue:46

    Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Discovery; Humans; Immunoconjugates; Kinesins; Neoplasms; Pyrroles

2018
Microwave-assisted ultrafast fabrication of high-performance polypyrrole nanoparticles for photothermal therapy of tumors in vivo.
    Biomaterials science, 2018, Sep-25, Volume: 6, Issue:10

    Topics: Animals; Cell Line, Tumor; Cell Survival; Hyperthermia, Induced; Lasers; Mice; Microscopy, Electron, Transmission; Microwaves; Nanoparticles; Neoplasms; Phototherapy; Polymers; Pyrroles

2018
Chemoresistance of cancer floating cells is independent of their ability to form 3D structures: Implications for anticancer drug screening.
    Journal of cellular physiology, 2019, Volume: 234, Issue:4

    Topics: Antibodies; Antigens, CD; Antineoplastic Agents; Cadherins; Cell Adhesion; Cell Culture Techniques; Cell Survival; Colchicine; Culture Media, Serum-Free; Drug Resistance, Neoplasm; Female; Humans; Hydroxyurea; Indoles; Male; MCF-7 Cells; Neoplasms; PC-3 Cells; Phenotype; Pyrroles; Spheroids, Cellular

2019
Influence of Sorafenib, Sunitinib and Capecitabine on the Antioxidant Status of the Skin.
    Anticancer research, 2018, Volume: 38, Issue:9

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antioxidants; Capecitabine; Carotenoids; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Skin; Sorafenib; Sunitinib

2018
Synthesis of 5H-pyrido[3,2-b]pyrrolizin-5-one tripentone analogs with antitumor activity.
    European journal of medicinal chemistry, 2018, Oct-05, Volume: 158

    Topics: Antineoplastic Agents; Apoptosis; Caco-2 Cells; Cell Line, Tumor; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; MCF-7 Cells; Neoplasms; Pyridines; Pyrroles; Structure-Activity Relationship

2018
Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling.
    Bioorganic chemistry, 2018, Volume: 81

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Human Umbilical Vein Endothelial Cells; Humans; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Urea; Vascular Endothelial Growth Factor Receptor-2

2018
Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2.
    European journal of medicinal chemistry, 2018, Oct-05, Volume: 158

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrroles; Triazines; Vascular Endothelial Growth Factor Receptor-2

2018
Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells.
    Cell death & disease, 2018, 09-24, Volume: 9, Issue:10

    Topics: Acetylation; AMP-Activated Protein Kinases; Apoptosis; Autophagosomes; Autophagy; Autophagy-Related Protein-1 Homolog; Cell Cycle; Cell Proliferation; Enzyme Activation; HCT116 Cells; HeLa Cells; Histones; Humans; Intracellular Signaling Peptides and Proteins; Neoplasms; Pyrroles; Quinoxalines; Reactive Oxygen Species; Signal Transduction; Sirtuins

2018
Mutagenic assessment of chemotherapy and Smac mimetic drugs in cells with defective DNA damage response pathways.
    Scientific reports, 2018, 09-26, Volume: 8, Issue:1

    Topics: Apoptosis Regulatory Proteins; Biomimetic Materials; Cell Line, Tumor; Cyclohexanes; DNA Damage; DNA End-Joining Repair; Drug Delivery Systems; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Mitochondrial Proteins; Mutagenesis; Neoplasm Proteins; Neoplasms; Pyrroles

2018
Sterically induced conformational restriction: Discovery and preclinical evaluation of novel pyrrolo[3,2-d]pyrimidines as microtubule targeting agents.
    Bioorganic & medicinal chemistry, 2018, 11-01, Volume: 26, Issue:20

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Mice, Nude; Microtubules; Molecular Docking Simulation; Neoplasms; Pyrimidines; Pyrroles; Stereoisomerism; Tubulin; Tubulin Modulators

2018
Fe
    ACS applied materials & interfaces, 2018, Dec-12, Volume: 10, Issue:49

    Topics: Animals; Cell Line; Delayed-Action Preparations; Doxorubicin; Hydrogels; Infrared Rays; Mice; Neoplasms; Polymers; Pyrroles

2018
Maritoclax Enhances TRAIL-Induced Apoptosis via CHOP-Mediated Upregulation of DR5 and miR-708-Mediated Downregulation of cFLIP.
    Molecules (Basel, Switzerland), 2018, Nov-20, Volume: 23, Issue:11

    Topics: A549 Cells; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasms; Pyrroles; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Transcription Factor CHOP; Up-Regulation

2018
Evaluation of Pyrrolobenzodiazepine-Loaded Nanoparticles: A Targeted Drug Delivery Approach.
    Journal of pharmaceutical sciences, 2019, Volume: 108, Issue:4

    Topics: Animals; Antibiotics, Antineoplastic; Benzodiazepines; Body Weight; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Drug Liberation; Humans; Inhibitory Concentration 50; Injections, Intravenous; Mice; Nanoparticles; Neoplasms; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrroles; Xenograft Model Antitumor Assays

2019
Pyrrolopyrrole aza-BODIPY near-infrared photosensitizer for dual-mode imaging-guided photothermal cancer therapy.
    Chemical communications (Cambridge, England), 2019, Jan-15, Volume: 55, Issue:6

    Topics: Animals; Boron Compounds; HeLa Cells; Humans; Infrared Rays; Mice; Microscopy, Confocal; Neoplasms; Optical Imaging; Photoacoustic Techniques; Photosensitizing Agents; Phototherapy; Pyrroles; Transplantation, Heterologous

2019
Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea.
    JCI insight, 2019, 02-21, Volume: 4, Issue:4

    Topics: Acetamides; Afatinib; Animals; Cell Membrane Permeability; Clotrimazole; Colon; Cystic Fibrosis Transmembrane Conductance Regulator; Diarrhea; Disease Models, Animal; Epithelial Cells; ErbB Receptors; Female; Humans; Intestinal Mucosa; Neoplasms; Oxazines; Potassium Channel Blockers; Potassium Channels; Protein Kinase Inhibitors; Pyrimidinones; Pyrroles; Rats; Trityl Compounds

2019
Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells.
    JCI insight, 2019, 03-07, Volume: 4, Issue:5

    Topics: Animals; Antibodies; Arginase; Breast Neoplasms; Cell Line, Tumor; Cytokines; Disease Models, Animal; Female; Immunoconjugates; Immunotherapy; Immunotoxins; Macrophages; Mice; Mice, Nude; Monocytes; Neoplasms; Neutrophils; Piperidines; Pyrimidines; Pyrroles; RNA, Messenger; Tumor Microenvironment; Xenograft Model Antitumor Assays

2019
Synthesis and evaluation of novel 7
    Future medicinal chemistry, 2019, Volume: 11, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Neoplasms; Pyrimidines; Pyrroles; Structure-Activity Relationship

2019
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
    International journal of cancer, 2019, 09-01, Volume: 145, Issue:5

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Human Umbilical Vein Endothelial Cells; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Phosphorylation; Piperazines; Pyrroles; Random Allocation; Rats; Receptors, Fibroblast Growth Factor; Thiophenes; Xenograft Model Antitumor Assays

2019
Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.
    International journal of rheumatic diseases, 2019, Volume: 22, Issue:6

    Topics: Adult; Arthritis, Rheumatoid; Asia; Clinical Trials as Topic; Evidence-Based Medicine; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Neoplasms; Opportunistic Infections; Piperidines; Pyrimidines; Pyrroles; Recovery of Function; Remission Induction; Risk Factors; Time Factors; Treatment Outcome

2019
Engineered Cell-Assisted Photoactive Nanoparticle Delivery for Image-Guided Synergistic Photodynamic/Photothermal Therapy of Cancer.
    ACS applied materials & interfaces, 2019, Apr-17, Volume: 11, Issue:15

    Topics: Animals; Cell Line, Tumor; Female; Humans; Ketones; Lasers; Mice; Mice, Inbred BALB C; Mice, Nude; Monocytes; Nanoparticles; Neoplasms; Oligopeptides; Peptides, Cyclic; Photochemotherapy; Photosensitizing Agents; Phototherapy; Pyrroles; Quantum Theory; Singlet Oxygen; Transplantation, Heterologous

2019
PRMT1 loss sensitizes cells to PRMT5 inhibition.
    Nucleic acids research, 2019, 06-04, Volume: 47, Issue:10

    Topics: A549 Cells; Animals; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Ethylenediamines; Gene Deletion; Humans; Isoquinolines; MCF-7 Cells; Mice, Knockout; Neoplasms; Protein-Arginine N-Methyltransferases; Pyrimidines; Pyrroles; Repressor Proteins; Signal Transduction

2019
Development of a p38α-selective radioactive probe for qualitative diagnosis of cancer using SPECT.
    Annals of nuclear medicine, 2019, Volume: 33, Issue:5

    Topics: Animals; Biological Transport; Cell Line, Tumor; Humans; Male; Mice; Mitogen-Activated Protein Kinase 14; Neoplasms; Phosphorylation; Pyrroles; Tissue Distribution; Tomography, Emission-Computed, Single-Photon

2019
TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models.
    Molecular cancer therapeutics, 2019, Volume: 18, Issue:7

    Topics: Animals; Cell Line, Tumor; Humans; Male; Mice; Mice, SCID; NEDD8 Protein; Neoplasms; Pyrimidines; Pyrroles

2019
    Current drug discovery technologies, 2020, Volume: 17, Issue:5

    Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Artemisinins; Crystallography, X-Ray; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Pyrroles

2020
Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity.
    Journal of computer-aided molecular design, 2019, Volume: 33, Issue:8

    Topics: Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Humans; Methylation; Molecular Docking Simulation; Neoplasms; Protein Binding; Protein-Arginine N-Methyltransferases; Pyrimidines; Pyrroles; Quinolines; Structure-Activity Relationship; Triazoles

2019
Synthesis and antiproliferative activity of 2,5-bis(3'-indolyl)pyrroles, analogues of the marine alkaloid nortopsentin.
    Marine drugs, 2013, Mar-01, Volume: 11, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Imidazoles; Indoles; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasms; Pyrroles; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays

2013
Thienopyrrole-expanded BODIPY as a potential NIR photosensitizer for photodynamic therapy.
    Chemical communications (Cambridge, England), 2013, May-11, Volume: 49, Issue:38

    Topics: Boron Compounds; Cell Survival; HeLa Cells; Humans; Neoplasms; Photochemotherapy; Photosensitizing Agents; Pyrroles

2013
Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.
    Bioorganic & medicinal chemistry letters, 2013, May-15, Volume: 23, Issue:10

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Humans; Male; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor, TIE-2; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2013
Update in rheumatology: evidence published in 2012.
    Annals of internal medicine, 2013, Jun-18, Volume: 158, Issue:12

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Antiviral Agents; Arthritis; Arthritis, Gouty; Arthritis, Rheumatoid; Autoimmune Diseases; Bacterial Infections; Calcitonin; Colchicine; Cryoglobulinemia; Death, Sudden, Cardiac; Drug Resistance, Viral; Enzyme Inhibitors; Female; Gout; Gout Suppressants; Hand Joints; Hepatitis C, Chronic; Humans; Hyperuricemia; Immunologic Factors; Janus Kinase 3; Male; Myocardial Infarction; Neoplasms; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Practice Guidelines as Topic; Protein Precursors; Pyrimidines; Pyrroles; Registries; Tumor Necrosis Factor-alpha

2013
Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ.
    Current cancer drug targets, 2013, Volume: 13, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line; Cell Proliferation; Female; Humans; JNK Mitogen-Activated Protein Kinases; Mammary Glands, Human; MAP Kinase Kinase 4; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; MCF-7 Cells; Neoplasm Proteins; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Protein Stability; Pyrroles; Quinolones; Transforming Growth Factor beta2; Ubiquitination; Up-Regulation

2013
[Advantages of volume perfusion CT for evaluating the response of solid tumors to treatment with sunitinib].
    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 2013, Volume: 185, Issue:7

    Topics: Aged; Female; Humans; Imaging, Three-Dimensional; Indoles; Male; Middle Aged; Neoplasms; Perfusion Imaging; Prognosis; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden

2013
Iron oxide @ polypyrrole nanoparticles as a multifunctional drug carrier for remotely controlled cancer therapy with synergistic antitumor effect.
    ACS nano, 2013, Aug-27, Volume: 7, Issue:8

    Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Cell Line, Tumor; Drug Carriers; Female; Ferric Compounds; Humans; Magnetic Resonance Imaging; Magnetics; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nanocomposites; Nanoparticles; Nanotechnology; Neoplasm Transplantation; Neoplasms; Polyethylene Glycols; Polymers; Pyrroles

2013
Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; DNA Replication; Gemcitabine; Humans; Mitosis; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles

2013
Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize lysosomes, and inhibit multidrug resistance.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:10

    Topics: Apoptosis; Cell Survival; Drug Resistance, Neoplasm; HeLa Cells; Humans; Indoles; Lysosomes; MCF-7 Cells; Neoplasms; Pyrroles; Sphingomyelin Phosphodiesterase; Sunitinib

2013
Synthesis and evaluation of pyrrole polyamide-2'-deoxyguanosine 5'-phosphate hybrid.
    Nucleosides, nucleotides & nucleic acids, 2013, Volume: 32, Issue:4

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Deoxyguanine Nucleotides; Dose-Response Relationship, Drug; Female; Mammary Neoplasms, Animal; Mice; Molecular Structure; Neoplasms; Nylons; Pyrroles

2013
Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:11

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbolines; Cell Cycle Checkpoints; Checkpoint Kinase 1; Dacarbazine; Deoxycytidine; DNA Damage; Gemcitabine; HCT116 Cells; High-Throughput Nucleotide Sequencing; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2013
Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
    BMC veterinary research, 2013, Sep-30, Volume: 9

    Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Female; Indoles; Male; Neoplasms; Pyrroles; Vascular Endothelial Growth Factor A

2013
Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Cytochrome P-450 CYP3A; Female; Humans; Indoles; Male; Midazolam; Middle Aged; Neoplasms; Phenotype; Prospective Studies; Pyrroles; Sunitinib

2014
Multifunctional polypyrrole@Fe(3)O(4) nanoparticles for dual-modal imaging and in vivo photothermal cancer therapy.
    Small (Weinheim an der Bergstrasse, Germany), 2014, Mar-26, Volume: 10, Issue:6

    Topics: Animals; Ferric Compounds; HeLa Cells; Humans; Hyperthermia, Induced; Magnetic Resonance Imaging; Mice; Mice, Nude; Multimodal Imaging; Nanoparticles; Neoplasms; Phototherapy; Polymers; Pyrroles; Spectrophotometry, Ultraviolet; Temperature

2014
Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
    Therapeutic drug monitoring, 2014, Volume: 36, Issue:3

    Topics: Aged; Antineoplastic Agents; Benzamides; Body Weight; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Monitoring; Erlotinib Hydrochloride; Female; Gastric Acid; Half-Life; Histamine H2 Antagonists; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasms; Outpatients; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Tandem Mass Spectrometry

2014
Protein kinase inhibitor SU6668 attenuates positive regulation of Gli proteins in cancer and multipotent progenitor cells.
    Biochimica et biophysica acta, 2014, Volume: 1843, Issue:4

    Topics: Animals; Cell Differentiation; Cells, Cultured; Gene Expression Regulation, Developmental; Hedgehog Proteins; Humans; Indoles; Kruppel-Like Transcription Factors; Leukocytes, Mononuclear; Mice; Multipotent Stem Cells; Neoplasms; Nuclear Proteins; Oxindoles; Propionates; Protein Serine-Threonine Kinases; Pyrroles; Signal Transduction; Transcription Factors; Transforming Growth Factor beta; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2

2014
Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF.
    International journal of cancer, 2014, Sep-01, Volume: 135, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Genetic Therapy; Humans; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Oncolytic Virotherapy; Oncolytic Viruses; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Vaccinia virus; Vascular Endothelial Growth Factor A

2014
A benign tumor as the apparent trigger for myopathy.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2014, Volume: 20, Issue:2

    Topics: Aged; Atorvastatin; Female; Gynecologic Surgical Procedures; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Leg; Leiomyoma; Muscle Weakness; Muscle, Skeletal; Muscular Diseases; Neoplasms; Pyrroles; Treatment Outcome; Uterine Neoplasms

2014
Methods for adjusting for bias due to crossover in oncology trials.
    PharmacoEconomics, 2014, Volume: 32, Issue:6

    Topics: Antineoplastic Agents; Bias; Cost-Benefit Analysis; Cross-Over Studies; Humans; Indoles; Kaplan-Meier Estimate; Models, Statistical; Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib

2014
In vivo imaging of tumor physiological, metabolic, and redox changes in response to the anti-angiogenic agent sunitinib: longitudinal assessment to identify transient vascular renormalization.
    Antioxidants & redox signaling, 2014, Sep-10, Volume: 21, Issue:8

    Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Contrast Media; Cyclic N-Oxides; Electron Spin Resonance Spectroscopy; Female; Humans; Indoles; Magnetic Resonance Imaging; Mice, Inbred C3H; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Oxidation-Reduction; Oxygen; Pyrroles; Pyruvic Acid; Sunitinib; Xenograft Model Antitumor Assays

2014
An electroactive biotin-doped polypyrrole substrate that immobilizes and releases EpCAM-positive cancer cells.
    Angewandte Chemie (International ed. in English), 2014, Apr-25, Volume: 53, Issue:18

    Topics: Antigens, Neoplasm; Biotin; Cell Adhesion Molecules; Electric Conductivity; Epithelial Cell Adhesion Molecule; Humans; Neoplasms; Polymers; Pyrroles; Streptavidin; Surface Properties; Tumor Cells, Cultured

2014
Polypyrrole-coated chainlike gold nanoparticle architectures with the 808 nm photothermal transduction efficiency up to 70%.
    ACS applied materials & interfaces, 2014, Apr-23, Volume: 6, Issue:8

    Topics: Animals; Cell Line, Tumor; Gold; Hot Temperature; Humans; Hyperthermia, Induced; Metal Nanoparticles; Mice; Neoplasms; Phototherapy; Polymers; Pyrroles

2014
Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cohort Studies; Decision Making; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Netherlands; Niacinamide; Phenylurea Compounds; Pyrroles; Quality of Life; Self Report; Sorafenib; Sunitinib; Treatment Outcome

2014
Encapsulating tantalum oxide into polypyrrole nanoparticles for X-ray CT/photoacoustic bimodal imaging-guided photothermal ablation of cancer.
    Biomaterials, 2014, Volume: 35, Issue:22

    Topics: Animals; Contrast Media; Female; HeLa Cells; Humans; Hyperthermia, Induced; Infrared Rays; Injections, Intralesional; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Oxides; Photoacoustic Techniques; Phototherapy; Polymers; Pyrroles; Tantalum; Tomography, X-Ray Computed

2014
Pyrrole alkaloids with potential cancer chemopreventive activity isolated from a goji berry-contaminated commercial sample of African mango.
    Journal of agricultural and food chemistry, 2014, Jun-04, Volume: 62, Issue:22

    Topics: Alkaloids; Animals; Drug Contamination; Fruit; Lycium; Mangifera; Neoplasms; Plant Extracts; Pyrroles; Rats

2014
Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:12

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Humans; Hypertension; Incidence; Indoles; Interferon-alpha; Kaplan-Meier Estimate; Middle Aged; Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Sunitinib

2014
Determinants for in vivo antitumor effect of angiogenesis inhibitor SU5416 formulated in PEGylated emulsion.
    Journal of pharmaceutical sciences, 2014, Volume: 103, Issue:8

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Emulsions; Endothelium, Vascular; Humans; Indoles; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Neovascularization, Pathologic; Pharmaceutical Vehicles; Polyethylene Glycols; Protein Kinase Inhibitors; Pyrroles; Vascular Endothelial Growth Factor A

2014
Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal.
    Cell metabolism, 2014, Aug-05, Volume: 20, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Disease Progression; Fatty Acid Synthases; Homeodomain Proteins; Humans; Indoles; Lipids; Metabolomics; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteomics; Pyrroles; RNA Interference; Sorafenib; Sunitinib; Transplantation, Heterologous

2014
New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer.
    Journal of medicinal chemistry, 2014, Aug-14, Volume: 57, Issue:15

    Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Cell Survival; Colchicine; Drug Screening Assays, Antitumor; Guanidines; Hedgehog Proteins; Humans; M Phase Cell Cycle Checkpoints; Mice; Molecular Docking Simulation; Neoplasms; Polymerization; Protein Binding; Pyrroles; Signal Transduction; Structure-Activity Relationship; Tubulin; Tubulin Modulators

2014
Exploration of potential EGFR inhibitors: a combination of pharmacophore-based virtual screening, atom-based 3D-QSAR and molecular docking analysis.
    Journal of receptor and signal transduction research, 2015, Volume: 35, Issue:2

    Topics: Antineoplastic Agents; Binding Sites; ErbB Receptors; Humans; Molecular Docking Simulation; Neoplasms; Protein Binding; Pyrimidines; Pyrroles; Quantitative Structure-Activity Relationship; User-Computer Interface

2015
An integrated multifunctional platform based on biotin-doped conducting polymer nanowires for cell capture, release, and electrochemical sensing.
    Biomaterials, 2014, Volume: 35, Issue:36

    Topics: Antibodies, Immobilized; Biosensing Techniques; Biotin; Cell Line, Tumor; Cell Separation; Electrochemical Techniques; Equipment Design; Humans; Immunohistochemistry; Limit of Detection; Nanowires; Neoplasms; Polymers; Pyrroles

2014
Synthesis, hydrolytic DNA-cleaving activities and cytotoxicities of EDTA analogue-tethered pyrrole-polyamide dimer-based Ce(IV) complexes.
    European journal of medicinal chemistry, 2014, Nov-24, Volume: 87

    Topics: Antineoplastic Agents; Cell Proliferation; Cerium; Coordination Complexes; DNA Cleavage; DNA, Superhelical; Drug Design; Drug Screening Assays, Antitumor; Edetic Acid; Flow Cytometry; Humans; Molecular Structure; Neoplasms; Nylons; Organometallic Compounds; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured

2014
Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.
    EMBO molecular medicine, 2014, Volume: 6, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Humans; Indoles; Mice; Mice, SCID; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A

2014
Assessing metastasis risk after pre-operative anti-angiogenic therapy.
    EMBO molecular medicine, 2014, Volume: 6, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Humans; Indoles; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms; Pyrroles

2014
Synthesis of Novel Hybrids Inspired from Bromopyrrole Alkaloids Inhibiting MMP-2 and -12 as Antineoplastic Agents.
    Chemical biology & drug design, 2015, Volume: 86, Issue:2

    Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Matrix Metalloproteinase 12; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; MCF-7 Cells; Neoplasms; Pyrroles; Semicarbazides; Structure-Activity Relationship

2015
HDAC inhibitors increase NRF2-signaling in tumour cells and blunt the efficacy of co-adminstered cytotoxic agents.
    PloS one, 2014, Volume: 9, Issue:11

    Topics: Acrolein; Antineoplastic Agents; Antioxidant Response Elements; Cell Line, Tumor; Cytotoxins; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Neoplasms; NF-E2-Related Factor 2; Proto-Oncogene Proteins c-pim-1; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction

2014
Interactions of multitargeted kinase inhibitors and nucleoside drugs: Achilles heel of combination therapy?
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:1

    Topics: Axitinib; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Nucleoside Transport Proteins; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib

2015
Dithiocarbamate/piperazine bridged pyrrolobenzodiazepines as DNA-minor groove binders: synthesis, DNA-binding affinity and cytotoxic activity.
    Bioorganic chemistry, 2015, Volume: 59

    Topics: Antineoplastic Agents; Benzodiazepines; Binding Sites; Cell Line, Tumor; Cell Survival; DNA; Humans; Models, Molecular; Neoplasms; Nucleic Acid Conformation; Piperazines; Pyrroles; Structure-Activity Relationship; Thiocarbamates

2015
Synthesis, molecular docking and antitumor activity of novel pyrrolizines with potential as EGFR-TK inhibitors.
    Bioorganic chemistry, 2015, Volume: 59

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Drug Design; ErbB Receptors; Humans; MCF-7 Cells; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Structure-Activity Relationship

2015
Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy.
    Scientific reports, 2015, Mar-11, Volume: 5

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Axitinib; Cell Line, Tumor; Chick Embryo; Combined Modality Therapy; Cymenes; Disease Models, Animal; Doxorubicin; Drug Synergism; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Organometallic Compounds; Oxygen Consumption; Photochemotherapy; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tumor Burden

2015
Dual Functioning Thieno-Pyrrole Fused BODIPY Dyes for NIR Optical Imaging and Photodynamic Therapy: Singlet Oxygen Generation without Heavy Halogen Atom Assistance.
    Chemistry, an Asian journal, 2015, Volume: 10, Issue:6

    Topics: Animals; Apoptosis; Boron Compounds; Cell Line, Tumor; Crystallography, X-Ray; Drug Design; Fluorescent Dyes; Halogens; Heterocyclic Compounds, 4 or More Rings; Humans; Lasers; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Conformation; Neoplasms; Photochemotherapy; Photosensitizing Agents; Pyrroles; Quantum Theory; Singlet Oxygen; Spectroscopy, Near-Infrared; Structure-Activity Relationship; Transplantation, Heterologous

2015
Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Adult; Aged, 80 and over; Canada; Cardiovascular Diseases; Female; Humans; Indoles; Male; Middle Aged; Myocardial Ischemia; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sorafenib; Sunitinib

2015
3-[4-(1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridines, nortopsentin analogues with antiproliferative activity.
    Marine drugs, 2015, Apr-03, Volume: 13, Issue:4

    Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Design; G2 Phase; Halogenation; Humans; Imidazoles; Indoles; Membrane Potential, Mitochondrial; Methylation; Mitochondria; Molecular Structure; Neoplasms; Pyridines; Pyrroles; Resting Phase, Cell Cycle; Thiazoles

2015
Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:7

    Topics: Angiogenesis Inhibitors; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Gene Deletion; Humans; Indazoles; Indoles; Lapatinib; Membrane Proteins; Neoplasms; Polymorphism, Genetic; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Sulfonamides; Sunitinib

2015
Hollow mesoporous silica nanoparticles for tumor vasculature targeting and PET image-guided drug delivery.
    Nanomedicine (London, England), 2015, Volume: 10, Issue:8

    Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Indoles; Mice, Nude; Nanoparticles; Neoplasms; Peptides, Cyclic; Porosity; Positron-Emission Tomography; Pyrroles; Silicon Dioxide; Sunitinib

2015
Microwave-Assisted Synthesis of Novel Pyrazolo[3,4-g][1,8]naphthyridin-5-amine with Potential Antifungal and Antitumor Activity.
    Molecules (Basel, Switzerland), 2015, May-12, Volume: 20, Issue:5

    Topics: Antifungal Agents; Antineoplastic Agents; Candida albicans; Cell Line, Tumor; Chlorides; Cryptococcus neoformans; Humans; Ketones; Microbial Sensitivity Tests; Microwaves; Naphthyridines; Neoplasms; Pyrroles; Zinc Compounds

2015
CCR 20th Anniversary Commentary: Determining a Pharmacokinetic/Pharmacodynamic Relationship for Sunitinib—A Look Back.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Jun-01, Volume: 21, Issue:11

    Topics: Anniversaries and Special Events; History, 21st Century; Humans; Indoles; Neoplasms; Pyrroles; Sunitinib

2015
A calixpyrrole derivative acts as an antagonist to GPER, a G-protein coupled receptor: mechanisms and models.
    Disease models & mechanisms, 2015, Oct-01, Volume: 8, Issue:10

    Topics: Animals; Biological Assay; Cell Line, Tumor; Cell Movement; Endoplasmic Reticulum; Fibroblasts; Humans; Ligands; Models, Biological; Models, Molecular; Neoplasms; Pyrroles; Receptors, G-Protein-Coupled; Signal Transduction; Xenopus

2015
Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs.
    Oncotarget, 2015, Sep-29, Volume: 6, Issue:29

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; HeLa Cells; Hep G2 Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Jurkat Cells; MCF-7 Cells; Neoplasms; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcriptome

2015
Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib.
    PloS one, 2015, Volume: 10, Issue:10

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzoates; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Drug Tolerance; Esterases; Female; Humans; Hydrolysis; Indoles; Mice; Neoplasms; Phosphorylation; Prodrugs; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; STAT3 Transcription Factor; Sunitinib; Tissue Distribution; Tumor Burden; Xenograft Model Antitumor Assays

2015
Targeting Mutant AKT in Cancer.
    Cancer discovery, 2016, Volume: 6, Issue:1

    Topics: Clinical Trials, Phase I as Topic; Drug Synergism; Estradiol; Fulvestrant; Humans; Mutation; Neoplasms; Neoplastic Cells, Circulating; Precision Medicine; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Treatment Outcome

2016
Drug therapy: Preclinical oncology - reporting transparency needed.
    Nature reviews. Clinical oncology, 2016, Volume: 13, Issue:1

    Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Carcinoma, Renal Cell; Clinical Trials as Topic; Evidence-Based Medicine; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Medical Oncology; Meta-Analysis as Topic; Neoplasms; Pancreatic Neoplasms; Practice Guidelines as Topic; Pyrroles; Research Design; Research Report; Stomach Neoplasms; Sunitinib; Treatment Outcome

2016
Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
    Bioorganic & medicinal chemistry letters, 2016, Apr-01, Volume: 26, Issue:7

    Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridines; Pyrroles; Structure-Activity Relationship; Triazoles

2016
Retrospective evaluation of toceranib phosphate (Palladia®) toxicity in cats.
    Veterinary and comparative oncology, 2017, Volume: 15, Issue:3

    Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Azotemia; Cat Diseases; Cats; Female; Gastrointestinal Tract; Indoles; Male; Neoplasms; Neutropenia; Pyrroles; Retrospective Studies; Thrombocytopenia

2017
Bromo-Substituted Diketopyrrolopyrrole Derivative with Specific Targeting and High Efficiency for Photodynamic Therapy.
    ACS applied materials & interfaces, 2016, 05-04, Volume: 8, Issue:17

    Topics: Hyaluronic Acid; Neoplasms; Photochemotherapy; Photosensitizing Agents; Pyrroles

2016
Evaluation on the inhibition of pyrrol-2-yl ethanone derivatives to lactate dehydrogenase and anticancer activities.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2016, 08-05, Volume: 165

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Hep G2 Cells; Humans; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Neoplasms; Pyrroles; Pyruvic Acid

2016
Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs.
    Journal of veterinary internal medicine, 2016, Volume: 30, Issue:4

    Topics: Animals; Antineoplastic Agents; Blood Pressure; Case-Control Studies; Cohort Studies; Dog Diseases; Dogs; Hypertension; Indoles; Neoplasms; Prospective Studies; Protein-Tyrosine Kinases; Proteinuria; Pyrroles

2016
Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia.
    Oncogene, 2016, 12-01, Volume: 35, Issue:48

    Topics: Animals; Benzylamines; Biomarkers; Cachexia; Chemokine CXCL12; Cyclams; Cytokines; Disease Models, Animal; Female; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Indoles; Male; Mice; Muscle Fibers, Skeletal; Muscle, Skeletal; Muscular Atrophy; Neoplasms; Pyrroles; Rats; Receptors, CXCR4; Signal Transduction; Sunitinib

2016
High-Throughput Screening and Hit Validation of Extracellular-Related Kinase 5 (ERK5) Inhibitors.
    ACS combinatorial science, 2016, 08-08, Volume: 18, Issue:8

    Topics: Amides; Antineoplastic Agents; High-Throughput Screening Assays; Humans; Mitogen-Activated Protein Kinase 14; Mitogen-Activated Protein Kinase 7; Molecular Structure; Neoplasms; Protein Binding; Protein Kinase Inhibitors; Pyrroles; Structure-Activity Relationship

2016
Chemical Structure and Concentration of Intratumor Catabolites Determine Efficacy of Antibody Drug Conjugates.
    Drug metabolism and disposition: the biological fate of chemicals, 2016, Volume: 44, Issue:9

    Topics: Animals; Antibodies, Monoclonal, Humanized; Benzodiazepines; Female; Immunoconjugates; Mice; Mice, SCID; Neoplasms; Pyrroles; Xenograft Model Antitumor Assays

2016
Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.
    Clinical rheumatology, 2017, Volume: 36, Issue:3

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Neoplasms; Opportunistic Infections; Piperidines; Pyrimidines; Pyrroles; Risk Assessment

2017
Nucleophilic Aromatic Substitution on Pentafluorophenyl-Substituted Dipyrranes and Tetrapyrroles as a Route to Multifunctionalized Chromophores for Potential Application in Photodynamic Therapy.
    Chemistry (Weinheim an der Bergstrasse, Germany), 2016, Sep-19, Volume: 22, Issue:39

    Topics: Amines; Benzaldehydes; Boron Compounds; Cell Line, Tumor; Chemistry Techniques, Synthetic; Halogenation; Humans; Models, Molecular; Neoplasms; Photochemotherapy; Photosensitizing Agents; Porphyrins; Pyrroles; Tetrapyrroles

2016
Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism.
    Nature communications, 2016, 09-01, Volume: 7

    Topics: Angiogenesis Inhibitors; Animals; Female; Humans; Indoles; Liver; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Metastasis; Neoplasms; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A

2016
Synthesis and Anticancer Activity of 3-(Substituted Aroyl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole Derivatives.
    Chemistry & biodiversity, 2017, Volume: 14, Issue:2

    Topics: Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Human Umbilical Vein Endothelial Cells; Humans; Molecular Structure; Neoplasms; Pyrroles; Structure-Activity Relationship

2017
Quantitative Chemical Proteomic Profiling of Ubiquitin Specific Proteases in Intact Cancer Cells.
    ACS chemical biology, 2016, 12-16, Volume: 11, Issue:12

    Topics: Alkynes; Cell Line, Tumor; Humans; Molecular Probe Techniques; Molecular Probes; Neoplasms; Proteomics; Pyrroles; Small Molecule Libraries; Ubiquitin-Specific Proteases

2016
Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib.
    Clinical pharmacology and therapeutics, 2017, Volume: 101, Issue:6

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Delayed-Action Preparations; Drug Administration Schedule; Drug Approval; Humans; Janus Kinases; Male; Metabolic Clearance Rate; Models, Animal; Models, Biological; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats, Sprague-Dawley; Therapeutic Equivalency; Treatment Outcome; United States; United States Food and Drug Administration

2017
Dual modulation of MCL-1 and mTOR determines the response to sunitinib.
    The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1

    Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Stability; Glycogen Synthase Kinase 3 beta; Humans; Indoles; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Inbred NOD; Mice, Nude; Multiprotein Complexes; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2017
Robust Colloidal Nanoparticles of Pyrrolopyrrole Cyanine J-Aggregates with Bright Near-Infrared Fluorescence in Aqueous Media: From Spectral Tailoring to Bioimaging Applications.
    Chemistry (Weinheim an der Bergstrasse, Germany), 2017, Mar-28, Volume: 23, Issue:18

    Topics: Animals; Cell Line, Tumor; Cell Survival; Colloids; Fluorescent Dyes; Humans; Mice; Mice, Nude; Nanoparticles; Neoplasms; Polymers; Pyrroles; Sonication; Spectrophotometry; Spectroscopy, Near-Infrared; Transplantation, Heterologous; Water

2017
Targeted drug delivery of Sunitinib Malate to tumor blood vessels by cRGD-chiotosan-gold nanoparticles.
    International journal of pharmaceutics, 2017, Jan-30, Volume: 517, Issue:1-2

    Topics: Cell Survival; Cells, Cultured; Chitosan; Drug Carriers; Drug Liberation; Gold; Humans; Indoles; Nanoparticles; Neoplasms; Particle Size; Peptides, Cyclic; Pyrroles; Sunitinib; Surface Properties

2017
Synthesis and Evaluation of Cytotoxic Activity of Some Pyrroles and Fused Pyrroles.
    Anti-cancer agents in medicinal chemistry, 2017, Volume: 17, Issue:7

    Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Caspases; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Neoplasms; Pyrroles; Signal Transduction

2017
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
    Annals of the rheumatic diseases, 2017, Volume: 76, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Herpes Zoster; Humans; Immunocompromised Host; Incidence; Infections; Male; Middle Aged; Neoplasms; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Tuberculosis; Young Adult

2017
Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors.
    Redox biology, 2015, Volume: 5

    Topics: Female; Humans; Hypertension; Indoles; Male; Neoplasms; Neovascularization, Pathologic; Nitric Oxide Donors; Pyrroles; Sunitinib

2015
Pyrrolo[3',2':6,7]cyclohepta[1,2-b]pyridines with potent photo-antiproliferative activity.
    European journal of medicinal chemistry, 2017, Mar-10, Volume: 128

    Topics: Antineoplastic Agents; Antioxidants; Blotting, Western; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Light; Neoplasms; Photosensitizing Agents; Pyridines; Pyrroles; Reactive Oxygen Species; Structure-Activity Relationship; Tumor Cells, Cultured

2017
Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers.
    Molecular cancer therapeutics, 2017, Volume: 16, Issue:5

    Topics: Animals; Antibodies; Antineoplastic Agents; Benzodiazepines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disulfides; Humans; Immunoconjugates; Mice; Neoplasms; Pyrroles; Xenograft Model Antitumor Assays

2017
Multifunctional biocompatible chitosan-polypyrrole nanocomposites as novel agents for photoacoustic imaging-guided photothermal ablation of cancer.
    Scientific reports, 2017, 03-02, Volume: 7

    Topics: Animals; Cell Line, Tumor; Chitosan; Disease Models, Animal; Female; Humans; Hyperthermia, Induced; Mice; Nanocomposites; Neoplasms; Photoacoustic Techniques; Phototherapy; Polymers; Pyrroles; Xenograft Model Antitumor Assays

2017
Patient-specific blood pressure correction technique for arterial stiffness: evaluation in a cohort on anti-angiogenic medication.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2017, Volume: 40, Issue:8

    Topics: Adult; Aged; Algorithms; Angiogenesis Inhibitors; Blood Pressure; Carotid Arteries; Cohort Studies; Cross-Sectional Studies; Female; Humans; Indoles; Male; Manometry; Middle Aged; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pulse Wave Analysis; Pyrroles; Sorafenib; Sunitinib; Vascular Stiffness

2017
Duocarmycin-based prodrugs for cancer prodrug monotherapy.
    Bioorganic & medicinal chemistry, 2008, Jun-15, Volume: 16, Issue:12

    Topics: Antineoplastic Agents; Cell Line, Tumor; Duocarmycins; Glucuronates; Glucuronic Acid; Humans; Indoles; Inhibitory Concentration 50; Neoplasms; Prodrugs; Pyrroles

2008
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory can
    Journal of medicinal chemistry, 2008, Jul-24, Volume: 51, Issue:14

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Enzyme Inhibitors; Humans; Kinesins; Neoplasms; Piperidines; Pyrroles; Taxoids

2008
Bcl-2 family members as molecular targets in cancer therapy.
    Biochemical pharmacology, 2008, Oct-15, Volume: 76, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Benzopyrans; BH3 Interacting Domain Death Agonist Protein; Biological Products; Genes, bcl-2; Gossypol; Humans; Indoles; Neoplasms; Nitriles; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Pyrroles

2008
Documentation of thyroid function in clinical studies with sunitinib: why does it matter?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Nov-01, Volume: 26, Issue:31

    Topics: Angiogenesis Inhibitors; Female; Humans; Hypothyroidism; Indoles; Male; Neoplasms; Pyrroles; Sunitinib; Thyroid Function Tests; Treatment Outcome

2008
Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Nov-10, Volume: 26, Issue:32

    Topics: Antineoplastic Agents; Benzenesulfonates; Cardiovascular Diseases; Humans; Indoles; Neoplasms; Niacinamide; Patient Care Team; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Time Factors; Treatment Outcome

2008
Cost effectiveness of sunitinib.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-10, Volume: 26, Issue:35

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Data Interpretation, Statistical; Drug Costs; Humans; Indoles; Neoplasms; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome

2008
Asymmetric synthesis and biological evaluation of glycosidic prodrugs for a selective cancer therapy.
    ChemMedChem, 2008, Volume: 3, Issue:12

    Topics: Antineoplastic Agents; beta-Galactosidase; Cell Line, Tumor; Duocarmycins; Glycosides; Humans; Indoles; Inhibitory Concentration 50; Neoplasms; Prodrugs; Pyrroles; Stereoisomerism

2008
Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature.
    Cancer science, 2009, Volume: 100, Issue:1

    Topics: Animals; Benzamides; Benzenesulfonates; Cell Line, Tumor; Extravasation of Diagnostic and Therapeutic Materials; Humans; Imatinib Mesylate; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptors, Transforming Growth Factor beta; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A

2009
Synthesis and CHK1 inhibitory potency of Hymenialdisine analogues.
    Bioorganic & medicinal chemistry letters, 2009, Feb-01, Volume: 19, Issue:3

    Topics: Antineoplastic Agents; Azepines; Checkpoint Kinase 1; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; Electrons; Humans; Inhibitory Concentration 50; Models, Chemical; Molecular Structure; Neoplasms; Protein Kinases; Pyrroles; Structure-Activity Relationship; Thiophenes

2009
Synthesis and biological studies of different duocarmycin based glycosidic prodrugs for their use in the antibody-directed enzyme prodrug therapy.
    Journal of medicinal chemistry, 2009, Jan-22, Volume: 52, Issue:2

    Topics: Antibodies; beta-Galactosidase; Chromatography, High Pressure Liquid; Duocarmycins; Glycosides; Indoles; Magnetic Resonance Spectroscopy; Neoplasms; Prodrugs; Pyrroles; Spectrometry, Mass, Electrospray Ionization

2009
The TNT study, women and cancer.
    Heart (British Cardiac Society), 2009, Volume: 95, Issue:3

    Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Estrogens; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Neoplasms; Pyrroles; T-Lymphocytes, Regulatory

2009
Statin therapy as the fundamental therapy for cardiovascular prevention: be careful.
    Clinical endocrinology, 2009, Volume: 71, Issue:3

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Humans; Indoles; Male; Neoplasms; Prospective Studies; Pyrroles; Sunitinib

2009
Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Cancer letters, 2009, Jun-28, Volume: 279, Issue:1

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Indoles; Inhibitory Concentration 50; Methotrexate; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; RNA, Messenger; Sunitinib; Time Factors; Topotecan; Transfection; Up-Regulation; Vincristine

2009
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
    Cancer cell, 2009, Mar-03, Volume: 15, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Humans; Indoles; Mice; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays

2009
Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma.
    Clinica chimica acta; international journal of clinical chemistry, 2009, Jun-27, Volume: 404, Issue:2

    Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Indoles; Linear Models; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sunitinib

2009
VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
    Cancer biology & therapy, 2009, Volume: 8, Issue:13

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Disease Models, Animal; Humans; Indoles; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A

2009
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009, Jul-15, Volume: 877, Issue:22

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles

2009
How well do angiogenesis inhibitors work? Biomarkers of response prove elusive.
    Journal of the National Cancer Institute, 2009, Jun-16, Volume: 101, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Cytokines; Disease-Free Survival; Endothelial Cells; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Vascular Endothelial Growth Factor A

2009
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
    Cancer letters, 2010, Feb-01, Volume: 288, Issue:1

    Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Mice; Myocytes, Cardiac; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Prenylation; Pyridines; Pyrroles; Rats; Sorafenib; Sunitinib

2010
Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies.
    Chemical biology & drug design, 2009, Volume: 74, Issue:3

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; beta-Galactosidase; Cell Line, Tumor; Drug Design; Duocarmycins; Glycosides; Humans; Indoles; Neoplasms; Prodrugs; Pyrroles; Stereoisomerism

2009
Apricoxib, a COX-2 inhibitor for the potential treatment of pain and cancer.
    IDrugs : the investigational drugs journal, 2009, Volume: 12, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclooxygenase 2 Inhibitors; Humans; Inflammation; Neoplasms; Pain; Pyrroles; Sulfonamides

2009
Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice.
    Clinical immunology (Orlando, Fla.), 2010, Volume: 135, Issue:1

    Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cytokines; Dermatitis, Contact; Female; Flow Cytometry; Histocytochemistry; Humans; Indoles; Lymphocyte Activation; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Middle Aged; Neoplasms; Picryl Chloride; Pyrroles; Specific Pathogen-Free Organisms; Sunitinib; T-Lymphocytes

2010
Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzazepines; Carbamates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Microtubules; Neoplasm Proteins; Neoplasms; Oxazepines; Pyrroles; Tubulin Modulators

2010
Tyrosine kinase inhibitor-induced macrocytosis.
    Anticancer research, 2009, Volume: 29, Issue:12

    Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Neoplasm Staging; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate

2009
In vitro and in vivo antineoplastic activity of a novel bromopyrrole and its potential mechanism of action.
    British journal of pharmacology, 2010, Volume: 159, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Calcium; Caspase 3; Caspase 9; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Female; Flow Cytometry; HeLa Cells; Hemiterpenes; Hep G2 Cells; Humans; Lethal Dose 50; Male; Mice; Neoplasms; Porifera; Pyrroles; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays

2010
Comparative analysis of DNA alkylation by conjugates between pyrrole-imidazole hairpin polyamides and chlorambucil or seco-CBI.
    Bioorganic & medicinal chemistry, 2010, Volume: 18, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Chlorambucil; DNA; Humans; Imidazoles; Lymphocytes; Molecular Structure; Neoplasms; Nylons; Pyrroles

2010
Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib.
    Kidney international, 2010, Volume: 77, Issue:9

    Topics: Biomarkers; Carcinoma, Renal Cell; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Gelatinases; Humans; Indoles; Kidney; Kidney Neoplasms; Lipocalins; Neoplasms; Neutrophils; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2010
Risk of bleeding not increased by sorafenib or sunitinib.
    The Lancet. Oncology, 2010, Volume: 11, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Hemorrhage; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib

2010
A new prognostic score derived from phase I study participants with advanced solid tumours is also valid in patients with brain metastasis.
    Anticancer research, 2010, Volume: 30, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Databases, Factual; Erlotinib Hydrochloride; Humans; Indoles; Middle Aged; Neoplasms; Prognosis; Pyrroles; Quinazolines; Severity of Illness Index; Sunitinib; Trastuzumab

2010
The promise of biomarkers for personalized renal cancer care.
    Kidney international, 2010, Volume: 77, Issue:9

    Topics: Biomarkers; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney; Kidney Neoplasms; Neoplasms; Nervous System Neoplasms; Patients; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A

2010
Control of leucocyte differentiation from embryonic stem cells upon vasculogenesis and confrontation with tumour tissue.
    Journal of cellular and molecular medicine, 2010, Volume: 14, Issue:1-2

    Topics: Angiogenesis Inhibitors; Animals; Antigens, CD; Biomarkers; Cell Differentiation; Cell Line; Embryonic Stem Cells; Indoles; Leukocytes; Lipopolysaccharides; Macrophage Colony-Stimulating Factor; Macrophages; Male; Mice; Monocytes; Neoplasms; Neovascularization, Physiologic; Pyrroles

2010
Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:5

    Topics: Animals; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Biopsy; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Cyclin-Dependent Kinases; E2F Transcription Factors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasms; Oligonucleotide Array Sequence Analysis; Pyrazoles; Pyrroles; Skin; Transcriptional Activation; Xenograft Model Antitumor Assays

2010
Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth.
    Proceedings of the National Academy of Sciences of the United States of America, 2010, May-18, Volume: 107, Issue:20

    Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Crystallography; Guanine Nucleotide Exchange Factors; Humans; Models, Molecular; Neoplasms; p21-Activated Kinases; Phosphorylation; Pyrazoles; Pyrroles; Rho Guanine Nucleotide Exchange Factors; Signal Transduction

2010
Tyrosine kinase inhibitors and acute pancreatitis.
    JOP : Journal of the pancreas, 2010, May-05, Volume: 11, Issue:3

    Topics: Acute Disease; Antineoplastic Agents; Humans; Indoles; Neoplasms; Pancreatitis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib

2010
ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:6

    Topics: Animals; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Humans; Immunosuppression Therapy; Mice; Mice, Nude; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Pyrroles; Pyrrolidinones; Quinolines; Signal Transduction; Xenograft Model Antitumor Assays

2010
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
    Investigational new drugs, 2011, Volume: 29, Issue:5

    Topics: Adult; Benzenesulfonates; Disease Progression; Fatal Outcome; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pneumatosis Cystoides Intestinalis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2011
Close encounters of a novel kind: a multi-targeted cancer drug meets a metabolic sensor.
    Cancer biology & therapy, 2010, Jul-01, Volume: 10, Issue:1

    Topics: AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Animals; Humans; Indoles; Neoplasms; Pyrroles; Sunitinib

2010
Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1alpha synthesis in HT-29 colon cancer cells.
    Biochemical and biophysical research communications, 2010, Jul-23, Volume: 398, Issue:2

    Topics: Antineoplastic Agents; Cell Hypoxia; HT29 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Neoplasms; Protein Biosynthesis; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Sunitinib

2010
Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors.
    Molecular pharmacology, 2010, Volume: 78, Issue:4

    Topics: Animals; Antineoplastic Agents; CHO Cells; Cricetinae; Cricetulus; Drug Delivery Systems; Female; Folic Acid Antagonists; Growth Inhibitors; HeLa Cells; Humans; Membrane Transport Proteins; Neoplasms; Proton-Coupled Folate Transporter; Purines; Pyrimidines; Pyrroles; Xenopus laevis

2010
SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity.
    Cancer research, 2010, Sep-01, Volume: 70, Issue:17

    Topics: Animals; Antibiotics, Antineoplastic; Benzodiazepinones; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Female; Humans; Mice; Neoplasms; Prodrugs; Pyrroles; Xenograft Model Antitumor Assays

2010
Synthesis of 5,6-dihydropyrrolo[2,1-a]isoquinolines featuring an intramolecular radical-oxidative cyclization of polysubstituted pyrroles, and evaluation of their cytotoxic activity.
    Organic & biomolecular chemistry, 2010, Oct-07, Volume: 8, Issue:19

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclization; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Models, Molecular; Neoplasms; Oxidation-Reduction; Pyrroles; Structure-Activity Relationship

2010
Discovery of drug mode of action and drug repositioning from transcriptional responses.
    Proceedings of the National Academy of Sciences of the United States of America, 2010, Aug-17, Volume: 107, Issue:33

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Algorithms; Antineoplastic Agents; Autophagy; Blotting, Western; Camptothecin; Cell Line, Tumor; Doxorubicin; Drug Discovery; Drug Screening Assays, Antitumor; Flavonoids; Fuzzy Logic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Irinotecan; Neoplasms; Oligonucleotide Array Sequence Analysis; Phosphorylation; Piperidines; Pyrazoles; Pyrroles; RNA Polymerase II

2010
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2011, Volume: 17, Issue:3

    Topics: Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Blood Glucose; Dasatinib; Diabetes Mellitus; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Imatinib Mesylate; Indoles; Linear Models; Male; Middle Aged; Neoplasms; Niacinamide; Pennsylvania; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thiazoles; Time Factors; Treatment Outcome

2011
Design, synthesis and qualitative structure-activity evaluations of novel hexahydropyrano[3,2-c][1,2]diazepin-3(4H)-one and tetrahydropyrano[3,2-b]pyrrol-2(1H)-one derivatives as anticancer agents.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:10

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Neoplasms; Pyrans; Pyrroles; Structure-Activity Relationship

2010
Preclinical pharmacology of BA-TPQ, a novel synthetic iminoquinone anticancer agent.
    Marine drugs, 2010, Jul-13, Volume: 8, Issue:7

    Topics: Animals; Antineoplastic Agents; Drug Evaluation, Preclinical; Female; Humans; Male; Mice; Neoplasms; Protein Binding; Pyrroles; Quinolones; Tissue Distribution; Xenograft Model Antitumor Assays

2010
The cancer-HIV/AIDS treatment conundrum.
    Journal of the National Cancer Institute, 2010, Nov-03, Volume: 102, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Cytochrome P-450 CYP3A; Drug Administration Schedule; Drug Antagonism; HIV Infections; HIV Protease Inhibitors; Humans; Indoles; Neoplasms; Pyrroles; Risk Factors; Ritonavir; Sunitinib

2010
Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis.
    Apoptosis : an international journal on programmed cell death, 2011, Volume: 16, Issue:3

    Topics: Adenosine Triphosphate; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Cell Line, Tumor; Cell Survival; Cisplatin; DNA Damage; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Indoles; Mitochondria; Neoplasms; Peptides; Platinum; Protein Structure, Tertiary; Protein Transport; Pyrroles

2011
Circulating perivascular progenitors: a target of PDGFR inhibition.
    International journal of cancer, 2011, Sep-15, Volume: 129, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Bone Marrow Cells; Cell Count; Cell Differentiation; Cell Survival; Humans; Indoles; Mice; Neoplasms; Pericytes; Platelet Endothelial Cell Adhesion Molecule-1; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Stem Cells; Sunitinib

2011
Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells in vitro.
    Cancer biology & therapy, 2011, Feb-15, Volume: 11, Issue:4

    Topics: Aerobiosis; Apoptosis; Cell Cycle; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Microtubules; Neoplasms; Oxazepines; Pyrroles; Radiation Tolerance; Radiation-Sensitizing Agents

2011
Novel pyrrolo[2,1-f][1,2,4]triazin-4-amines: Dual inhibitors of EGFR and HER2 protein tyrosine kinases.
    Bioorganic & medicinal chemistry letters, 2011, Jan-15, Volume: 21, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; ErbB Receptors; Humans; Male; Mice; Mice, Inbred BALB C; Models, Molecular; Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Receptor, ErbB-2; Stomach Neoplasms; Triazines; Xenograft Model Antitumor Assays

2011
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Biomarkers, Pharmacological; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Hair Follicle; HCT116 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Xenograft Model Antitumor Assays

2011
Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jun-15, Volume: 17, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Proliferation; Endothelial Cells; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Piperidines; Pyrroles; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Regional Blood Flow; Signal Transduction; Triazines; Xenograft Model Antitumor Assays

2011
Isomalyngamide A, A-1 and their analogs suppress cancer cell migration in vitro.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:9

    Topics: Amides; Blotting, Western; Cell Line, Tumor; Cell Movement; Focal Adhesion Protein-Tyrosine Kinases; Humans; Integrin beta1; Magnetic Resonance Spectroscopy; Neoplasm Metastasis; Neoplasms; Proto-Oncogene Proteins c-akt; Pyrroles; Spectrometry, Mass, Electrospray Ionization; Spectrometry, Mass, Fast Atom Bombardment; Spectrophotometry, Infrared

2011
Synthesis of aryl-substituted naphthalene-linked pyrrolobenzodiazepine conjugates as potential anticancer agents with apoptosis-inducing ability.
    ChemMedChem, 2011, Sep-05, Volume: 6, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Benzodiazepines; Caspase 9; Cell Line, Tumor; Drug Design; Humans; Naphthalenes; Neoplasms; Pyrroles; Tumor Suppressor Protein p53

2011
Atorvastatin and clopidogrel interfere with photosensitization in vitro.
    Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2011, Volume: 10, Issue:10

    Topics: Animals; Anticholesteremic Agents; Aspirin; Atorvastatin; Cathepsin B; Cell Line; Clopidogrel; Heptanoic Acids; Humans; Light; Macrophages; Mice; Neoplasms; Photochemotherapy; Photosensitizing Agents; Polyethylene Glycols; Polylysine; Porphyrins; Pyrroles; Ticlopidine

2011
A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors.
    PloS one, 2011, Volume: 6, Issue:7

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Humans; Indoles; Mice; Microvessels; Neoplasms; Neovascularization, Pathologic; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays; Zebrafish

2011
Production of anticancer polyenes through precursor-directed biosynthesis.
    Organic & biomolecular chemistry, 2011, Sep-21, Volume: 9, Issue:18

    Topics: Antineoplastic Agents; Fungi; HeLa Cells; Humans; Inhibitory Concentration 50; Neoplasms; Polyenes; Proline; Pyrones; Pyrroles

2011
[Adverse effects of new oncologic therapies].
    Praxis, 2011, Jul-27, Volume: 100, Issue:15

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Facial Dermatoses; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Trastuzumab

2011
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Dec-01, Volume: 17, Issue:23

    Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; HCT116 Cells; HT29 Cells; Humans; Indoles; Kidney Neoplasms; Lysosomes; Mice; Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Sunitinib

2011
Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:12

    Topics: Antineoplastic Agents; ErbB Receptors; HeLa Cells; Humans; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Structure-Activity Relationship

2011
Silencing p110β prevents rapid depletion of nuclear pAkt.
    Biochemical and biophysical research communications, 2011, Dec-02, Volume: 415, Issue:4

    Topics: Animals; Atorvastatin; Cell Line, Tumor; Cell Nucleus; Class I Phosphatidylinositol 3-Kinases; Fibroblasts; Gene Silencing; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Knockout; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrroles; RNA, Small Interfering; Tacrolimus Binding Proteins

2011
Polypyrrole nanoparticles: a potential optical coherence tomography contrast agent for cancer imaging.
    Advanced materials (Deerfield Beach, Fla.), 2011, Dec-22, Volume: 23, Issue:48

    Topics: Contrast Media; Diagnostic Imaging; Humans; Medical Oncology; Models, Statistical; Nanoparticles; Neoplasms; Phantoms, Imaging; Polymers; Pyrroles; Scattering, Radiation; Spectrophotometry, Ultraviolet; Spectroscopy, Near-Infrared; Tomography, Optical Coherence

2011
Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.
    Veterinary and comparative oncology, 2012, Volume: 10, Issue:3

    Topics: Adenocarcinoma; Anal Gland Neoplasms; Anal Sacs; Animals; Antineoplastic Agents; Apocrine Glands; Bone Neoplasms; Carcinoma; Dog Diseases; Dogs; Female; Head and Neck Neoplasms; Indoles; Male; Neoplasms; Nose Neoplasms; Osteosarcoma; Pyrroles; Receptor Protein-Tyrosine Kinases; Skin Neoplasms; Thyroid Neoplasms

2012
Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
    Biomedical chromatography : BMC, 2012, Volume: 26, Issue:11

    Topics: Antineoplastic Agents; Chromatography, Liquid; Clinical Trials, Phase I as Topic; Drug Stability; Humans; Indoles; Neoplasms; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Tandem Mass Spectrometry

2012
Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.
    Molecular pharmacology, 2012, Volume: 81, Issue:5

    Topics: Antineoplastic Agents; Autophagy; bcl-X Protein; Cell Line, Tumor; ErbB Receptors; Humans; Indoles; Lapatinib; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Pyrroles; Quinazolines; Receptor, ErbB-3; Receptor, ErbB-4

2012
N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.
    Bioorganic & medicinal chemistry, 2012, Apr-01, Volume: 20, Issue:7

    Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Drug Design; Humans; Indoles; Mice; Mice, Nude; Molecular Dynamics Simulation; Neoplasms; Oxindoles; Propionates; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2

2012
Antiangiogenic agents: fueling cancer's hypoxic roots.
    Cell cycle (Georgetown, Tex.), 2012, Apr-01, Volume: 11, Issue:7

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Hypoxia; Humans; Indoles; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Pyrroles; Sunitinib

2012
Underestimating cardiac toxicity in cancer trials: lessons learned?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jun-01, Volume: 30, Issue:16

    Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Drug Labeling; Drug Monitoring; Heart Diseases; Humans; Indoles; Neoplasms; Pyrroles; Stroke Volume; Sunitinib; Ventricular Dysfunction, Left

2012
The molecular mechanism of the anticancer effect of atorvastatin: DNA microarray and bioinformatic analyses.
    International journal of molecular medicine, 2012, Volume: 30, Issue:4

    Topics: Antineoplastic Agents; Atorvastatin; Cell Cycle; Cell Line; Computational Biology; Endothelial Cells; Gene Expression Profiling; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kruppel-Like Transcription Factors; Neoplasms; Oligonucleotide Array Sequence Analysis; Pyrroles

2012
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jul-15, Volume: 18, Issue:14

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; Xenograft Model Antitumor Assays

2012
S1, a novel pan-BH3 mimetic, induces apoptosis in Mcl-1-overexpressing cells through Bak.
    Journal of pharmacological sciences, 2012, Volume: 119, Issue:4

    Topics: Acenaphthenes; Animals; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Biphenyl Compounds; Cell Line, Tumor; Humans; Mice; Mice, Inbred BALB C; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Nitrophenols; Peptide Fragments; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays

2012
Polypyrrole nanoparticles for high-performance in vivo near-infrared photothermal cancer therapy.
    Chemical communications (Cambridge, England), 2012, Sep-14, Volume: 48, Issue:71

    Topics: Animals; Cell Line, Tumor; Cell Survival; Humans; Infrared Rays; Mice; Nanoparticles; Neoplasms; Phototherapy; Polymers; Pyrroles; Tissue Distribution

2012
Lab reports and cat scans: can veterinary oncology guide our way to new treatments for human cancers?
    Future medicinal chemistry, 2012, Volume: 4, Issue:11

    Topics: Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Cats; Disease Models, Animal; Dogs; Female; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mast-Cell Sarcoma; Neoplasms; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Thiazoles; Transcriptome

2012
In vitro and in vivo near-infrared photothermal therapy of cancer using polypyrrole organic nanoparticles.
    Advanced materials (Deerfield Beach, Fla.), 2012, Nov-02, Volume: 24, Issue:41

    Topics: Animals; Cell Line, Tumor; Cell Survival; Female; HEK293 Cells; Humans; Infrared Rays; L-Lactate Dehydrogenase; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Phototherapy; Polymers; Polyvinyl Alcohol; Pyrroles; Transplantation, Heterologous

2012
Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients.
    British journal of pharmacology, 2013, Volume: 168, Issue:7

    Topics: Administration, Oral; Adult; Antineoplastic Agents; Biotransformation; Cytochrome P-450 Enzyme System; Female; Hepatocytes; Humans; Indoles; Isoenzymes; Male; Microsomes, Liver; Middle Aged; Neoplasms; Oxidation-Reduction; Pyrroles; Receptor Protein-Tyrosine Kinases; Tissue Distribution

2013
3-Thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (S1) derivatives as pan-Bcl-2-inhibitors of Bcl-2, Bcl-xL and Mcl-1.
    Bioorganic & medicinal chemistry, 2013, Jan-01, Volume: 21, Issue:1

    Topics: Acenaphthenes; Antineoplastic Agents; Apoptosis; bcl-X Protein; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Nitriles; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Structure-Activity Relationship

2013
Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:4

    Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Gene Expression; Hedgehog Proteins; Humans; Mice; Models, Biological; Neoplasms; Oncogene Proteins; Pyridines; Pyrroles; RNA, Messenger; Skin; Trans-Activators; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1

2013
Taking cancer-drug toxicity to heart.
    Cancer discovery, 2013, Volume: 3, Issue:2

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Doxorubicin; Heart Failure; Heart Function Tests; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Trastuzumab

2013
Synthetic lethality: killing cancer with cancer.
    Journal of the National Cancer Institute, 2002, Nov-20, Volume: 94, Issue:22

    Topics: Animals; Antineoplastic Agents; Benzamides; Benzoquinones; Cell Cycle Proteins; DNA-Binding Proteins; E2F Transcription Factors; Gefitinib; Genes, Tumor Suppressor; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Mutation; Neoplasms; Phosphoric Monoester Hydrolases; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Signal Transduction; Sirolimus; Transcription Factors; Tumor Suppressor Proteins

2002
Comparative study of isoflavone, quinoxaline and oxindole families of anti-angiogenic agents.
    Angiogenesis, 2002, Volume: 5, Issue:1-2

    Topics: Angiogenesis Inhibitors; Endothelium, Vascular; Humans; Indoles; Isoflavones; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Quinoxalines

2002
Interleukin-2 and cancer: critical analysis of results, problems and expectations.
    Medical hypotheses, 2003, Volume: 60, Issue:2

    Topics: Cytokines; Humans; Immunotherapy; Indoles; Interleukin-2; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles; Receptors, Interleukin-2

2003
[Perspectives on the oncologist pharmacopoeia].
    Bulletin du cancer, 2003, Volume: 90, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Dioxoles; Indoles; Isoquinolines; Neoplasms; Organoplatinum Compounds; Protease Inhibitors; Pyrazines; Pyrroles; Quinazolines; Sesquiterpenes; Tetrahydroisoquinolines; Trabectedin

2003
ASCOT-LLA: questions about the benefits of atorvastatin.
    Lancet (London, England), 2003, Jun-07, Volume: 361, Issue:9373

    Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Neoplasms; Pyrroles

2003
Research retreat: Pfizer eliminates Sugen, shrinks cancer infrastructure.
    Journal of the National Cancer Institute, 2003, Jul-16, Volume: 95, Issue:14

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomedical Research; Drug Design; Drug Industry; Drugs, Investigational; Endothelial Growth Factors; Erlotinib Hydrochloride; Germany; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasms; Pyrroles; Quinazolines; Signal Transduction; United States; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2003
Myofibroblasts enable invasion of endothelial cells into three-dimensional tumor cell clusters: a novel in vitro tumor model.
    Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:4

    Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cells, Cultured; Endothelial Cells; Fibroblasts; Humans; Immunohistochemistry; Indoles; Metalloproteases; Neoplasm Invasiveness; Neoplasms; Oxindoles; Paclitaxel; Propionates; Protease Inhibitors; Pyrroles; Stromal Cells

2003
Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Aug-01, Volume: 9, Issue:8

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Head and Neck Neoplasms; Humans; In Situ Nick-End Labeling; Ligands; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Mouth Neoplasms; Neoplasms; Paclitaxel; Phosphorylation; Propidium; Pyrimidines; Pyrroles; Tongue; Tongue Neoplasms; Tyrosine

2003
Analysis of prothrombotic mechanisms and endothelial perturbation during treatment with angiogenesis inhibitors.
    Pathophysiology of haemostasis and thrombosis, 2003, Volume: 33 Suppl 1

    Topics: Angiogenesis Inhibitors; Endothelium, Vascular; Humans; Indoles; Neoplasms; Pyrroles; Thromboembolism; Thrombophilia; Treatment Outcome

2003
THE HUMAN TUMOR-EGG HOST SYSTEM. III. TUMOR-INHIBITORY PROPERTIES OF TENUAZONIE ACID.
    Cancer research, 1964, Volume: 24

    Topics: Adenocarcinoma; Antineoplastic Agents; Aspergillus; Azaserine; Carcinoma, Bronchogenic; Chick Embryo; Glycine; Mercaptopurine; Neoplasms; Neoplasms, Experimental; Puromycin; Pyrroles; Research; Saccharomyces; Tissue Culture Techniques; Triethylenemelamine

1964
THE METABOLISM AND EXCRETION OF CO57 TETRAPHENYLPORPHINESULFONATE IN CANCER PATIENTS.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1964, Volume: 5

    Topics: Abdominal Neoplasms; Brain Neoplasms; Cobalt Isotopes; Humans; Metabolism; Neoplasms; Pyrroles; Radiometry

1964
PORPHOBILINOGEN AND DELTA-AMINOLEVULINIC ACID EXCRETION IN MULTIPLE SCLEROSIS.
    Canadian Medical Association journal, 1965, Jun-26, Volume: 92

    Topics: Amino Acids; Aminolevulinic Acid; Demyelinating Diseases; Diagnosis, Differential; Fluids and Secretions; Humans; Levulinic Acids; Multiple Sclerosis; Neoplasms; Poliomyelitis; Porphobilinogen; Porphyrias; Porphyrins; Pyrroles; Urine

1965
Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.
    Molecular cancer therapeutics, 2003, Volume: 2, Issue:11

    Topics: Binding Sites; Cell Division; Cell Line, Tumor; Cell Movement; Enzyme Inhibitors; Hepatocyte Growth Factor; Humans; Indoles; Models, Molecular; Neoplasm Invasiveness; Neoplasms; Phosphorylation; Phosphotyrosine; Protein Conformation; Proto-Oncogene Proteins c-met; Pyrroles; Signal Transduction

2003
Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2004, Volume: 18, Issue:2

    Topics: Animals; Apoptosis; Cell Survival; Hypoxia; Indoles; Microcirculation; Models, Biological; Neoplasms; Neovascularization, Pathologic; Oxindoles; Pericytes; Platelet-Derived Growth Factor; Propionates; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2004
Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
    Cancer research, 2003, Dec-15, Volume: 63, Issue:24

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Movement; Cell Survival; Drug Synergism; Endostatins; Endothelium, Vascular; Female; Glioblastoma; Humans; Indoles; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrroles; Ultrasonography; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2003
C-H to N substitution dramatically alters the sequence-specific DNA alkylation, cytotoxicity, and expression of human cancer cell lines.
    Journal of the American Chemical Society, 2004, Mar-24, Volume: 126, Issue:11

    Topics: Alkylation; Antineoplastic Agents, Alkylating; Cell Line, Tumor; DNA, Neoplasm; Duocarmycins; Humans; Imidazoles; Neoplasms; Nylons; Pyrroles; Pyrrolidinones; Structure-Activity Relationship; Substrate Specificity

2004
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.
    Cancer cell, 2004, Volume: 5, Issue:3

    Topics: Antineoplastic Agents; Bone Marrow; Enzyme Inhibitors; Flow Cytometry; Gene Expression Profiling; Hematologic Neoplasms; Humans; Insulin-Like Growth Factor I; Multiple Myeloma; Neoplasms; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Transplantation, Heterologous; Vascular Endothelial Growth Factor A

2004
New cancer therapeutics: target-specific in, cytotoxics out?
    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2004, Volume: 7, Issue:2

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Delivery Systems; Enzyme Inhibitors; Gefitinib; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Neoplasms; Proteomics; Pyrroles; Quinazolines; Sunitinib

2004
Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.
    International journal of radiation oncology, biology, physics, 2004, Nov-15, Volume: 60, Issue:4

    Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Combined Modality Therapy; Endothelial Cells; Glutamates; Guanine; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Pemetrexed; Protein-Tyrosine Kinases; Pyrroles; Tumor Stem Cell Assay

2004
Spectral characteristics of the supramolecular complexes of polypyrrolic sensitizers and cyclodextrin carriers: usage in photodynamic therapy of tumors.
    Acta medica (Hradec Kralove), 2004, Volume: 47, Issue:4

    Topics: Cyclodextrins; Drug Carriers; Neoplasms; Photochemistry; Photochemotherapy; Polymers; Porphyrins; Pyrroles; Radiation-Sensitizing Agents; Spectrometry, Fluorescence; Spectrophotometry

2004
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2005, Aug-02, Volume: 102, Issue:31

    Topics: Aminoquinolines; Aniline Compounds; Cell Line; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Indoles; Kinetics; Morpholines; Mutation; Naphthalenes; Neoplasms; Oncogene Proteins v-abl; Organic Chemicals; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Sunitinib

2005
Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer.
    Hematology. American Society of Hematology. Education Program, 2005

    Topics: Animals; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Cell Survival; Genes, myc; Humans; Indoles; Models, Animal; Neoplasms; Nitrophenols; Oncogenes; Piperazines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrroles; Sulfonamides

2005
New targets, therapies, and toxicities: lessons to be learned.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-01, Volume: 24, Issue:1

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Neoplasms; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib

2006
AACR-NCI-EORTC--17th symposium: Molecular targets and cancer therapeutics. 14-18th November 2005, Philadelphia, PA, USA.
    IDrugs : the investigational drugs journal, 2006, Volume: 9, Issue:1

    Topics: Angiopoietin-2; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodiazepinones; Clinical Trials, Phase I as Topic; ErbB Receptors; Humans; Neoplasms; Ornithine; Pterins; Pyrroles; Receptor, EphA2; Societies, Scientific

2006
Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy.
    International journal of radiation oncology, biology, physics, 2006, Jan-01, Volume: 64, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Class I Phosphatidylinositol 3-Kinases; Combined Modality Therapy; Endothelial Cells; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Fibroblast Growth Factor 2; Humans; Indoles; Mice; Neoplasms; Neovascularization, Pathologic; Oxindoles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Propionates; Pyrroles; Quinazolines; Radiation Tolerance; Receptor Protein-Tyrosine Kinases; Sunitinib; Vascular Endothelial Growth Factor A

2006
Antitumor activity of sequence-specific alkylating agents: pyrolle-imidazole CBI conjugates with indole linker.
    Cancer science, 2006, Volume: 97, Issue:3

    Topics: Adenine; Alkylation; Animals; Antineoplastic Agents, Alkylating; Base Sequence; Cell Line, Tumor; Cyclopropanes; Humans; Imidazoles; Indoles; Models, Molecular; Molecular Sequence Data; Molecular Structure; Neoplasms; Nucleic Acid Conformation; Nylons; Polymerase Chain Reaction; Pyrroles; Thymine

2006
Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy.
    Angewandte Chemie (International ed. in English), 2006, Oct-06, Volume: 45, Issue:39

    Topics: Alkylating Agents; Antibodies; Cell Line, Tumor; Drug Delivery Systems; Duocarmycins; Humans; Indoles; Neoplasms; Prodrugs; Pyrroles; Streptomyces; Tumor Stem Cell Assay

2006
Sequence-specific alkylation of double-strand human telomere repeat sequence by pyrrole-imidazole polyamides with indole linkers.
    Journal of the American Chemical Society, 2006, Sep-20, Volume: 128, Issue:37

    Topics: Alkylation; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Electrophoresis, Polyacrylamide Gel; Humans; Indoles; Molecular Sequence Data; Neoplasms; Pyrroles; Repetitive Sequences, Nucleic Acid; Substrate Specificity; Telomere

2006
Pharmacy benefit spending on oral chemotherapy drugs.
    Journal of managed care pharmacy : JMCP, 2006, Volume: 12, Issue:7

    Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States

2006
Statin treatment, reduced T-cell content of atherosclerotic plaques and cancer.
    Journal of internal medicine, 2006, Volume: 260, Issue:6

    Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Heptanoic Acids; Humans; Immunity, Cellular; Neoplasms; Pyrroles; T-Lymphocytes

2006
Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Feb-27, Volume: 104, Issue:9

    Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Endothelium, Vascular; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta

2007
[Anti-angiogenetic agents for solid tumors].
    La Revue de medecine interne, 2007, Volume: 28 Suppl 1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Transformation, Neoplastic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A

2007
Sunitinib malate and multiple receptor tyrosine kinases inhibitors: are they also novel drugs for chronic and neurophatic pain?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jul-01, Volume: 25, Issue:19

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Indoles; Neoplasms; Pain; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, trkA; Signal Transduction; Sunitinib

2007
5-((4-Aminopiperidin-1-yl)methyl)pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases.
    Bioorganic & medicinal chemistry letters, 2007, Sep-01, Volume: 17, Issue:17

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Inhibitory Concentration 50; Insecta; Models, Chemical; Neoplasm Transplantation; Neoplasms; Piperidines; Pyrroles; Receptor, ErbB-2; Triazines

2007
American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
    IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:8

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Technology Transfer; Treatment Outcome

2007
Introduction to 'A multitargeted approach: clinical advances in the treatment of solid tumours'.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18 Suppl 10

    Topics: Antineoplastic Agents; Humans; Indoles; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Receptors, Cell Surface; Sunitinib

2007
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Oct-23, Volume: 104, Issue:43

    Topics: Angiogenesis Inducing Agents; Animals; Antineoplastic Agents; Blood Proteins; Cell Hypoxia; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Mice; Mice, SCID; Neoplasms; Organ Specificity; Placenta Growth Factor; Pregnancy Proteins; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays

2007
Unanswered questions regarding the management of sunitinib-induced hypothyroidism.
    Nature clinical practice. Oncology, 2007, Volume: 4, Issue:12

    Topics: Antineoplastic Agents; Drug Therapy, Combination; Humans; Hypothyroidism; Indoles; Neoplasms; Pyrroles; Sunitinib; Thyroid Hormones

2007
BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines.
    Molecular pharmacology, 2008, Volume: 73, Issue:2

    Topics: Apoptosis; Cell Line, Tumor; HL-60 Cells; Humans; K562 Cells; Mitosis; Neoplasms; Oxazepines; Protein Serine-Threonine Kinases; Pyrroles; Spindle Apparatus; Tubulin

2008
Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells.
    British journal of cancer, 2007, Dec-17, Volume: 97, Issue:12

    Topics: Aneugens; Animals; Aurora Kinase A; Aurora Kinases; Cell Survival; Genes, p53; HCT116 Cells; HT29 Cells; Humans; Mice; Mice, Nude; Neoplasms; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Radiation-Sensitizing Agents; RNA, Small Interfering; Xenograft Model Antitumor Assays

2007
Cardiac toxicity of sunitinib.
    Lancet (London, England), 2007, Dec-15, Volume: 370, Issue:9604

    Topics: Antineoplastic Agents; Cardiovascular Diseases; Humans; Indoles; Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Sunitinib

2007
Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-26, Volume: 104, Issue:52

    Topics: Animals; Anticarcinogenic Agents; Azoxymethane; Cell Proliferation; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genomic Imprinting; Insulin-Like Growth Factor II; Mice; Mice, Inbred C57BL; Neoplasms; Oligonucleotide Array Sequence Analysis; Pyrimidines; Pyrroles; Signal Transduction

2007
Synthesis of 1,2,3-triazole-linked pyrrolobenzodiazepine conjugates employing 'click' chemistry: DNA-binding affinity and anticancer activity.
    Bioorganic & medicinal chemistry letters, 2008, Feb-15, Volume: 18, Issue:4

    Topics: Antineoplastic Agents; Benzodiazepines; Cell Line, Tumor; DNA; Humans; Kinetics; Neoplasms; Pyrroles; Triazoles

2008
Analyzing the results of the treating to new targets study.
    Annals of internal medicine, 2008, Feb-19, Volume: 148, Issue:4

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Neoplasms; Pyrroles

2008
Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Apr-01, Volume: 14, Issue:7

    Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Endothelial Cells; Flow Cytometry; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Radiation-Sensitizing Agents; Radiotherapy; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Xenograft Model Antitumor Assays

2008
Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor.
    Cancer, 2008, Volume: 112, Issue:11

    Topics: Aged; Antineoplastic Agents; Female; Heart Failure; Humans; Indoles; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sunitinib

2008
Molecule of the month. Elesclomol and obatoclax mesylate.
    Drug news & perspectives, 2008, Volume: 21, Issue:2

    Topics: Antineoplastic Agents; Controlled Clinical Trials as Topic; Humans; Hydrazines; Indoles; Melanoma; Neoplasm Metastasis; Neoplasms; Pyrroles

2008
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
    Journal of immunology (Baltimore, Md. : 1950), 2008, May-01, Volume: 180, Issue:9

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Hematopoietic Stem Cells; Humans; Lactones; Neoplasms; NF-kappa B; Protease Inhibitors; Pyrazines; Pyrroles; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Messenger; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Up-Regulation; YY1 Transcription Factor

2008
Statins, leptin and regulatory T cells.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2008, Volume: 18, Issue:6

    Topics: Animals; Atorvastatin; Heptanoic Acids; Humans; Leptin; Lymphocyte Activation; Neoplasms; Obesity; Pyrroles; Risk Factors; T-Lymphocytes, Regulatory; Thinness

2008
Atorvastatin and celecoxib: a future role in cancer chemoprevention.
    International journal of cancer, 2008, Aug-01, Volume: 123, Issue:3

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antineoplastic Agents; Atorvastatin; Celecoxib; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Pyrazoles; Pyrroles; Sulfonamides

2008
Activity of bis-carbamoyloxymethyl derivatives of pyrroles and pyrrolizines against human tumor xenografts in nude mice.
    Cancer research, 1982, Volume: 42, Issue:6

    Topics: Adenocarcinoma; Animals; Breast Neoplasms; Carcinoma, Small Cell; Cell Line; Colonic Neoplasms; Drug Evaluation, Preclinical; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Pyrroles; Pyrrolidines; Transplantation, Heterologous

1982
A hypothesis for dietary components as blocking agents of chemical carcinogenesis: plant phenolics and pyrrole pigments.
    Nutrition and cancer, 1984, Volume: 6, Issue:1

    Topics: Animals; Carcinogens; Diet; Glycosides; Humans; Neoplasms; Phenols; Pyrroles; Structure-Activity Relationship

1984
Skin sensitization with the new reagents NOPYE (4-nitro-1-cyclohexyl-3-ethoxy-2-oxo-3-pyrroline) and NOPY-L-phenylalanine.
    Journal of surgical oncology, 1980, Volume: 13, Issue:2

    Topics: Adjuvants, Immunologic; Animals; Cross Reactions; Cyclohexanes; Dinitrochlorobenzene; Female; Guinea Pigs; Hypersensitivity, Delayed; Immunotherapy; Neoplasms; Ovalbumin; Phenylalanine; Pyrroles; Skin; Tuberculin

1980
A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo.
    International journal of cancer, 1998, Mar-30, Volume: 76, Issue:1

    Topics: 3T3 Cells; Animals; Cell Division; Enzyme Inhibitors; Epithelial Cells; ErbB Receptors; Female; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Phosphorylation; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Time Factors

1998
Researchers describe findings for targeted cancer therapies.
    JAMA, 2000, Jul-19, Volume: 284, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Division; Cetuximab; Clinical Trials as Topic; Endothelial Growth Factors; ErbB Receptors; Humans; Indoles; Lymphokines; Neoplasms; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2000
Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:7

    Topics: Acute Disease; Apoptosis; Atorvastatin; Cell Division; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Leukemia, Myeloid; Lovastatin; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Pyrroles; Sensitivity and Specificity; Tumor Cells, Cultured

2001
Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:10

    Topics: Animals; Antineoplastic Agents; Biopsy; Carmustine; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Doxorubicin; Fenretinide; Guanine; Humans; Indoles; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Pyrroles; Tomography, X-Ray Computed; Treatment Outcome; Xenograft Model Antitumor Assays

2001
Pyrrolo[2,1-c][1,2,4]triazines from 2-diazopyrroles: synthesis and antiproliferative activity.
    European journal of medicinal chemistry, 2002, Volume: 37, Issue:3

    Topics: Antineoplastic Agents; Cell Division; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Neoplasms; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured

2002
Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives.
    Journal of medicinal chemistry, 1989, Volume: 32, Issue:4

    Topics: Alkylating Agents; Animals; Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; Circular Dichroism; Distamycins; DNA; Humans; Leukemia L1210; Leukemia, Experimental; Mice; Neoplasms; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured

1989
Synthesis and antineoplastic activity of 5-aryl-2,3-dihydropyrrolo[2,1-b]thiazole-6,7-dimethanol 6,7-bis(isopropylcarbamates).
    Journal of medicinal chemistry, 1988, Volume: 31, Issue:7

    Topics: Carbamates; Cell Division; Cell Survival; Chemical Phenomena; Chemistry; Colonic Neoplasms; Humans; Leukemia, Myeloid; Neoplasms; Pyrroles; Structure-Activity Relationship; Thiazoles; Tumor Cells, Cultured

1988
Nature of distamycin A-inducible fragile sites.
    Cancer genetics and cytogenetics, 1988, Volume: 34, Issue:2

    Topics: Chromosome Banding; Chromosome Fragile Sites; Chromosome Fragility; Distamycins; Female; Genetic Markers; Humans; Karyotyping; Male; Neoplasms; Pedigree; Pyrroles; Tumor Cells, Cultured

1988
Distamycin A-inducible fragile sites and cancer proneness.
    Cancer genetics and cytogenetics, 1988, Volume: 34, Issue:2

    Topics: Chromosome Fragile Sites; Chromosome Fragility; Disease Susceptibility; Distamycins; Female; Humans; Karyotyping; Male; Neoplasms; Pyrroles; Tumor Cells, Cultured

1988
Familial fragile site found at the cancer breakpoint (1)(q32). Inducibility by distamycin A, concomitance with fragile (16)(q22).
    Human genetics, 1986, Volume: 73, Issue:3

    Topics: Cells, Cultured; Chromosome Banding; Chromosome Fragile Sites; Chromosome Fragility; Chromosomes, Human, 1-3; Chromosomes, Human, 16-18; Distamycins; Female; Genetic Markers; Humans; Infant, Newborn; Intellectual Disability; Karyotyping; Male; Neoplasms; Pyrroles

1986
Studies on the effects of chemicals on the processing of nuclear RNA. Some possible implications with respect to carcinogenesis.
    Biochemical pharmacology, 1971, Volume: 20, Issue:5

    Topics: Adenine Nucleotides; Animals; Antibiotics, Antineoplastic; Benzazepines; Carcinoma, Ehrlich Tumor; Cell Line; Cell Nucleus; Dactinomycin; Daunorubicin; Drug Stability; Neoplasms; Plicamycin; Polynucleotides; Pyrroles; Ribonucleases; RNA

1971
Structural requirements for nicotine and cyclic imine-induced amine release from neoplastic mast cells.
    Biochemical pharmacology, 1974, Aug-15, Volume: 23, Issue:16

    Topics: Amines; Animals; Azetines; Azirines; Cell Line; Chemical Phenomena; Chemistry; Electrons; Hydrogen-Ion Concentration; Imidazoles; Imines; Kinetics; Mast Cells; Mice; Mice, Inbred Strains; Neoplasms; Nicotine; Piperidines; Pyrroles; Pyrrolidines; Serotonin; Solubility; Spectrometry, Fluorescence; Structure-Activity Relationship

1974